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The transformation of healthy mammalian cells to cancerous cells is a complex, 
multi-factorial process involving aberrations in normal cell control mechanisms and 
feedback systems. Together these features are known as the hallmarks of cancer, as 
described by Hanahan and Weinberg 1,2 (Figure 1) and include sustained proliferative 
signalling, evasion of growth suppression, cell death resistance, replicative immortality, 
sustained angiogenesis, activation of invasion and metastasis, deregulation of 
cellular metabolism, avoidance of immune destruction, genome instability and 
tumour-promoting inflammation 2. For the scope of this thesis, a few of these hallmarks 
are addressed in more detail below.
Figure 1. The hallmarks of cancer. With every cancer hallmark, opportunities for therapeutic 
targeting are indicated. Figure is based on Hanahan et al., 2011 (Cell).
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1Sustained proliferative signalling
Whereas normal tissues harbour feedback mechanisms limiting the production and 
release of growth-promoting signals, cancer cells have adapted these mechanisms 
to promote cell proliferation 3,4 (Figure 2). Cell proliferation and differentiation are 
generally controlled through growth factors binding to receptor tyrosine kinases 
(RTKs), thereby activating downstream signalling pathways 2,3. Examples are 
hepatocyte growth factor (HGF) being a ligand for MET, epithelial growth factor 
(EGF) and transforming growth factor α (TGFα) being a ligand for EGF receptor 
(EGFR), and GAS6 as a ligand for AXL. Through PI3K/AKT, MEK/ERK and JNK cascades 
extracellular signals are transferred from the cell surface to the nucleus, and they can 
affect cell proliferation, differentiation, survival and migration, as well as regulate 
gene expression and cell cycle progression 5-7. Protein tyrosine phosphatases (PTPRJ, 
PTPRZ), phosphatase and tensin homolog (PTEN) and protein phosphatase 2 (PP2A) 
are negative regulators of such signal transduction pathways 8,9. In addition to RTK 
signalling, WNT and hedgehog signalling pathways can also regulate gene expression 
by transferring extracellular proliferation and differentiation signals to the cell nucleus 
10,11.
Figure 2. Cell signalling pathways. Extracellular signals are transferred to the nucleus through 
cell-surface receptors and proteins (pink), and cytoplasmic (blue) and nuclear (green) signalling 
cascades in order to regulate cell proliferation, differentiation, survival, migration, gene 
expression and cell cycle progression. Protein phosphatases (orange) negatively regulate these 
signalling pathways. PTPs, protein tyrosine phosphatases; RTKs, receptor tyrosine kinases.
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Chapter 1
There are multiple ways in which controlled RTK signalling is modified in malignant 
or pre-malignant cells 2-4,12,13. Cells may produce growth factor ligands themselves 
to induce autocrine signalling, or send signals to healthy neighbouring cells to 
stimulate growth factor supply by paracrine signalling 14-16. Alternatively, cells can 
become hyperresponsive to growth factor stimulation by receptor overexpression 2,3. 
Ligand-independent signalling may be achieved by structural alterations in the receptor 
itself or in downstream protein components that result in constitutive activation of 
the signalling pathway 2,3. Additionally, disruption of negative feedback loops may 
promote proliferative signalling 2.
Gain-of-function genetic aberrations or overexpression of numerous RTKs have been 
identified in cancer. For example, the activating EGFR exon 2-7 deletion (EGFRvIII) 
is frequently found in glioblastoma 17,18. MET overexpression or amplification and 
oncogenic MET exon 14 (METΔ14) skipping, resulting in decreased ubiquitination of 
the protein, are well described in non-small cell lung carcinoma (NSCLC) 19-23. The 
auto-activating MET exon 7-8 (METΔ7-8) intragenic deletion has been detected in 
glioblastoma 24. Activating mutations in downstream pathway components have 
been described for amongst others KRAS (G12C) 25 and BRAF (V600E) 26,27. Loss or 
downregulation of protein tyrosine phosphatases (PTPs), most notably PTEN, are 
frequently found in glioma 28-31. These and other molecular aberrations highlight key 
mechanisms of tumorigenic proliferative signalling.
Deregulation of cellular metabolism
Cancer cells adjust their metabolism to promote cell growth, survival and proliferation 
(Figure 3). When nutrient sources are abundant, cancer metabolism is directed 
towards the production of macromolecules such as lipids, proteins and nucleic acids 
32. Enhanced glycolysis, glutamine metabolism and tricarboxylic acid cycle (TCA) 
activity result in nucleotide and amino acid synthesis for biomass acquisition 32. 
Redox homeostasis is maintained through the pentose phosphate pathway (PPP) 33. 
In the tumour microenvironment, where nutrients are often scarce, cancer cells may 
compensate for loss of one nutrient by increasing metabolism of another 32.
A common feature of cancer is hypoxia, induced by 1) oxygen demand surpassing 
oxygen supply in intensively proliferating tumours, and/or 2) high distance between 
tumour cells and vasculature 34. Hypoxia acts as a driving force of tumour progression 
and metastasis through induction of multiple intracellular signalling pathways, the 
major one being effectuated through hypoxia-inducible factor 1 (HIF1α) 34-36. HIF1α 
is a transcriptional regulator with target genes involved in many pathways, thereby 
promoting blood vessel formation (vascular endothelial growth factor [VEGF], VEGF 
receptor [VEGFR], fibroblast growth factor [FGF], PDGF) 37,38, cell cycle and apoptosis 
regulation (TP53) 39, metastasis through acidification of the tumour microenvironment 
(carbonic anhydrase IX [CAIX]) 40,41 and glucose metabolism (GLUT1, GLUT3) 42-44. 
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1
Figure 3. Cancer metabolism. Illustration of the main cancer metabolic pathways: glycolysis, 
pentose phosphate pathway, glutamine/glutamate metabolism, lipogenesis, TCA cycle and pH 
regulation. The mitochondrial contribution is depicted in blue.
Even under aerobic conditions, cancer cells often reprogram their energy metabolism 
from glycolysis/TCA/oxidative phosphorylation to mainly glycolysis, with accompanying 
lactate production. This phenomenon was first described by Otto Warburg and 
is known as aerobic glycolysis or the Warburg effect 45,46. In other proliferating or 
developing cells, such as embryonic tissues, Warburg rewiring is present as well 
2,47,48. This metabolic switch seems counterintuitive, as ATP production via glycolysis 
is ~18-fold less efficient than through oxidative phosphorylation. However, the fast 
rate of glycolysis as compared to complete oxidative phosphorylation makes the 
amount of synthesized ATP per unit of time comparable between the two 49. Although 
a functional rationale remains elusive, there are several proposed explanations for 
Warburg rewiring in cancer cells 33. Higher rates of ATP production, though with a lower 
yield, may provide a selective advantage in environments of limited energy source 
50,51, such as tumour microenvironments 52. Moreover, the Warburg effect has been 
proposed to be an adaptation mechanism to support the biosynthetic requirements 
for high rates of cell proliferation, i.e. increased generation of nucleic acid precursors, 
amino acid building blocks and lipid components 32,48,53. Moreover, acidification of the 
tumour microenvironment through lactate production may promote invasion and 
metastasis 54-56. 
Boek 1.indb   11 23-3-2020   11:50:17
542469-L-bw-vd Heuvel




Angiogenesis plays a role in vasculature development during embryogenesis, but 
subsequently it is only transiently turned on to accommodate in physiological 
functions such as wound healing and the female menstrual cycle 57-59. To attain the 
necessary supply of nutrients and oxygen, as well as the ability to eliminate metabolic 
waste products and carbon dioxide, tumour cells have acquired the competence of 
activating angiogenesis 37,60,61 (Figure 4).
Figure 4. Angiogenic response. In phase 1), angiogenesis is initiated by hypoxic (HIF1A) 
or oncogenic, pro-angiogenic signalling. VEGFA, FGF and ANGPT2 together stimulate the 
proliferation and migration of endothelial cells. In phase 2), orderly vessel development is 
promoted by DLL4-NOTCH signalling in endothelial tip and stalk cells. PDGFB and ANGPT1 recruit 
pericytes for vessel maturation and stabilization. A growing, vascularized tumour may promote 
vessel development into hypoxic tumour areas through the HIF1A signalling cascade (phase 3).
Angiogenesis activation causes normal vasculature to sprout new vessels, enriching 
the tumour micro-environment with blood supply, thereby sustaining tumour survival, 
proliferation and metastasis formation 62. Tumour angiogenesis can be activated both 
by hypoxia and by oncogenic, pro-angiogenic signalling 37,61. The main effector of the 
hypoxic response is HIF1α, inducing transcription of many genes including VEGFA 37. 
The VEGFA/VEGFR pathway is one of the best-known stimulatory signalling pathways 
for angiogenesis. Alternative splicing of VEGFA results in different isoforms, the most 
frequent ones being VEGF-121, VEGF-165 and VEGF-189 63,64. VEGFA signalling is mainly 
mediated through VEGFR2 (KDR), expression of which is elevated by angiogenic 
endothelial cells and activation of which leads to a cascade of downstream pathways 
to promote endothelial cell survival, proliferation and migration, and vascular 
permeability 63. FGF can act synergistically with VEGFA to amplify tumour angiogenesis 
64-66, while angiopoietin 2 (ANGPT2) may destabilize vessels to potentiate VEGFA-induced 
angiogenesis 67,68. PDGFB and ANGPT1 are involved in vessel maturation and pericyte 
recruitment 64,69. Orderly development of new vessels is promoted by delta-like ligand 
4 (DLL4)-NOTCH signalling. VEGFA induces expression of DLL4 in endothelial tip cells, 
which reacts with NOTCH receptors on adjacent stalk cells in a negative feedback loop 
to prevent excessive angiogenic response 63. 
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1The neovasculature formed by angiogenesis is generally immature and leaky and is 
structurally and functionally abnormal, inducing heterogeneity in tumour blood flow 
61,70. This has implications for the tumour blood supply, and consequently also for the 
delivery of therapeutics 61. The extent of angiogenesis activation differs per tumour 
type. An example of a highly vascularised cancer type is clear cell renal cell carcinoma 
(ccRCC) 71,72, and also glioblastomas are characterized by marked angiogenesis 
activation 60,73. 
Avoidance of immune destruction
Upon detection of neo-antigens, for example during infection or in the context 
of cancer, the immune system is activated to eliminate foreign bodies. Distinct 
subtypes of effector T-cells mediate this protective immunity. CD4+ helper T-cells 
recognize neoantigens presented by antigen-presenting cells (APC) in the lymph 
nodes, while CD8+ cytotoxic T-cells can directly react with antigen-presenting tumour 
cells in the periphery 74. To prevent immunopathology or autoimmunity, the T-cell 
response is regulated by regulatory cells (a.o. regulatory T-cells and macrophages), 
anti-inflammatory cytokines and immune checkpoints 75. Cancers may limit immune 
recognition by downregulating antigen presentation, and may exploit negative T-cell 
regulation to avoid immune destruction 74-76. 
Examples of inhibitory checkpoint molecules are cytotoxic T-lymphocyte-associated 
protein 4 (CTLA4), and programmed death 1 (PD-1) expressed on T-cells (Figure 5). 
Binding of CTLA4 to its ligands CD80/86 (expressed by antigen-presenting cells) or 
binding of PD-1 to its ligands PD-L1/2 (expressed by cells in the periphery, including 
dendritic cells, epithelial cells and cancer cells) inhibits T-cell co-stimulation and 
inactivates T-cell response 75,76. The presence of cytotoxic T-cells in tumours has 
been correlated with a favourable prognosis in multiple cancer types 77-84. Immune 
checkpoint expression and high tumour regulatory T-cell infiltration on the other hand 
are associated with poorer patient outcome 85-90.
Genome instability
Alterations occurring in cancer cell signalling, metabolism and other cancer hallmarks 
are effectuated through the acquisition of genomic changes in the tumour cells. 
Healthy cells are protected from DNA damage, at least to the best of their abilities, 
by control checkpoints, DNA damage repair systems and apoptosis (Figure 6). On 
the other hand, cancer cells generally have compromised DNA damage recognition 
and repair systems, in this way promoting mutagenesis 91,92. Germline mutations in 
some of the most important genes involved in DNA damage repair, cell cycle arrest 
and apoptosis can predispose to hereditary forms of cancer, whereas somatic 
mutations and epigenetic silencing may be involved in the initiation and progression 
of non-inherited cancers 92-98.
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Figure 5. Immune checkpoint inhibition. T-cell receptors (TCR) recognize neoantigens presented 
by MHC molecules on antigen presenting cells (APC, left) or tumour cells (right). Immune 
checkpoint molecules CTLA4 (expressed by CD4+ helper T-cells) and PD-1 (expressed by CD8+ 
cytotoxic T-cells) may inhibit subsequent T-cell response by binding to their respective ligands, 
CD80/86 and PD-L1. APC, antigen-presenting cell; MHC, major histocompatibility complex; TCR, 
T-cell receptor.
Figure 6. DNA damage control and repair. Upon detection of DNA damage, cell division is 
prevented by induction of cell cycle arrest. Single-strand breaks may be repaired by base excision 
repair (BER), nucleotide excision repair (NER) or mismatch-mediated repair (MMR). Double-strand 
breaks can be repaired through homology directed repair (HDR) or non-homologous end-joining 
(NHEJ). When DNA damage repair is not successful, apoptosis is induced.
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1Cancer is generally initiated by a succession of persistent genomic alterations. When 
genomic mutations are not detected and/or repaired, and cells are not sent into 
senescence or apoptosis, mutant genotypes may provide a selective advantage 
on survival or proliferation. This may enable selective outgrowth of cell subclones 
2. Cancers often harbour one or more of such driver mutations 99,100. Next to its 
importance in tumorigenesis, genome instability may also have a functional role in 
tumour progression by allowing multistep selective tumour cell expansion. 
Targeted therapeutics
Currently, cancer treatment often consists of conventional therapies such as surgery 
and chemo- or radiotherapy. These conventional cancer treatments are stratified 
based on tumour tissue type and anatomical origin, and their non-selectiveness causes 
healthy, especially dividing normal cells to be harmed in the process. However, the 
previously described cancer hallmarks now offer opportunities for targeted therapy. 
The concept of targeted therapeutics is taking advantage of the oncogenic addiction 
pathways (signalling pathways, metabolic pathways etc.) of cancer cells while leaving 
healthy, non-mutant cells unharmed. The emerging understanding of the molecular 
biology of cancers has enabled the development of such targeted agents, most of 
which are small-molecule tyrosine kinase inhibitors (TKI), monoclonal antibodies or 
antibody-drug conjugates. This increasing armamentarium of targeted drugs can be 
grouped according to their effects on one or more of the cancer hallmarks 2 (Figure 1). 
A few well-known examples of successful targeted therapies directed at oncogenic cell 
signalling pathways are EGFR inhibitors being effective in EGFR-mutated lung cancers 
(gefitinib, erlotinib) 101-105, BRAF inhibitors giving response in melanomas with mutant 
BRAF V600E (vemurafenib) 106-108, or ERBB2 (HER2) targeted monoclonal antibodies 
or antibody-drug conjugates showing effect in HER2-overexpressing breast cancers 
(trastuzumab, trastuzumab emtansine) 109-113. Recently, also tumour suppressor 
loss was shown to be amenable for targeted therapeutic approaches as witnessed 
by the approval of PARP inhibitors for synthetic lethal therapy of Breast Cancer 
(BRCA)-mutated ovarian and breast cancer 114-116. Anti-angiogenic therapies emerge 
as well, such as the treatment of angiogenesis-dependent ccRCC metastases with 
sunitinib, although this is only effective in a subpopulation of patients 117-119. Immune 
checkpoint inhibition with monoclonal antibodies against CTLA4 (ipilimumab) or PD-1 
(pembrolizumab, nivolumab) is successfully applied in patient subsets of multiple 
cancer types, including advanced melanoma and NSCLC 120-123. 
The targeted nature of these precision drugs, together with the fact that efficacy of 
targeted therapy is generally limited to subsets of patients with similar cancer histology 
and molecular make-up 27,101-113,117,119,123, highlights the need for biomarkers to predict 
therapeutic response 124-131. Non-responsiveness to targeted drugs can be explained by 
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Chapter 1
absence of the therapeutic target, or by presence of intrinsic resistance mechanisms 
126,132,133. Furthermore, initial therapeutic effects are often transient because of acquired 
drug resistance 26,126,133-139. Both intrinsic and acquired mechanisms of resistance may 
cause selective advantage and outgrowth of resistant cancer cells (Figure 7). Due 
to tumour heterogeneity or multiple driver mutations, targeted treatment may only 
be effective on a selective part of the tumour cells (Figure 7A) 126,140,141. Furthermore, 
targeted pathways may be reactivated by downstream gene amplification (Figure 7B) 
or mutation (Figure 7C) 126. The therapy target itself may change through mutation, 
thereby intervening with the drug-target interaction (Figure 7D). An example here is the 
T790M mutation in EGFR, rendering tumour cells resistant to most EGFR inhibitors 136,142. 
Parallel signalling pathways may be present or upregulated upon therapy to provide 
a rescue mechanism (Figure 7E) 126. A well-known example of resistance by parallel 
signalling is overexpression or amplification of MET in NSCLC patients with acquired 
resistance to EGFR inhibitors 22,143. Finally, membrane-bound drug transporters have 
also been shown to influence cellular TKI concentrations 144-149. Upregulation of efflux 
transporters (ATP-binding cassette, ABC) or downregulation of influx transporters 
(solute carrier transporters, SLC) may cause therapy resistance by interfering with 
cellular drug exposure (Figure 7F).
Genomic instability plays an essential role in tumour flexibility and resistance 
development. Co-targeting of primary oncogenic pathways and possible compensatory 
pathways may interfere with drug resistance development 150,151. When resistance 
manifests, successful continuation of therapy may only be achieved by sequential 




Advances in molecular cancer research have led to the knowledge that whereas the 
anatomical location of a cancer may be the same, the molecular make-up of each 
individual tumour is different. On the other hand, the same cancer-causing changes may 
affect patients with different cancer types. Targeted therapeutics will therefore only be 
effective when tailored to the individual patient and individual tumour characteristics, 
and not to an anatomical group of cancers. With this molecular orientation rises a new 
field in oncology, called precision medicine (Figure 8).
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1
Figure 7. Modes of intrinsic or acquired therapy resistance. A) Due to tumour 
heterogeneity targeted drugs (petrol green capsules) may only be effective 
on part of the tumour cells (pink), allowing selective outgrowth of resistant 
cancer cells (green). B) Pathways targeted with therapy (pink) may be 
reactivated by downstream gene amplification (green). C) Pathways targeted 
with therapy (pink) may be reactivated by downstream gene mutation (green). 
D) The therapy target may be altered, for example through mutation, thereby 
preventing drugs to bind to their target. E) Parallel signalling pathways (green) 
may provide a rescue mechanism for the targeted signalling pathway (pink). 
F) Upregulation of efflux drug transporters or downregulation of influx drug 
transporters may interfere with target cell drug exposure.
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Chapter 1
Figure 8. Cancer precision medicine. Molecular profiling of cancer patients provides information 
on the molecular make-up of individual tumours, as illustrated by the different colours in the 
profiled population group (upper right). This allows identification of diagnostic (lower left), 
prognostic (lower middle) and therapeutic (lower right) biomarkers, which can be applied in 
precision medicine protocols.
The concept of precision medicine is that clinical decisions are based on the molecular 
signature of individual cancers, rather than tumour tissue type or anatomical site of 
origin 130,152,153. Precision medicine is playing an increasingly important role in cancer care 
and can be applied on the diagnostic, prognostic as well as therapeutic level. Currently, 
precision medicine in clinical oncology practice is mainly executed through the search 
for genomic biomarkers, mostly via screening for oncologic driver mutations. In 
diagnostics, screening is amongst others performed for mutations in BRCA1/2 in breast 
and ovarian cancer 154-157, presence of early detection markers such as prostate-specific 
antigen (PSA) in prostate cancer 158-160, or presence of oncogenic pathogens such as 
human papillomavirus (HPV) for cervical cancer 161,162. Gene mutations may also function 
as prognostic biomarkers. As an example, in glioma the isocitrate dehydrogenase 
1 (IDH1) R132H mutation is a favourable marker for patient prognosis 163-165. Lastly, 
gene mutations as well as gene expression levels offer opportunities for therapeutic 
decision making. A high tumour mutational load for example is associated with 
higher candidate neoantigen burden, and this feature as well as immune checkpoint 
expression are associated with better response to immune checkpoint inhibition 166-175.
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1Tumour profiling
Essential for the application of precision medicine are tumour profiling methods to 
chart the molecular make-up of a cancer. Multiple tumour profiling approaches have 
entered the clinic, most of which are based on next-generation sequencing (NGS) 
technologies for DNA analyses. A relatively new method of NGS is targeted sequencing 
using single molecule molecular inversion probes (smMIPs; Figure 9), where smMIP 
probes are designed that target a genetic region of interest. After hybridization of 
a probe to its target region (Figure 9A), the target region is copied into the probe. 
The circular product can be amplified by PCR (Figure 9B). PCR amplicons may be 
sequenced, using a unique molecule identifier to quantify the presence of the target 
sequence and mutational variants.
Figure 9. Single molecule molecular inversion probes. After capture of a smMIP to the target 
sequence, the gene target region is copied into the smMIP probe (A) and PCR-amplified (B). 
PCR reads can be sequenced, using unique molecule identifiers to quantify the presence of the 
original target sequence
DNA sequence analysis using smMIPs is already implemented in molecular diagnostics 
of clinical samples and has advantageous properties as scalability, flexibility and easy 
automation 157,176. Moreover, it can be used to detect low-frequency targets and is 
applicable to samples with limited starting material 157,176. However, whereas genomic 
analyses give information on molecular aberrations 22, they do not provide information 
on gene expression levels. Since gene overexpression does not necessarily require a 
genomic aberration, valuable therapeutic candidates may be missed. 
Targeted RNA next-generation sequencing
In addition to genomic templates, smMIP sequencing may also be applied to 
transcriptomic templates. This way of targeted RNA next-generation sequencing 
(t/RNA-NGS) may allow the analysis of activity of oncogenic and possible addiction 
pathways in cancers, the omission of tumour suppressor activity, but also activity of 
oncogenic pathogens such as HPV. The information provided with t/RNA-NGS may as 
such aid in the establishment of cancer diagnosis and prognosis, but also in therapeutic 
decision making of individual cancer patients. 
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Outline of this thesis
In this thesis, I apply t/RNA-NGS using smMIPs to map the molecular make-up of 
different cancer types on the transcriptome level. t/RNA-NGS is based on a panel of 
smMIPs targeting a specified group of transcripts and provides quantitative gene 
expression data, sensitive detection of specific transcript splice variants as well 
as mutation detection. The smMIP panel is designed to measure expression of and 
molecular aberrations in cancer-related transcripts (Figure 10 and Appendix IV). 
All transcripts included in the smMIP panel are grouped by pathway or cancer type 
(realizing that many genes play a role in multiple pathways or cancers, genes are 
included in the subgroup most relevant for this thesis). The main groups of transcripts 
included in the smMIP panel are related to proliferative (tyrosine kinase) signalling, 
cell cycle and transcription regulation, angiogenesis, metabolism, immune response 
and inflammation, DNA damage repair and apoptosis, cell adhesion, and hormone and 
HPV signalling.
Figure 10. SmMIP panel composition. With the concurrent smMIP panel expression of 371 
transcripts is measured, using a total of 1956 smMIPs. The diagram visualizes the respective 
contribution of different transcript categories to the panel.
The major aim of the research described in this thesis is to investigate the value of 
transcriptome information for diagnostic, prognostic and therapeutic precision 
medicine in oncology and to evaluate t/RNA-NGS as a tool to obtain this knowledge. 
In Chapter 2, I build on a previously published study reporting the successful targeting 
of the MET oncogene in a METΔ7-8-addicted glioblastoma model, however with 
development of acquired resistance 177. Reasoning that the effects of targeted therapy 
depend on the abundance of the target molecule and the level of the tumour cell’s 
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1oncogene addiction to that molecule or pathway, I compare effects of MET inhibition 
in MET amplified and MET wild-type cells in vitro. Furthermore, I compare multi-specific 
inhibition of MET with mono-specific therapy in the same glioblastoma model, and 
consider mechanisms of in vivo resistance development. 
In Chapter 3, I describe the technique and validation of smMIP-based t/RNA-NGS 
based on a panel of metabolic transcripts in an isogenic ccRCC cell line pair. I compare 
smMIP-based t/RNA-NGS data with whole RNA next-generation sequencing (w/
RNA-NGS) results and pursue variant detection through t/RNA-NGS in cell lines, 
xenograft models and patient tissues.
Heterogeneity in the cellular or molecular make-up of cancers may lead to suboptimal 
application of targeted therapies and to therapy resistance. Analysis of DNA or RNA 
samples that are extracted from cancer tissues unfortunately does not allow detection 
of heterogeneity within the sample, nor differentiation between cancer cells and 
healthy tissue cells. In Chapter 4 I therefore apply in situ padlock probe rolling circle 
amplification to visualize oncogenic splice variant transcripts in cancer cell lines and 
glioblastoma xenograft models. The combination of transcript localization using 
padlock probes with smMIP-based t/RNA-NGS data should provide simultaneous 
spatial and quantitative information on the expression of oncogenic transcripts. 
In Chapter 5 I evaluate the diagnostic and prognostic value of t/RNA-NGS in glioma 
by correlating transcript expression profiles with clinical patient diagnosis and 
patient survival. Known brain cancer-associated molecular aberrations will serve as 
benchmarks, and any identification of gene aberrations that are associated with other 
cancer types may promise new applications for existing drugs. I will also validate the 
expression of actionable transcripts on the protein level.
 
As argued above, molecular profiling of individual tumours may aid in the application 
of targeted therapeutics. Moreover, profiling of multiple biopsies of one tumour may 
give insights in intercellular tumour heterogeneity. In Chapter 6 I therefore explore t/
RNA-NGS for the profiling of multiple biopsies of ccRCC tumours, in order to evaluate 
heterogeneity and make suggestions for individualized targeted therapies. I also apply 
t/RNA-NGS on two renal carcinoma cell lines and use the expression profiles to predict 
drug sensitivity in vitro.
In Chapter 7 I apply t/RNA-NGS on a cohort of normal lung and lung carcinoma samples. 
I evaluate the transcriptome-based discrimination between healthy tissue and cancer 
tissue, different histological lung carcinoma subtypes and individual lung cancers, and 
discuss its implications for precision medicine.
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Nation-wide cervical cancer screening is currently performed by molecular testing for 
HPV DNA, but this does not allow discrimination of clinically relevant or irrelevant, 
silent infections. Detection of HPV transcriptional activity may allow such a distinction. 
In Chapter 8 I therefore apply t/RNA-NGS on normal cervix and cervical cancer tissues 
and compare HPV RNA with DNA detection. This approach may also enable me to 
identify possible biomarkers other than HPV that may be associated with cervical 
cancer.
HPV status in head and neck squamous cell carcinomas (HNSCCs) affects radiosensitivity. 
Mechanisms leading to radioresistance include DNA damage repair and metabolic 
changes. In Chapter 9, I apply t/RNA-NGS on 14 HNSCC cell lines and explore the 
correlation between radiosensitivity and gene expression profiles.
Finally, in Chapter 10 I will discuss the implications of the results presented in this thesis 
and will give an overview of the challenges in cancer precision medicine.
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The receptor tyrosine kinase (RTK) MET represents a promising tumour target 
in a subset of glioblastomas. Most RTK inhibitors available in the clinic today, 
including those inhibiting MET, affect multiple targets simultaneously. Previously 
it was demonstrated that treatment with cabozantinib (MET/VEGFR2/RET inhibitor) 
prolonged survival of mice carrying orthotopic patient-derived xenografts (PDX) of the 
MET-addicted glioblastoma model E98, yet did not prevent development of recurrent 
and cabozantinib-resistant tumours.
To exclude VEGFR2 inhibition-inflicted blood-brain barrier normalization and 
diminished tumour distribution of the drug, we have now investigated the effects 
of the novel MET-selective inhibitor Compound A in the orthotopic E98 xenograft 
model. In vitro, Compound A proved a highly potent inhibitor of proliferation of 
MET-addicted cell lines. In line with its target selectivity, Compound A did not restore 
the leaky blood-brain barrier, and was more effective than cabozantinib in inhibiting 
MET phosphorylation in vivo. Compound A treatment significantly prolonged survival 
of mice carrying E98 tumour xenografts, but did not prevent eventual progression. 
Contrasting in vitro results, the Compound A treated xenografts displayed high levels 
of AKT phosphorylation despite the absence of phosphorylated MET. Profiling by RNA 
sequencing showed that in vivo transcriptomes differed significantly from those in 
control xenografts. 
Collectively, these findings demonstrate the plasticity of paracrine growth factor 
receptor signalling in vivo and urge for prudency with in vitro drug testing strategies 
to validate mono-therapies.
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Introduction
Therapy for high-grade diffuse gliomas (glioblastomas) consists of surgery followed by 
radio-chemotherapy, but unfortunately these treatments only prolong median survival 
of patients to 15 months after first diagnosis 178. A high percentage of glioblastomas 
carry genetic alterations in receptor tyrosine kinases (RTK) such as EGFR, PDGFRα and 
MET 179-181. Constitutive activation of these RTKs contributes to oncogenic signalling, 
identifying these proteins as therapeutic targets. Of special interest as a tumour target 
in diffuse glioma is MET and its ligand hepatocyte growth factor (HGF). Whereas normal 
MET function is essential for wound healing, embryogenesis and organogenesis 182-186, 
MET dysregulation is associated with tumorigenesis and in glioblastomas is linked 
to cellular growth and migration, shorter patient survival time and poor treatment 
response 177,180,182,187-190. 
Besides playing an important role in tumour development and progression, MET is 
involved in the stem-cell like phenotype in glioma and may provide a rescue pathway 
for tumour progression under treatment with drugs targeting EGFR, ALK 191-196, FGFR 
197 and mutated BRAF 26,198-200 in different cancer types. In addition, MET has been 
described as a mediator of resistance to radiotherapy 192,201,202. Therefore, inhibition of 
MET may provide direct anti-tumour effects and prevent development of resistance to 
other therapies.
Several small-molecule tyrosine kinase inhibitors (TKIs) have been developed that 
effectively inhibit RTK activity. However, due to the conserved tyrosine kinase 
catalytic domain, many of these drugs have activity against multiple RTKs. An 
example is cabozantinib, a TKI with activity against MET, VEGFR2, KIT, RET, TEK and 
FLT3 203, which was recently tested for glioblastoma in a phase I/II clinical trial 204. 
We previously reported that cabozantinib inhibits phosphorylation of MET and its 
downstream signalling intermediates AKT and ERK1/2 (p44/p42) in E98 glioma cells, a 
patient-derived astrocytoma cell line which harbours amplification of a mutated MET 
gene that is representative for some 8% of glioblastoma cases 24. Inhibition of MET 
signalling using cabozantinib in vitro resulted in absence of phosphorylated (p)MET, 
diminished migratory capacity and in cytotoxicity. Mice carrying orthotopic xenografts 
generated from E98 glioma cells experienced a survival benefit when treated with 
cabozantinib. Notwithstanding these positive effects, treatment with cabozantinib 
in the end did not prevent progression of diffuse infiltrative tumours and, opposing 
the in vitro data, treated tumours presented with prominent pMET levels 177. This 
brought us to postulate that efficacy of cabozantinib on tumour cells in vivo may have 
been compromised by concomitant inhibition of VEGFR2 on the tumour-associated 
endothelial cells, leading to vascular normalization, restoration of the blood-brain 
barrier and subsequent inefficacy of cabozantinib as a tumour drug 205,206. 
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In the current study we therefore tested two novel small-molecule MET tyrosine 
kinase inhibitors, Compound A (MET-selective) 207 and AMG 458 (multi-specific, 
inhibiting among others MET and RON 208), in a number of MET-expressing cell 
lines and performed in vivo analysis of the effects of Compound A on mice carrying 
subcutaneous U87-MG and intracerebral E98 xenografts. 
Materials and Methods
Cell culture
The PDX astrocytoma model E98 and the generation of the lentivirally transduced 
E98 cell line expressing firefly luciferase and mCHERRY (E98FM) have been described 
before 209,210. MKN45, HT-29, parental E98, E98FM, E98FMA (generated from Compound 
A-resistant E98FM xenografts), LN18, Hs746T and TOV-112D cells were grown in 
DMEM medium containing 4.5 g/l glucose and L-glutamin (Lonza, Basel, Switzerland) 
supplemented with 10% fetal calf serum (FCS, Gibco, Waltham, MA, USA) and 40 µg/
ml gentamicin (Centrafarm, Etten-Leur, The Netherlands) at 37°C in the presence 
of 5% CO2. Origin and relevant molecular characteristics of all cell lines are outlined 
in Supplementary File S1, Table S1. Human umbilical vein endothelial cells (HUVEC, 
isolated in-house from umbilical cords) were grown on 1% gelatine coated culture 
dishes in EndoPrime medium (PAA Laboratories/GE Healthcare, Little Chalfont, UK) 
supplemented with additives according to manufacturer’s instructions. All cell lines, 
except HUVEC, expressed MET as validated by western blot analysis. 
Prior to intracerebral xenografting, E98FM cells were grown as spheroids for at least 
2 passages in serum-free Neurobasal/B27 medium (Gibco/Invitrogen, Waltham, MA, 
USA), supplemented with EGF and basic FGF (both PromoCell, Heidelberg, Germany) 
as described previously 30,211. For passaging, spheres were dissociated with Accutase 
(Sigma-Aldrich, St. Louis, MI, USA). 
For in vitro analyses stock solutions of 10 mM of Compound A, AMG 458 (both Amgen, 
Thousand Oaks, CA, USA 207) or cabozantinib (Exelixis, San Francisco, CA, USA 212) 
were prepared in DMSO. Characteristics of AMG 458 and cabozantinib have been 
described before 203,208. Chemical structures of Compound A and AMG 458 are shown 
in Supplementary File S1.
Immunoblotting
Cell lines were seeded in 6-well plates and allowed to adhere. E98 cells at ~80% 
confluence were treated with Compound A (0 to 300 nM) or DMSO vehicle (0.03%) for 
20 min. MKN45 and Hs746T cells were stimulated with HGF for 10 min, following 20 
min treatment with Compound A or AMG 458 (0-3000 nM). After treatment, cells were 
washed twice with ice-cold PBS and lysed in 1x RIPA buffer (Cell Signalling Technology, 
CST, Danvers, MA) with 1 mM phenylmethylsulfonyl fluoride (PMSF), according to 
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manufacturer’s instructions. Protein lysates were subjected to electrophoresis on 10% 
SDS-PAGE gels and electroblotted onto nitrocellulose membranes (Whatman Optitran 
BA-S85, GE Healthcare, Little Chalfont, UK). After blocking aspecific binding sites in 
blocking buffer (1:1 PBS/Odyssey blocking buffer [LI-COR Biosciences, Lincoln, NE, 
USA]) blots were incubated o/n at 4°C with primary antibodies (see Supplementary 
File 2 for detailed information). Primary antibodies were detected with appropriate 
IRDye680- or IRDye800-conjugated secondary antibodies (1:20,000, Invitrogen 
Molecular Probes, Waltham, MA, USA) and signals were visualized using the Odyssey 
imaging system (LI-COR Biosciences, Lincoln, NE, USA).
Proliferation assays
Cells were seeded in 96-well plates (5,000, 10,000 and 20,000 cells/well for U87-MG/
TOV-112D/LN18, HUVEC/Hs746T/HT-29/MKN45 and E98 cells, respectively). The next 
day increasing concentrations of Compound A or vehicle only were added to the 
medium. Metabolic activity of cells was measured four days after start of Compound A 
treatment by incubation with 0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) in PBS (Sigma-Aldrich, St. Louis, MO, USA). After 3.5 hr incubation 
at 37°C formazan crystals were dissolved in MTT solvent (0.1% NP40 and 3.4 mM HCl in 
isopropanol) and optical densities were measured at 560 nm. IC50 concentrations were 
determined using sigmoidal dose-response (variable slope) statistics in GraphPad 
Prism. Data represent the mean ± SEM (N=4).
Animal experiments 
All animal experimentation at AMGEN Inc. was conducted in an American Association 
for Laboratory Animal Care (AALAC)-accredited facility with Institutional Animal Care 
and Use Committee (IACUC) approved protocols. Animal experiments performed at 
Radboudumc were approved by the Radboudumc local ethical committee for animal 
experimentation. Based on the results of our previous experiments with cabozantinib, 
animal numbers were calculated by power analysis and kept as low as possible while 
retaining sufficient power. Pharmacodynamic assays are described in Supplementary 
File 3.
U87-MG (5x106) cells were injected subcutaneously into the right flank of female CD1 
nu/nu mice (Charles River Laboratories, MA, USA). Treatment was initiated when 
tumour volume reached approximately 400 mm3. Compound A (suspension in soybean 
oil) was administered either once or twice daily by oral gavage at the indicated doses. 
Vehicle group received 100% soybean oil by oral gavage once daily. Tumour volume was 
measured twice weekly as length (mm) x width (mm) x height (mm) and expressed as 
cubic mm using a PRO-MAX electronic digital caliper (Japan Micrometer Mfg. Co. Ltd.). 
Statistical analysis of observed differences between growth curves was performed 
by repeated-measures analysis of variance followed by Dunnett’s test for multiple 
comparisons. A paired t-test was performed to determine regression using JMP 
software v7.0 interfaced with SAS v9.1 (SAS institute, Cary, NC, USA).
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For generation of intracerebral glioma xenografts, E98FM cells grown as spheroids for 
at least 2 passages, were injected orthotopically via standard procedures 209. In short, 
five to six-week-old female BALB/c nu/nu mice (Janvier Labs, Le Genest-Saint-Isle, 
France) were anesthetized by inhalation of 3% isoflurane/O2. Per animal 200,000 cells 
in 10 μl PBS were injected. Mice were checked weekly for tumour development using 
bioluminescent imaging (BLI) on an IVIS imager (procedure is described below). 
When tumour growth was observed (typically 3-5 weeks after tumour cell injection) 
treatment was initiated by daily oral gavage of 60 mg/kg Compound A in 100 µl soy 
bean oil (Spectrum, New Brunswick, NJ, USA; N=12) or soy bean oil only (N=10).
Two Compound A-treated and two control animals were sacrificed after 10 days of 
treatment to analyse the short-term effects of therapy. Fifteen minutes before 
sacrifice these animals were injected intraperitoneally with BrdU (Sigma-Aldrich, St. 
Louis, MO, USA; 1.25 mg/animal). The other animals were sacrificed when signs of 
tumour-related symptoms started to develop (usually >15% weight loss within two 
days). Prior to sacrifice, vehicle (N=3) and Compound A-treated animals (N=4) were 
subjected to Gd-DTPA-MRI (see Supplementary File 4). Brain, liver and kidneys from 
each animal were partially snap frozen in liquid nitrogen and partially processed to 
formalin-fixed paraffin-embedded (FFPE) tissue blocks. Statistical significance in 
survival was determined in Graphpad Prism v5.03 (GraphPad Software, LaJolla, CA) 
using the Log-rank Mantel-Cox test.
To generate a cell line from Compound A-resistant xenografts, tumours were 
macroscopically dissected from brains of Compound A-treated animals, cut in small 
pieces in PBS containing 4.5 g/l glucose and enzymatically dissociated in PDD buffer 
(HBSS containing 12.4 mM MgSO4, 0.01% papain (Sigma-Aldrich, St. Louis, MO, USA), 
0.1% Dispase 2 and 0.01% DNase [both Roche Diagnostics, Basel, Switzerland]). After 
1 hr at 37°C tissue was processed to a single-cell suspension by pipetting and filtering 
over a 70 μm mesh nylon filter. After washing with PBS, cells were suspended in 
serum-containing DMEM and cultured under standard conditions. MTT assays were 
performed after 2 and 3 passages as described above.
In vivo bioluminescence 
Tumour burden in mice carrying orthotopic E98FM xenografts was measured via 
luciferase bioluminescence imaging at least once a week and prior to sacrifice. Mice 
were imaged under 3% isoflurane/O2 anaesthesia in an IVIS Lumina system (Caliper Life 
Sciences, Hopkington, MA, USA) 10 min after intraperitoneal injection of 200 μl PBS 
containing 15 mg/ml D-luciferin (Caliper Life Sciences, Hopkington, MA, USA). Images 
were analysed using the Living Image 3.0 software (Caliper Life Sciences, Hopkington, 
MA, USA). Two-dimensional regions of interest (ROIs) were drawn around the 
skull. Luciferase activity was expressed as photons emitted per second per square 
centimetre. 
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Immunohistochemical analysis
Immunohistochemistry (IHC) on 4 μm FFPE tissue sections was performed as previously 
described 205. In short, after epitope retrieval (10 min boiling in citrate buffer pH 6.0 or 
EDTA) and permeabilization in 1% Triton-X-100 (10 min, for phospho-histone H3 stainings 
only) tissue sections were incubated o/n at 4°C with primary antibodies against 
MET, pMET Tyr1234/Tyr1235, pAKT S473, Ki-67, BrdU, phospho-histone H3 Ser10, and 
caspase-3A. Appropriate biotinylated secondary antibodies were used for detection 
using the Avidin-Biotin Complex (ABC) method (Vector Laboratories, Burlingame, CA, 
USA). Mouse IgG in tissue sections was visualized via direct incubation with biotinylated 
horse-anti-mouse-IgG, followed by ABC-visualization. See Supplementary File S2 for 
detailed primary antibody information. Antibody complexes were visualized by a 7 min 
incubation with 3,3’-diaminobenzidine solution (Power-DAB, ImmunoLogic, Duiven, 
The Netherlands). All sections were counterstained with haematoxylin and mounted 
in Quick-D mounting medium (Klinipath BV, Duiven, The Netherlands). 
Additionally, for some stainings IHC was performed on 4 µm frozen sections that were 
air-dried and fixed with 4% paraformaldehyde for 10 min. After washing with distilled 
water and PBS, sections were incubated for 1h at RT with antibodies against MET and 
pMET Tyr1234/Tyr1235 in PBS/1%BSA (see Supplementary File 2 for detailed information). 
The ABC method and Power-DAB were used for detection and visualization as 
described above. All sections were counterstained with haematoxylin and mounted in 
Quick-D mounting medium. 
Immunohistochemical stainings were interpreted by two observers, blinded to 
the origin of the material. Diffuse and more compact areas of tumour were scored 
separately as negative (-), heterogeneous/weakly positive (+/-) or positive (+). 
Statistical significance was determined in Graphpad Prism v5.03 (GraphPad Software, 
LaJolla, CA) using a Kruskal Wallis post-hoc Dunn’s multiple comparison test (placebo 
N=6, Compound A and cabozantinib N=5).
RNA next-generation sequencing
Total RNA was isolated from 5x 20 µm sections of snap-frozen control, Compound A- or 
cabozantinib-treated E98FM xenograft tissues using TRIzol reagent (Life Technologies, 
ThermoFisher Scientific, Waltham, MA, USA) according to the manufacturer’s 
instructions. After validation of RNA quality by a RIN score >8 in Bioanalyzer assays 
(Agilent Technologies, Amstelveen, The Netherlands) and depletion of ribosomal 
RNA, whole transcriptome RNA next-generation sequencing (w/RNA-NGS) was 
performed by ServiceXS (Leiden, The Netherlands). Each sample yielded 30-50 million 
reads (paired-end sequencing protocol) and resulting dataset was analysed using the 
‘Tuxedo’ protocol; reads were mapped against the RefSeq human genome (hg19) 
with TopHat and final transcript assembly was done with the Cufflinks package 213. 
Normalization was done with Cuffquant. Relative values for each transcript were 
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expressed as transcript per million mapped reads (TPM). Human reads were separated 
from mouse reads by using the Xenome algorithm 214. Statistical analysis (N=1) was 
performed using RStudio 1.0.136.
Quantitative real-time PCR
RNA was isolated from 5x 20 µm sections of snap-frozen control, Compound A- or 
cabozantinib-treated E98FM xenograft tissues using TRIzol reagent (Life Technologies, 
ThermoFisher Scientific, Waltham, MA, USA) and reverse-transcribed into cDNA 
using Superscript II (Invitrogen, Waltham, MA, USA) according to the manufacturer’s 
instructions. Primer sequences for qPCR were: β2M-Fw 5’-ATGAGTATGCCTGCCGTGTG-
3’, β2M-Rv 5’-CCAAATGCGGCATCTTCAAAC-3’, IFI6-Fw 5’-CTTGTGCTACCTGCTGCT-3’, 
IFI6-Rv 5’-TTCTTACCTGCCTCCACC-3’ (Biolegio, Nijmegen, The Netherlands). Power 
SYBR Green PCR Master Mix (Applied Biosystems) was used for qPCR on a 7500 Fast 
real-time PCR system (Applied Biosystems) and data was normalized to the human 
housekeeping gene β2M. Experiments involved Compound A treated xenografts (N=4) 
and cabozantinib treated xenografts (N=1), and for each sample 4 technical replicates 
were performed.
Results
Compound A and AMG 458 inhibit MET signalling in MET amplification-positive cell lines 
in vitro
In order to test whether MET inhibitors that do not act upon VEGFR2, and thus leave 
the blood-brain barrier leaky to support drug delivery to brain tumour regions, provide 
added value for glioblastoma treatment, we tested the MET inhibitors Compound A 
and AMG 458.
Compound A (Supplementary Figure S1A) is a tyrosine kinase inhibitor with high 
selectivity for MET (IC50 in MET phosphorylation assays of 5-7 nM) 
207, while AMG 458 
(Supplementary Figure S1B) inhibits multiple RTKs including MET and RON (IC50 in MET 
phosphorylation assays of 60 nM) 208. We tested the effects of both compounds in 
MKN45 gastric cancer cells, carrying a MET amplification, and Hs746T gastric cancer 
cells, carrying both a MET amplification and activating METΔ14 mutation 215. Compound 
A dose-dependently inhibited MET phosphorylation and activation of the downstream 
effector molecules AKT and ERK1/2 (p44/p42) in both cell lines (Figure 1A), while not 
affecting total MET levels 216. Parallel tests with AMG 458 showed that Compound A 
was 10-fold more potent in inhibiting phosphorylation of MET and its downstream 
targets (Figure 1A), and this translated in increased cell killing activity of Compound 
A as compared to AMG 458 in MKN45 cells (IC50 values of 20.0 nM and 445.0 nM 
for Compound A and AMG 458, respectively, Figure 1B) identifying Compound A as 
the superior compound with respect to MET inhibition. We therefore continued our 
study using Compound A in the E98 glioma model, which carries an amplification of 
a mutated MET gene encoding the auto-active METΔ7-8 oncoprotein 24. Compound A 
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dose-dependently inhibited MET phosphorylation and activation of downstream 
effector molecules AKT and ERK1/2 (p44/p42; Figure 1A) and potently inhibited E98 cell 
proliferation with an IC50 value of 9.4 nM (Figure 1B). IC50 values of Compound A on cell 
lines with low to moderate levels of MET ranged from 947.5 nM to 6570.0 nM (Figure 
1C), providing a therapeutic window for MET-specific tumoricidal effects.
Figure 1. Compound A efficiently inhibits MET signaling in vitro in MET amplified cells. A) 
MKN45, Hs746T and E98 cells harboring a MET amplification, were treated for 20 min with Com-
pound A or the multi-targeted kinase inhibitor AMG 458 before stimulation with HGF (10 min). 
Phosphorylation levels of MET (Tyr1234/Tyr1235), AKT (Ser473) and ERK1/2 (Thr202/Tyr204) were 
monitored by western blot, with GAPDH or actin as a loading control. Note that in MKN45 and 
Hs746T cells Compound A was approximately 10-fold more effective than AMG 458. B, C) IC50 
concentrations of Compound A in MET overexpressing cell lines E98, MKN45 and Hs746T (B), 
and the low-to-non-expressing cell lines LN18, TOV-112D, HUVEC and HT-29 (C) as determined by 
MTT assays. Consistent with the higher efficacy of Compound A on MET phosphorylation (A), 
Compound A had higher activity in inhibiting MET-associated cell proliferation as compared with 
AMG 458. Data represent mean ± SEM (N=4). 
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Compound A inhibits MET signalling and improves survival of MET-dependent xenografts 
in vivo
In preparation for in vivo studies, we first investigated the pharmacodynamic (PD) 
properties of Compound A as described in Supplementary File S3. Compound A 
dose-dependently inhibited HGF-mediated MET phosphorylation in liver with an 
approximate ED90 of 10 mg/kg and an associated plasma exposure of approximately 800 
ng/ml (Supplementary File 3, Figure S2A, p<0.0001 compared to HGF vehicle, ANOVA/
Bonferroni Dunn post hoc test) and these results were validated in an assay in which 
mice bearing TPR-MET tumours 217 were treated with Compound A at a dose of 5, 10 or 
30 mg/kg, followed by measurement of phosphorylation levels of the MET substrate 
Gab-1. Treatment with 30 mg/kg Compound A resulted in complete inhibition of Gab-1 
phosphorylation at 6 hours which was maintained for up to 10 hours (Supplementary 
File 3, Figure S2B). We next performed an efficacy study in mice bearing subcutaneous 
U87-MG tumour xenografts. Although this model bears no relevance for clinical diffuse 
glioma 211 it is appropriate for the investigation of the effects of MET-inhibition via 
tumour volume measurements. Treatment with Compound A completely prevented 
tumour growth and even induced tumour regression with twice daily dosing as low as 
30 mg/kg (Figure 2, p<0.0001). 
Figure 2. Compound A reduces growth of HGF-dependent U87-MG xenografts. Mice bearing 
subcutaneous U87-MG xenografts were treated orally once or twice daily with vehicle or Com-
pound A at doses of 15, 30 or 60 mg/kg (N=12/group). The arrow denotes the start of therapy. 
Compound A significantly prevented growth of U87-MG xenografts at all doses, and induced 
tumour regression at doses > 30 mg/kg. * p<0.0006 at day 27 post-treatment vehicle vs. Com-
pound A (Repeated measures ANOVA and Dunnett’s post-hoc test); # p<0.0001 at day 17 vs. day 
41 post-treatment for Compound A at 30 mg/kg BID, 60 mg/kg BID or QD (regression paired 
Student’s t-test). 
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The impressive efficacy of Compound A in this model, the favourable pharmacodynamic 
profile, and the potent anti-proliferative activity of this compound on E98 cells in 
vitro, led us to test the effects of Compound A on orthotopic E98FM xenografts. Unlike 
U87-MG cells that develop into bulky tumours upon intracerebral implantation 218, 
E98FM xenografts present with the diffuse infiltrative phenotype that is characteristic of 
human glioblastoma, having areas with more compact growth in which angiogenesis 
occurs, and diffuse areas with a largely intact blood-brain barrier 205. In this very same 
model we previously tested the multi-specific inhibitor cabozantinib 177,206, allowing us 
to compare the effects of both drugs.
Daily treatment of E98FM-tumour bearing mice with 60 mg/kg Compound A, starting 
at 2-3 weeks after tumour implantation when BLI signals indicated tumour take, 
resulted in delayed tumour growth (see representative example in Figure 3A) and 
significantly improved survival (Figure 3B, p<0.03, log-rank test). We did not observe 
any drug-toxicity of Compound A in the tumour-bearing mice based on liver and 
kidney pathology, as determined by H&E stainings on FFPE preserved tissue (data not 
shown). To investigate the effects of Compound A on MET activation levels in E98FM 
xenografts we performed IHC with an antibody specific to phosphorylated tyrosine 
residues Y1234/1235 in the MET kinase domain (details in Supplementary File S2). To 
allow direct comparison of the effects of Compound A with those of cabozantinib, we 
also performed IHC stainings on mouse brains from cabozantinib-treated E98-tumour 
bearing animals from our previous study 177. While all placebo-treated animals showed 
high and homogeneously distributed MET and pMET levels throughout the tumour 
(Figure 4A) treatment with Compound A resulted in dramatic reduction in pMET, with 
some remnant traces of pMET in diffuse tumour areas (Figure 4A, arrow; note that 
all stainings were performed on animals that were sacrificed when tumour-related 
symptoms were apparent). pMET levels were significantly lower in Compound 
A-treated xenografts than in placebo- and cabozantinib-treated animals 177 both in 
diffuse and compact tumour regions (p=0.05 and p=0.03 respectively, Kruskal-Wallis, 
Dunn post-hoc multiple comparison test, Figure 4A right panel). Cabozantinib-treated 
xenografts presented with tumour cells co-opting pre-existent vessels (Figure 4A, 
arrowhead). Of note, we did not find significantly different pMET levels between 
cabozantinib- and placebo-treated xenografts (Figure 4A, right panel), confirming our 
previous results 177. 
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Figure 3. Prolonged survival of E98 glioma xenografts by Compound A. A) Bioluminescence 
imaging (BLI) of mice implanted with E98FM cells at different time points after xenografting. 
BLI was performed 1-2 times a week and prior to sacrifice. Examples of one placebo and one 
Compound A-treated animal are shown. Signals represent radiance in photons (p)/sec/cm2/sr ac-
cording to the legend on the right (log scale, color legend: min 5x104 and max 1x107 p/sec/cm2/sr). 
B) Survival curves for placebo (N=10) and Compound A (N=12) treated animals harboring E98 xe-
nografts. Treatment with 60 mg/kg Compound A or solvent (soybean oil) only was initiated after 
signs of tumour growth became evident in BLI. Data represent median survival probability from 
start of therapy. For ethical reasons, animals were sacrificed when evident tumour burden (e.g. 
weight loss) became visible. Median survival from start of therapy was significantly different 
between placebo- and Compound A-treated animals (7.5 and 16 days, respectively, p=0.0270, 
Log-rank (Mantel-Cox) test). 
Figure 4. Efficient MET inhibition in vivo does not affect pAKT levels or cell proliferation, but 
induces apoptosis in a small fraction of tumour cells. A) To determine phosphorylation of MET 
after therapy, 4 μm frozen sections of mouse brains xenografted with E98 (placebo N=6, Com-
pound A-treated N=5, and cabozantinib-treated N=5) were subjected to immunohistochemistry 
for MET and pMET. Representative examples of MET and pMET stainings are shown. Stainings 
for pMET were scored by two independent observers. pMET levels were significantly lower 
in Compound A-treated xenografts compared with placebo and cabozantinib-treated animals 
both in diffuse (p=0.05) and compact (p=0.03) tumour regions (Kruskal Wallis, post-hoc Dunn’s 
multiple comparison test). Note that Compound A-treated xenografts show remnant traces 
of pMET in diffuse tumour areas (arrow). Cabozantinib-treated xenografts show tumour cells 
co-opting pre-existent vessels (arrowhead). Magnification 10x. B) Representative IHC images 
of serial FFPE sections of brains from placebo- and Compound A-treated animals xenografted 
with E98, and stained for MET, pMET and pAKT as indicated. Note that whereas Compound A 
dramatically reduces/prevents MET activation, this does not translate into decreased pAKT lev-
els, in contrast to treatment of E98 cells in vitro (see Figure 1). Magnification 20x. C) Compound 
A does not significantly reduce proliferation as indicated by FFPE IHC for the cell cycle mark-
ers Ki-67 (active cell cycling), BrdU incorporation (S-phase) and phospho-histone H3 (M-phase). 
Magnification 40x. All stainings were performed on tumours harvested when animals started to 
develop tumour-related symptoms. Magnification 40x.  (Next page)
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Resistance of E98FM cells to Compound A is regulated by in vivo events that are not 
recapitulated in vitro 
Of high interest, although Compound A effectively blocked AKT activation in vitro 
(Figure 1A), in treated E98FM xenografts pAKT levels were not different from those in 
control xenografts (see IHC on serial sections in Figure 4B), despite absence of activated 
MET. In contrast to effective in vitro tumoricidal activity, Compound A treatment of 
E98FM xenografts did not notably affect tumour cell proliferation in end-stage tumours, 
as demonstrated by Ki-67 staining (indicative of active cell cycling), BrdU incorporation 
(indicative of an active S-phase) and phosphorylation of histone H3 (a marker of mitosis; 
Figure 4C). We did not detect significant changes in apoptosis using immunostainings 
for caspase 3A (data not shown). To investigate whether E98FM cells that survived 
Compound A treatment in vivo were intrinsically resistant to Compound A in vitro, we 
established a cell line from Compound A-treated E98FM xenografts. Interestingly, under 
normal culture conditions the resulting cell line (E98FMA) expressed reduced levels of 
MET, pMET and pAKT as compared to the parental cell line. However, E98FMA cells 
were still equally sensitive as E98FM to Compound A, which effectively inhibited MET 
activation and AKT phosphorylation (Figure 5A). There was also no difference between 
E98FM and E98FMA cells with respect to Compound A effects on cell proliferation (Figure 
5B).
Figure 5. In vivo resistance to Compound A does not affect in vitro Compound A sensitivity. A) 
E98FM cells and E98FMA cells, prepared from a Compound A-treated E98 xenograft, were treated 
with 0, 100 or 1000 nM Compound A (30 min). Protein extracts were analyzed for MET, pMET 
and pAKT levels by western blot. GAPDH was used as a loading control. Note the lower levels 
of MET in E98FMA cells, that does however not translate into lower sensitivity to Compound A. 
B) MTT assays of E98FM and E98FMA cells. Note that both cell lines are equally sensitive to MET 
inhibition.
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In our previous study we reported that cabozantinib prevented extravasation of 
Gd-DTPA in contrast-enhanced MRI experiments, despite large tumour volumes 177. We 
attributed this effect to the VEGFR2 inhibition and subsequent vascular normalization, 
rendering brain tumour capillaries impermeable to MR contrast agents 219-223. To 
examine effects of Compound A on the blood-brain barrier, we subjected control 
and Compound A-treated mice to Gd-DTPA-enhanced MRI prior to sacrifice (see 
Supplementary File 4). As expected, Compound A treatment did not reduce vessel 
leakage in E98FM xenografts, as evidenced by the contrast-enhancement in CE-MRI in 
compact tumour regions after treatment (representative example in Supplementary 
File 4, Figure S3, H&E and MET stained sections in this panel correspond to the MRI 
slices). In line with this, extravasated mouse IgG was detected in compact tumour 
regions of treated xenografts (arrow in Supplementary Figure S3). The phenotypes 
of the Compound A-treated xenografts with respect to vascular leakage and levels of 
diffuse infiltrative growth resembled that of control xenografts 219,224.
MET inhibition of E98FM xenografts alters transcription of growth-stimulatory genes
To investigate the mechanisms of resistance of E98FM xenografts to Compound A 
and the sustenance of AKT phosphorylation levels, we performed w/RNA-NGS and 
investigated expression levels of tyrosine kinases and other genes that may act to 
rescue cells from MET inhibition. Figure 6 shows the results of this assay for a limited 
subset of genes. We found altered expression levels of a number of genes, notably a 
10-fold and 3-fold upregulation of EGFR and IGF1-R (insulin like growth factor 1-receptor), 
respectively (Figure 6A, B). Possibly due to sensitivity issues, these differences 
could not be validated on the protein level in immunohistochemical stainings (data 
not shown). In Compound A-resistant xenografts expression levels of interferon-α 
inducible protein (IFI6) were downregulated (significant by R analysis on N=1), and this 
was confirmed in qPCR assays in 4 independent Compound A-treated E98 xenografts 
compared with their control group (Figure 6C, p=0.03). Although the relevance of IFI6 
in cancer is unknown so far, this protein has been described as a negative regulator of 
EGFR activity 225. 
To investigate whether similar changes in gene expression are found in response 
to cabozantinib, we also performed w/RNA-NGS analysis on a cabozantinib-treated 
xenograft. Interestingly, in these tumours there was a trend towards upregulation of 
IGF1-R and PDGFRα, whereas, again, IFI6 was significantly downregulated (Figure 6A, 
B) as validated by qPCR in the same cabozantinib-treated E98 xenograft (Figure 6C, 
p=0.03). 
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Figure 6. Expression levels of a selection of genes in Compound A- and cabozantinib-treated 
E98 xenografts. A) A targeted analysis of a selection of genes, among others tyrosine kinases, re-
veals upregulation of especially EGFR (Compound A) and IGF1R (Compound A and cabozantinib) 
in E98 xenografts under MET inhibition. IFI6 is significantly downregulated after treatment with 
either compound (R analysis N=1). Y-axis values are expressed as Fragments per kilobase per 
million (FPKM). B) Heatmap representation of the Log(FPKM+1) values as represented in A). C) 
qPCR analysis confirmed downregulation of IFI6 after Compound A (N=4, 4 technical replicates, 
p=0.03) and cabozantinib (N=1, 4 technical replicates, p=0.03) treatment in E98 xenografts.
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Discussion
MET is increasingly being recognized as a target for cancer therapy, based on its 
pleiotropic biological roles in stimulating migration and proliferation while blocking 
apoptosis 190,226. Also, MET is involved in the stem-cell like phenotype in glioma and may 
provide a rescue pathway allowing tumour progression under anti-EGFR treatment 191-194 
or radiotherapy 192,201,202. MET is amplified in a significant proportion of glioblastomas 180, 
providing a solid rationale to test MET-inhibition as a therapeutic approach for this 
subgroup of cancers. 
The remaining high levels of pMET in cabozantinib-treated E98 xenografts 177 lead us to 
postulate that the anti-VEGFR2 activity of cabozantinib results in vessel normalization 
and restoration of the blood-brain barrier 206, hence interferes with drug delivery to 
the tumour cells 177,205,219. Such effects have also been observed in non-small cell lung 
cancer, in which docetaxel uptake by the tumour is diminished when co-administered 
with bevacizumab 227. This provided rationale to test alternative MET inhibitors for 
treatment of brain tumours, and here we present results of Compound A treatment 
of mice carrying orthotopic E98FM xenografts. E98 cells have an amplified mutated 
MET gene encoding an auto-active MET protein 24, a deletion of the tumour suppressor 
PTEN, a hypermethylated MGMT promoter and a homozygous deletion of CDKN2A 
209, all frequent aberrations in glioblastoma. Phenotypically, the orthotopic E98FM 
xenografts present with areas of angiogenesis, next to large areas of non-angiogenic 
diffuse infiltrative growth, all relevant aspects of clinical glioblastoma and emphasizing 
the value of this model for glioma research 211. 
Compound A blocked MET phosphorylation in E98 cells in vitro with IC50 values in the 
low nanomolar range. Subcutaneous U87-MG glioma xenografts were highly sensitive 
to Compound A and regressed at doses higher than 30 mg/kg. Using CE-MRI we here 
show that, in contrast to cabozantinib, Compound A does not normalize tumour 
blood vessels, in line with its lack of activity against VEGFR2 177,206. Consistently, MET 
activation levels of Compound A-treated orthotopic E98FM xenografts were greatly 
reduced compared to control-treated animals and cabozantinib-treated animals 
(Figure 4A, B). It is noteworthy that the compact E98 tumour areas with permeable 
vasculature (see Supplementary File 4, Figure S3) in Compound A-treated xenografts 
were completely devoid of pMET, whereas in the diffuse areas (with a relatively intact 
blood-brain barrier) some pMET could still be observed (Figure 4A). This suggests that 
the permeability status of the vasculature is an important determinant for delivery of 
Compound A to cancer cells in the brain. 
Differences between Compound A and cabozantinib obviously extend beyond VEGFR2 
inhibition, and involve differences in potency, interactions with ABC transporters 
of the blood-brain barrier determining brain exposure, and pharmacodynamic 
properties. Further studies are therefore warranted to investigate whether combined 
activity against cancer cell tyrosine kinase targets and endothelial VEGFR2 hampers 
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brain distribution and is counter-effective for treatment of diffuse gliomas, as our work 
suggests. This especially holds for drugs that are substrate for the ABC transporters 
in brain endothelium (which comprise 95% of drugs 228). Detailed information on 
blood-brain barrier behaviour for Compound A is currently lacking. Additional 
experiments on drug pharmacokinetics and –dynamics are essential to prove that 
selective targeting with Compound A is superior over a multi-targeted approach with 
cabozantinib.
Compound A treatment of E98-xenografted mice resulted in a significant prolongation 
of survival, yet did not prevent progression of resistant tumours, opposite to its effects 
in vitro. An intriguing observation was that whereas Compound A effectively inhibited 
MET phosphorylation both in vitro and in vivo, it abolished phosphorylation of AKT 
in vitro but not in vivo (Figure 4B). This strongly suggests that in vivo, rescue signal 
transduction pathways are switched on that cannot be activated under standard in 
vitro culture conditions. Our data suggest that upregulation of alternative rescue 
kinases, such as IGF1-R and EGFR or PDGFRα, combined with downregulation of IFI6, 
may collectively add up to levels allowing tumour progression under monotherapy. By 
adjusting the collection of growth factor receptors on their surface, the glioblastoma 
cells apparently find novel ways to tap the catalogue of survival signals provided by 
the (in this case mouse) brain parenchyma. These data warrant further studies to 
investigate whether tyrosine kinase inhibitors cause resistance by induction of generic 
transcriptional rescue profiles.
In line with this hypothesis E98FMA cells, isolated from a Compound A treated animal, 
had already started to reduce MET expression (which indeed would be futile under 
Compound A therapy in vivo) whereas under in vitro culture conditions these cells 
remained highly dependent on MET signalling (Figure 5). This makes the combination 
of E98 xenografts and corresponding cell lines to a powerful model system to 
study the mode of resistance to MET inhibition 229 and simultaneously points to the 
importance of using models of glioma in which interactions between tumour and brain 
micro-environment are properly recapitulated 211. 
In conclusion, we show that Compound A is a highly selective MET kinase inhibitor with 
activity against glioblastoma. We further show that the plasticity of glioblastoma cells, 
especially when in the presence of their relevant brain tumour micro-environment, 
allows adaptation resulting in treatment resistance. Knowledge of the mechanisms of 
resistance may allow more effective individualized treatment protocols by combining 
targeted drugs with drugs that a priori block or circumvent resistance pathways. 
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Table S1. Molecular characteristics of MET in cell lines used in this study.
Chemical structures
Figure S1. Chemical structures of  Compound A (A) and AMG  458 (B).
Supplementary File S2
Immunoblotting and immunohistochemistry antibodies
Primary antibodies used for immunoblotting were: rabbit-anti-MET (1:2500, CST, 
#8198), rabbit-anti-pMET Tyr1234/Tyr1235 (1:2500, CST, #3077), rabbit-anti-pERK1/2 
Thr202/Tyr204 (p44/p42, 1:500, CST, #4376), rabbit-anti-pAKT S473 (1:2500, CST, 
#4060), anti-pGab-1 Tyr627 (1:2000, CST, #3231), rabbit-anti-VEGFR2 (1:2000, CST, 
#2479), rabbit-anti-pVEGFR2 Tyr1175 (1:1000, CST, #2478), mouse-anti-GAPDH (1:5000, 
Abcam, ab8245), mouse-anti-α-tubulin (1:5000, Molecular Probes/Thermo Fisher 
Scientific, A-11126).
Primary antibodies used for immunohistochemistry were: rabbit-anti-MET (FFPE 1:600, 
frozen sections 1:200, CST, #8198), rabbit-anti-pMET Tyr1234/Tyr1235 (FFPE 1:100, frozen 
sections 1:400, CST, #3027), rabbit-anti-pAKT S473 (1:50, CST, #4060), rabbit-anti-Ki-67 
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(1:200, Thermo Fisher Scientific, #RM-9106), sheep-anti-BrdU (1:2000, Abcam, ab1893), 
rabbit-anti-phospho-histone H3 Ser10 (1:100, CST, #9701), rabbit-anti-caspase-3A 
(1:1000, BD Medical Technology, #559565), and horse-anti-mouse-IgG (1:100, Vector 
laboratories, BA-2000).
Figure S2. Compound A blocks MET phosphorylation and activity in vivo. A) In vivo  mouse liver 
pharmacodynamics assay. Balb-C mice (n=3 per group) were treated with vehicle (black bars) or 
with the indicated doses of Compound A (grey bars). Six hours after dosing, the mice received 
an intravenous injection of HGF (12 µg) to induce MET phosphorylation, or BSA as a negative con-
trol. Liver and plasma samples were collected 5 minutes later and analyzed for MET phosphor-
ylation (left axis) and unbound plasma concentrations (black circles, right axis), respectively. 
Results represent the mean +/- SD. Percentages represent Compound A-mediated inhibition of 
MET phosphorylation, relative to the HGF control  group. * p<0.0001 (ANOVA/Bonferroni Dunn 
post-hoc test). B) In vivo xenograft PD assay. Nude mice bearing TPR-MET tumours were un-
treated (n=2 per group)or treated (n=3 per group) once with different doses of Compound A 
as indicated. Tumours were collected at different time points and analyzed by western blot for 
levels of Gab-1 phosphorylation.
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Supplementary File S3
Liver and tumour pharmacodynamics assays
The effect of Compound A on MET phosphorylation in normal mouse liver was 
evaluated as follows: a single dose of Compound A was administered by oral gavage at 
3, 10 or 30 mg/kg 6 hours prior to euthanasia. MET phosphorylation was induced in the 
livers of female Balb/C mice by intravenous injection of 12 µg of human recombinant 
HGF, 5 minutes prior to euthanasia. Levels of MET phosphorylation were determined 
by an electrochemiluminescent immunoassay (IGEN International, Inc., Gaithersburg, 
MD, USA). Statistical significance was determined by ANOVA followed by Bonferroni 
Dunn post-hoc test. Results are presented in Figure S2A.
To determine the effect of Compound A on phosphorylated (p)Gab-1 levels in 
MET-expressing tumours in vivo, female CD1 nu/nu mice were injected subcutaneously 
with 1x106 translocated promoter region (TPR)-MET cells 230. Mice were treated with a 
single dose of vehicle or Compound A (5, 10 or 30 mg/kg) when tumours reached 400 
to 700 mm3. Tumours were harvested at 1, 3, 6, 8, 10, or 12 hours post dose, and lysates 
were prepared for immunoblot analysis. Levels of pGab-1 were quantified using a 
ChemiDoc™ chemiluminescence imaging system (Bio-Rad, Hercules, CA, USA). Results 
are presented in Figure S2B.
Figure S3. Compound A does not normalize tumour blood vessels in E98 xenografts. Repre-
sentative example of T1-weighted MRI of a Compound A-treated E98-bearing animal before 
(pre) and 2-3 minutes after (post) Gd-DTPA injection. Post-pre represents the subtracted image. 
For comparison, an H&E staining and IHC images for MET (tumour marker for E98) and mouse 
IgG (demonstrating vessel leakage) of the same animal are shown. Note the arrow depicting a 
tumour region with IgG leakage. D=diffuse tumour, C=compact tumour, N=Normal brain.
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Magnetic Resonance Imaging 
Mice with orthotopic E98-FM xenografts were subjected to contrast-enhanced 
magnetic resonance imaging (MRI) when tumour-related symptoms were apparent 
(>15% weight loss within 2 days, neurologic abnormalities). Animals were anesthetized 
by isoflurane (3.5% for induction and 2% for maintenance) and placed in a stereotactic 
device in order to immobilize the head. Breathing frequency was monitored throughout 
the MR experiment and body temperature was monitored by a rectal thermometer 
and maintained at 37°C using a continuous warm air flow (SA Instruments, Inc., Sunny 
Brook, NY, USA). Images were acquired on an 11.7T BioSpec Avance III small animal 
MR system (Bruker BioSpin, Ettlingen, Germany) equipped with an actively shielded 
gradient set (600 mT/m) and Paravision 5.1 software. A circular polarized volume 
resonator and an actively decoupled mouse brain quadrature surface coil were 
employed as transmit and receive coils, respectively. 
After standard adjustments pre- and post-contrast MRI was performed on 
E98 xenografts by injecting gadolinium-DTPA (0.3 mmol/kg) using a RARE T1-w 
sequence with the following parameters: TR=1500ms, TE=7.5ms, FOV=30×30mm2, 
matrix=256×256, slice thickness=1mm, TA=1min. Post-contrast images were subtracted 
from pre-contrast images (post-pre) to visualize extravasated Gd-DTPA using Bruker 
software. Results are shown in Supplementary Figure S3.
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Cancer-specific metabolic alterations are of high interest as therapeutic targets. These 
alterations vary between tumour types, and to employ metabolic targeting to its 
fullest potential there is a need for robust methods that identify candidate targetable 
metabolic pathways in individual cancers. Currently, such methods include 13C-tracing 
studies and mass spectrometry/magnetic resonance spectroscopic imaging. Due to 
high cost and complexity, such studies are restricted to a research setting. 
We here present the validation of a novel technique of metabolic profiling, based on 
multiplex targeted next-generation sequencing of RNA with single molecule molecular 
inversion probes (smMIPs), designed to measure activity of and mutations in genes 
that encode metabolic enzymes. We here profiled an isogenic pair of cell lines, 
differing in expression of the Von Hippel Lindau protein, an important regulator of 
hypoxia-inducible genes. We show that smMIP profiling provides relevant information 
on active metabolic pathways.
Because smMIP-based targeted RNA sequencing is cost-effective and can be applied 
in a medium high-throughput setting (200 samples can be profiled simultaneously in 
one next-generation sequencing run) it is a highly interesting approach for profiling of 
the activity of genes of interest, including those regulating metabolism, in a routine 
patient care setting.
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Introduction
In the past four decades an overwhelming amount of data has become available on 
the molecular events that underlie carcinogenesis. Research has mainly focused on 
molecular alterations and their consequences for, among others, the PI3K/pAKT/
mTOR pathway 24,231-233 and cell cycle control, apoptosis 234,235 and DNA repair pathways 
236,237. Currently, numerous FDA-approved drugs are available that target cancer cells 
based on these genetic defects with a level of specificity that is not attainable with 
conventional chemotherapies 238,239, permitting personalized medicine. Whereas 
targeted cancer therapies may prolong survival, it is now widely recognized that 
inherent genetic instability and tumour plasticity ultimately leads to therapy resistance 
of most cancers 240-243. 
Whatever the underlying oncogenic mutations, for proliferation cancer cells need to 
generate ATP to maintain energy balance and ion homeostasis, import carbon and 
nitrogen sources for synthesis of amino acids, nucleotides and lipids 244,245 and maintain 
redox potential to protect cells against oxidative stress 246. Blocking one or more of 
these processes with specific inhibitors may prohibit proliferation and/or sensitize 
cells to toxic therapy in a synthetic lethality approach 247. As an example, increasing 
oxidative stress in a cancer with metabolic inhibitors (e.g. of enzymes that produce 
NADPH) may enhance the efficacy of radiotherapy 248 or chemotherapy 249. With the 
increasing knowledge of deranged metabolic pathways in cancer 250-253 (adjuvant) 
targeting of cancer-specific metabolic pathways may be a highly interesting addition 
to current treatment protocols. 
The best-known example of cancer-specific metabolic adaptation is aerobic glycolysis, 
also known as the Warburg effect 254. Warburg tumours produce lactate from pyruvate, 
rather than shuttle pyruvate into the mitochondrial tricarboxylic acid (TCA) cycle. 
As glycolysis is inefficient in terms of ATP production, cancer cells characteristically 
upregulate expression of genes encoding glucose transporters GLUT1 and/or GLUT3, 
hexokinase 2, monocarboxylate transporters (to secrete lactate) and carbonic 
anhydrase IX and XII (to ensure pH homeostasis) 255. Besides glucose, glutamine and 
fatty acids are recognized as important fuels for cancer cells that adjust expression of 
metabolic enzymes accordingly 206,256-258. 
While metabolic adaptations are mostly seen as a consequence of carcinogenesis, 
it has been unequivocally established that metabolic alterations can also cause 
cancer, examples being mutations in genes encoding succinate dehydrogenase (SDH, 
pheochromocytoma and paraganglioma), fumarate hydratase (FH, papillary renal 
cancers) and isocitrate dehydrogenase 1 and 2 (IDH1/2, among others acute myeloid 
leukaemia and gliomas) 259-265. Clear cell renal cell carcinoma (ccRCC) is also considered 
a metabolic cancer with metabolic alterations resulting from inactivating mutations in 
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or epigenetic silencing of VHL found in ~80% of cases 266,267. pVHL is a major regulator 
of ubiquitination and breakdown of hypoxia inducible transcription factors HIF-1α 
and HIF-2α 266. Mutations in the aforementioned metabolic enzymes and in VHL have 
been shown to induce epigenetic alterations that affect expression of other metabolic 
enzymes in an unpredictable fashion 268-271. 
To apply inhibitors of metabolism as potential additions to the current anti-tumour 
armamentarium, it is of high importance to identify which metabolic pathways 
are active in a specific cancer in a personalized fashion. Here we applied a novel 
next-generation sequencing-based method using single molecule molecular inversion 
probes (smMIPs 272), to detect expression levels of 104 genes involved in metabolism, 
and concomitantly identify variants therein. As a proof of concept, we applied smMIPs 
to map part of the metabolic transcriptome of a VHL-defective ccRCC cell line and a 
VHL-rescued isogenic derivative, as well as in four clinical samples of clear cell renal cell 
cancers, with matching normal kidney tissue, and patient-derived glioma xenograft 
models. We validated the technique by correlating results with whole transcriptome 
RNA next-generation sequencing data (w/RNA-NGS, as gold standard for transcriptome 
analysis) and protein expression. We further verified the ability of the assay to detect 
oncogenic mutations in cell lines and patient tumour tissues.
Our data show that targeted RNA next-generation sequencing (t/RNA-NGS) of 
transcripts encoding metabolic enzymes using smMIPs predict the predominant 
metabolic pathways that are operational in cancer and simultaneously allows variant 
detection in the targeted transcripts.
Materials and Methods
Cell lines
The cell line SKRC7 is derived from a primary human ccRCC and has been described 
before 273. Cells were cultured in RPMI 1640 (Lonza Group, Switzerland) supplemented 
with 10% fetal calf serum (FCS; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 
40 µg/ml gentamycin (Centrafarm, Etten-Leur, The Netherlands). An isogenic SKRC7 
cell line expressing a functional haemagglutinin (HA)-tagged VHL (SKRC7-VHLHA) 
was created by transfection with pcDNA3.1-VHLHA followed by selection of stable 
transfectants in the same medium with 400 µg/ml geneticin (Gibco, Thermo Fisher 
Scientific, Waltham, MA, USA). The patient-derived glioma xenograft models E478 and 
E98 have been described before 209,274.
Patient material
Use of patient material for this study was approved by the local ethical committee of 
Radboudumc, and involved prior informed consent. All methods were performed in 
accordance with the guidelines for use of human tissue of the Radboudumc. Tissue 
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was analysed in a to the researcher team anonymized manner. Surgically obtained 
tissue from a patient with a grade III astrocytoma was snap frozen in liquid nitrogen. 
From four patients suspected for clear cell renal cell cancer, tissue was collected 
shortly after tumour nephrectomy and snap frozen.
RNA and cDNA preparation
Total RNA was isolated from sections of snap-frozen E478 xenograft tissue, human 
tumour tissues and from 80% confluent SKRC7 and SKRC7-VHLHA cells using TRIzol 
reagent (Life Technologies, ThermoFisher Scientific, Waltham, MA, USA) according to 
the manufacturers’ instructions. RNA quality was estimated based on relative levels 
of 28S, 18S and 5S rRNA bands on agarose gel and with Bioanalyzer assays (Agilent 
Technologies, Amstelveen, The Netherlands). RNA was reverse transcribed to cDNA 
using Superscript II reverse transcriptase (Invitrogen, ThermoFisher Scientific, 
Waltham, MA, USA) and random hexamer primers (Promega, Madison, WI, USA) 
according to standard protocols. Next, cDNA was purified using the NucleoSpin Gel 
and PCR Clean-up kit (Macherey-Nagel, Düren, Germany). For quality control, cDNA 
was subjected to PCR for reference gene hydroxymethylbilane synthase (HBMS) 
with forward primer HMBSFw (5’-CTGGTAACGGCAATGCGGCT-3’) and reverse primer 
HMBSRv (5’-TTCTTCTCCAGGGCATGTTC-3’) using AmpliTaq Gold 360 master mix 
(Applied Biosystems, ThermoFisher Scientific, Waltham, MA USA). 
Whole transcriptome RNA next-generation sequencing analysis
High quality RNA with RIN scores >8 was subjected to w/RNA-NGS at the genomics core 
facility of the Netherlands Cancer Institute according to standard protocols. Sequencing 
was performed on an Illumina Hiseq and yielded 30-50 million reads per sample (paired 
end sequencing protocol). The dataset was analysed using the ‘Tuxedo’ protocol; reads 
were mapped against the RefSeq human genome (GRCh37.55) with TopHat and final 
transcript assembly was done with the Cufflinks package 213. FeatureCount was used on 
the BAM files to extract gene counts which were then transformed to transcript per 
million mapped reads (TPM) to obtain relative expression values. Occurrence of single 
nucleotide variants was visualized in the Integrated Genomics Viewer browser (IGV, 
the Broadinstitute).
smMIP design 
The technique of t/RNA-NGS using smMIPs is depicted in Figure 1. It is based on the 
hybridization of an extension and ligation probe, joined by a backbone sequence, in 
an inverted manner to a cDNA of interest, followed by gap-filling/ligation and PCR. 
SmMIPs against the antisense strand of 104 predicted transcripts (UCSC human genome 
assembly hg19) were designed based on the MIPgen algorithm as described by Boyle 
et al. 275. Whenever possible, smMIPs were designed with ligation and extension probes 
located on adjacent exons to prevent contribution of smMIP probes that hybridize 
to potential contaminations of genomic DNA. Transcripts of interest were encoding 
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enzymes and transporters functioning in various metabolic pathways, including lipid 
metabolism, glycolysis, oxidative phosphorylation (OXPHOS), tricarboxylic acid (TCA) 
cycle, pentose phosphate pathway (PPP), glutaminolysis and control of reductive 
potential (see Table 1). The smMIP set also contained probes for detection of β-actin 
and β-tubulin as housekeeping genes, and a number of tyrosine kinases with relevance 
for cancer. SmMIPs were designed with extension probes of 16 to 20 nt in length 
and ligation probes of 20-24 nt in length, joined by a constant backbone sequence 
(40 nt) with a stretch of 8 random nucleotides (unique molecule identifier, UMI) 
incorporated adjacent to the ligation probe. The UMI is incorporated to reduce all 
amplicons originating from one individual smMIP to one unique MIP (see below). The 
length of gap-fill was set at 112 nt. Whereas the design was based on full coverage, for 
the majority of transcripts 5-10 smMIPs per transcript were included in the panel with 
the target regions distributed evenly over the reading frame. For 18 transcripts (CS, 
D-2HGDH, L-2HGDH, FH, IDH1-3A-G, MDH1-2, MYC, OGDH, SDHA-D, VHL) smMIP sets were 
chosen that covered the full coding sequences. 
Figure 1. Principle of smMIP-based targeted RNA sequencing. The procedure depends on the 
hybridization of molecular inversion probes consisting of a ligation and an extension probe that 
are connected via a backbone. Capture hybridization leaves for each smMIP a gap of 112 nt that 
is enzymatically extended and closed by ligation. After exonuclease digestion of non-ligated 
probes, the remaining library of circularized smMIPS is PCR-amplified with primers in the smMIP 
backbone. Note that the ligation probe is flanked by a random 8N sequence that allows correc-
tion for PCR duplicates. During PCR, for each sample a unique barcode primer is used allowing 
identification of sample-specific reads.
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          Table 1. Metabolic transcripts for smMIP design.
Boek 1.indb   55 23-3-2020   11:50:20
542469-L-bw-vd Heuvel
Processed on: 24-3-2020 PDF page: 56
56
Chapter 3
Boek 1.indb   56 23-3-2020   11:50:21
542469-L-bw-vd Heuvel
Processed on: 24-3-2020 PDF page: 57
57
Profiling of the metabolic transcriptome via single molecule molecular inversion probes
3
Capture and library preparation 
Generation of libraries was performed with a procedure adapted from O’Roak et al 
276. In short, 642 smMIPs (IDT, Leuven, Belgium) were pooled at 100 µM/smMIP. The 
smMIP pool was phosphorylated using T4 Polynucleotide Kinase (New England Biolabs, 
NEB, Ipswich, MA, USA) in T4 DNA ligase buffer (NEB) at 37°C for 45 min, followed by 
inactivation for 20 min at 65°C. The capture reaction was performed with 50 ng of 
cDNA and an estimated 8000-fold molar excess of the phosphorylated smMIP pool 176 
in a 25 μl reaction mixture containing Ampligase buffer (Epicentre, Madison, WI, USA), 
dNTPs, Hemo KlenTaq enzyme (New England Biolabs, NEB, Ipswich, MA, USA) and 
thermostable DNA ligase (Ampligase, Epicentre). The capture mix was incubated for 
10 min at 95 °C (denaturation), followed by incubation for 18 h at 60 °C, during which 
hybridization and concomitant primer extension and ligation occurs. Directly after this 
step non-circularized smMIPs, RNA and cDNA were removed by treatment with 10 U 
Exonuclease I and 50 U of Exonuclease III (both NEB) for 45 min at 37°C, followed 
by heat inactivation (95°C, 2 min). The circularized smMIP library was subjected to 
standard PCR with 2x iProof High-Fidelity DNA Polymerase master Mix (Bio-Rad, 
Hercules, CA) with a primer set containing a unique barcoded reverse primer for each 
sample. Generation of PCR products of correct size (266 bp) was validated on agarose 
gel electrophoresis, and PCR-libraries from different samples were pooled based on 
relative band intensity. The pool was then purified using AMPureXP beads (Beckman 
Coulter Genomics, High Wycombe, UK) according to manufacturers’ instructions. The 
purified library was run on a TapeStation 2200 (Agilent Technologies, Santa Clara, CA, 
USA) and quantified via Qubit (Life Technologies, ThermoFisher Scientific, Waltham, 
MA USA) to assess quality of the library. 
Reproducibility of the technique was tested by preparing biological replica libraries, 
using different RNA preparations from the same cell lines.
Sequencing and annotation 
Libraries were sequenced on the Illumina NextSeq platform (Illumina, San Diego, CA) 
at the Radboudumc sequencing facility to produce 2x 150 bp paired-end reads. Reads 
were mapped to the reference transcriptome (hg19) using the SeqNext module of JSI 
SequencePilot version 4.2.2 build 502 (JSI Medical Systems, Ettenheim, Germany). The 
random 8 nt sequence flanking the ligation probe was used to reduce PCR amplicates 
to one smMIP (unique reads). 
Single nucleotide variant calling and expression analysis
All single nucleotide variants (SNV) called with a minimal variant percentage of 5% 
detected in at least 5 unique reads (forward and reverse) were selected for further 
analysis. Variants were annotated and classified into synonymous or non-synonymous. 
Next, they were validated in w/RNA-NGS data, generated from different RNA isolations 
from the same cell lines. 
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Individual read counts for each smMIP were divided by the total read count within 
a sample and multiplied by 106 resulting in a fragment per million (FPM) value for 
each smMIP in a sample. We choose for this normalization procedure instead of 
normalization against housekeeping genes because perfect housekeeping genes do 
not exist. 
Western blotting
Cell extracts were prepared from SKRC7 and SKRC7-VHLHA cells by solubilizing in 
RIPA buffer (Cell Signalling) and protein concentrations were determined using BCA 
assays. 20 µg of protein was separated on 12% SDS-PAGE gels and electroblotted 
on nitrocellulose. After blocking in Odyssey blocking buffer (1:1 in PBS) membranes 
were incubated overnight in Odyssey blocking buffer containing antibodies against 
HK-2 (2867S, Cell signalling technology), CAIX (M75, Dr. Oosterwijk) or γ-tubulin (C20, 
Santa Cruz Biotechnology, Dallas, TX) as loading control. Antibodies were detected 
with secondary antibodies conjugated with Alexa680 or DyLight800, and signal was 
visualized with the Odyssey scanner (LI-COR).
Statistics 
FPM values for each transcript (mean FPM values from all smMIPs targeting one 
transcript) were correlated with TPM values (transcripts per million values for the 
same transcript obtained from w/RNA-NGS data) from the same cell lines. For three 
samples replicate assays were performed. Correlation analyses were performed using 
GraphPad Prism v.5.03 (GraphPad, San Diego, CA, USA).
Data availability
Data relating to this manuscript (excel files with FPM values) will be made available to 
researchers upon request.
Results
SmMIP-based library preparation and sequencing
SmMIP-based next-generation sequencing (NGS) of genomic DNA was recently 
introduced in routine diagnostics in our institute to detect tumour-associated 
mutations in DNA 176. To investigate whether smMIPs can also be used for multiplex 
determination of gene expression levels, concomitant with variant detection, we 
designed a smMIP set for targeted detection and sequencing of 104 transcripts 
encoding metabolic enzymes (see Table 1) and 18 tyrosine kinases with relevance 
for oncology (not shown). The technique is summarized in Figure 1, and consists of 
annealing of a panel of hundreds of specifically designed smMIPs to cDNAs of interest 
in a sample. SmMIPs are composed of a ligation and extension probe, connected by a 
backbone. After hybridization of an individual smMIP to its target cDNA via its specific 
ligation and extension probes, a gap of 112 nt is left which is then enzymatically filled 
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and ligated, leaving a library of circularized smMIPs. After purification and PCR with 
barcoded primers in the smMIP backbone, the library is subjected to next-generation 
sequencing followed by bio-informatic analysis (see Materials and Methods for details).
To establish the strength of the technique we used the VHL-defective ccRCC cell line 
SKRC7 273 and its VHL-complemented variant SKRC7-VHLHA (expressing functional 
VHL with a haemagglutinin-tag) as a prototypical isogenic cell line pair with different 
metabolic characteristics: the lack of VHL in SKRC7 results in constitutive stabilization of 
HIF-1α and HIF-2α and a pseudohypoxic response 267,273,277. Re-introduction of VHL leads 
to restored HIF1/2 breakdown and normalized expression levels of hypoxia-induced 
genes. 
w/RNA-NGS derived gene expression data of SKRC7 cells (used here as gold standard) 
confirmed the presence of a nonsense and functionally inactivating Q132-stop 
mutation in 100% of VHL transcripts (Figure 2A) whereas only wild-type VHL transcripts 
were detected in the SKRC7-VHLHA (Figure 2B), and this was readily reproduced in the 
smMIP assay (Figure 2C, D). Overexpression of VHL transcripts in SKRC7-VHLHA cells 
was observed both in w/RNA-NGS datasets (expressed as Transcript per Million, TPM) 
and in smMIP based datasets (expressed as Fragment per Million, FPM; Figure 2E). 
Overexpression was also seen on the VHL protein level (see western blot in Figure 2F). 
Optimization of library preparation
Using an initial set of 642 smMIPs, covering the 104 transcripts of interest for this 
study (see Table 1), we tested our protocol of library preparation with 50 ng of 
hexamer-primed cDNA on 13 different RNA samples (cell line- and xenograft-derived) of 
which also w/RNA-NGS datasets were available. A 25-cycle PCR with barcoded primers 
on the circularized smMIP library yielded PCR fragments of the expected size of 266 
bp (not shown). Illumina NextSeq sequencing of the libraries generated with RNA 
from SKRC7 and SKRC7-VHL cells, yielded 286,000 and 69,000 annotated unique reads 
respectively (corrected for PCR-amplicates based on the unique molecule identifier 
[UMI] sequence in the smMIP), which is in the range of other samples run with the 
same smMIP panel (not shown). For most transcripts, performance of individual 
smMIPs varied greatly, a known phenomenon also in DNA smMIP NGS 176 (see example 
in Table 2, showing FPM values for 10 different smMIPs designed against the VHL 
transcript in both cell lines). This was a priori reason to include at least 5 smMIPs per 
gene transcript in our panel, allowing transcriptome analysis using mean FPM values 
for each transcript. This number was a trade-off between generating expensive, 
large panels which would yield in part futile and irrelevant data, and too small panels 
resulting in under- or overestimation of transcript levels. 
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Figure 2. A, B) IGV representation of the VHL locus of SKRC7 and SKRC7-VHLHA cells. BAM files 
containing whole RNAseq data from these cell lines were loaded into IGV. Note the CAA-UAA 
mutation, resulting in the VHL Q132-stop mutation at the protein level. C, D) SeqNext represen-
tations of the same VHL locus of SKRC7 (C) and SKRC7-VHLHA cells (D). E) Bar graph showing 
VHL-related TPM and FPM values of SKRC7 and SKRC7-VHLHA. F) Western blot of SKRC7 cells 
and the VHL-expressing derivative, stained with an anti-HA antibody and an antibody against 
γ-tubulin as control housekeeping protein. Panel (F) represents 2 cropped images from different 
western blots, loaded with the same protein samples, derived from SKRC7 and SKRC7-VHL cells 
as indicated. The corresponding full length blots are presented in Supplementary Figure S1.
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Table 2. Variability in FPM values for different smMIPs designed to detect VHL.
First, we compared the smMIP-based t/RNA-NGS dataset to a w/RNA-NGS dataset 
(considered as gold standard), performed on different RNA isolates from the same cell 
lines. The w/RNA-NGS dataset consisted of 3.2x107 and 3.4x107 reads, assigned to 44,503 
different transcripts for SKRC7 and SKRC7-VHLHA, respectively. For each transcript of 
interest, TPM values from the w/RNA-NGS dataset were plotted against mean FPM 
values from smMIP analyses. When performed separately for metabolic transcripts 
and tyrosine kinase transcripts, these analyses gave correlation coefficients of 0.903 
and 0.974, respectively, for SKRC7 (Figure 3A, B) and 0.784 and 0.903, respectively, 
for SKRC7-VHLHA (Figure 3C, D), suggesting that, as expected, expression of metabolic 
genes is subject to more biological variation than of tyrosine kinases. Plotting w/
RNA-NGS data against unique reads obtained with the best performing smMIP per 
transcript, or the median of unique reads for each transcript (to prevent bias by non- or 
poor-performing smMIPs) did not improve this correlation (not shown). 
One of the appealing characteristics of t/RNA-NGS using smMIPs is that panels can 
be expanded to detect additional transcripts. To test how this affects the outcome 
of the assay, we added to our initial panel 222 smMIPs for targeted detection and 
sequencing of other transcripts of interest and re-performed the assay using newly 
isolated RNA from the same cell lines. Relative levels of transcripts within samples 
correlated well between assays with the initial and the expanded smMIP set (SKRC7: 
r=0.903, SKRC7-VHLHA: r=0.876).
Functional validation of targeted smMIP data 
Having confirmed the validity of the smMIP dataset, we analysed expression levels 
of genes involved in metabolism in SKRC7 and SKRC7-VHLHA cells. Figure 4A and 4B 
show two biological duplicates of smMIP-based mean FPM values for a number of 
transcripts involved in glycolysis. Expression of HIF target genes glucose transporter 
1 and 3 (SLC2A1 and SCL2A3), monocarboxylate transporter MCT4 (SLC16A3), carbonic 
anhydrases IX and XII (CAIX, CAXII), hexokinase 2 (HK2), lactate dehydrogenase A
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Figure 3. SmMIP-based targeted RNA sequencing correlates well with whole transcriptome 
RNAseq. Mean smMIP-based metabolic FPM levels (A, C)  and tyrosine kinase transcript FPM 
levels (B, D) were plotted to TPM levels of the same transcripts, extracted from whole RNAseq 
data. Note that the transcripts with very low FPM values (10-2 FPM) were not detected in the 
RNAseq dataset. We included these transcripts in these analyses although they may have low-
ered the Pearson coefficient.
(LDHA) and phosphoglycerate kinase (PGK1) were significantly and reproducibly 
reduced in SKRC7-VHLHA cells relative to SKRC7 cells (Figure 4A, B), in line with data 
obtained from w/RNA-NGS data (Figure 4C). Relative expression levels of CAIX and HK2 
transcript levels were further confirmed on the protein level (Figure 4D). The strong 
reduction of CAIX, HK2 and LDHA, all target genes of HIF, was in line with expectations. 
We next tested the assay on clinical renal cell cancers. Of four tumour nephrectomies 
we sampled normal kidney tissue and matched tumour for smMIP profiling. Striking 
and highly significant differences were found between normal kidney and tumour 
tissue, with high levels in tumour samples of transcripts of HIF target genes SLC2A1 
(encoding glucose transporter GLUT-1), monocarboxylate transporter SLC16A3 (MCT4), 
CAIX, and LDHA, and low levels of LDHB in contrast to matched normal kidney (Figure 
4E). Furthermore, the assay readily detected a somatic stop mutation in VHL in renal 
cell cancer, but not in the corresponding normal kidney tissue (Table 3).
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Variant detection
To investigate whether smMIP based t/RNA-NGS allows efficient detection of SNVs, 
we performed variant calling of the smMIP library in SeqNext software. Several 
heterozygous and homozygous variants were detected that could be validated in the 
w/RNA-NGS dataset (see VHL example in Figure 2C and D). We then further validated 
the sensitivity of the assay to detect SNVs (called a variant in relation to reference 
genome hg19) and performed smMIP analysis on RNA, isolated from the IDH1R132H 
mutant oligodendroglioma line E478 278 and the astrocytoma cell line E98, in which 
we previously identified a novel mutation in IDH1 (IDH1R314C) 263. Both mutations were 
identified (Figure 5A, B). Finally, a patient glioma with a genetically confirmed IDH1R132H 
mutation was subjected to the assay. Again, the mutation was readily detected (Figure 
5C).
Figure 4. SmMIP-based targeted RNAseq reveals decreased expression levels in SKRC7-VHL cells 
of glycolysis related genes a.o. SLC2A1, CAIX, HK2 and LDHA in two independent duplicate ex-
periments (A, B). Relative values were comparable to those obtained from whole transcriptome 
RNAseq analysis (C), which is in agreement with the correlation shown in Figure 3. Differences in 
expression levels were validated on the protein level for HK2 and CAIX, using γ-tubulin as house-
keeping control (D). Gene transcript levels of hypoxia inducible genes are very high in surgically 
obtained clear cell renal cell cancer samples, relative to peri-tumourally obtained normal kidney 
tissue (E). *: p=0.01; **: p<0.003, ***: p<0.0003, Students’ T-test.
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Table 3. Somatic mutation (frame shift resulting in a stop) in VHL in renal cell cancer, but not in 
peritumoral non-neoplastic tissue.
Figure 5. SmMIP-based targeted RNA next generation sequencing can be used for adequate 
variant calling. Shown are the loci containing the IDH1-R132H mutation in E478 xenografts (A) 
and in a clinical grade III astrocytoma (C, this mutation was confirmed by genetic analysis), 
whereas the IDH1-R314C mutation in E98 cells could also be identified (B).
Discussion
Currently, identifying metabolic pathways in tissues is only feasible in a research 
setting, inferring metabolic pathways from metabolite concentrations as detected 
with in vivo 1H-, 13C- or 31P-based magnetic resonance spectroscopic imaging 206,279 or 
mass spectrometry 280-282. These techniques cannot be applied for routine patient 
diagnostics. Although profiling of the activity of metabolic genes cannot be considered 
as equivalent to metabolomic analysis or metabolic flux analysis, we here show that 
smMIP-based t/RNA-NGS can be applied to any tissue and does yield reliable functional 
information, as demonstrated here by analysis of effects of VHL-reconstitution in 
ccRCC. We further present evidence that profiling of clinical renal cell cancer tissues 
as expected shows high levels of hypoxia-induced genes suggesting extensive 
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glycolysis, while also unambiguously revealing the presence of VHL mutations, all 
in line with known biology of these cancers. Similarly, the assay unambiguously 
identifies the IDH1R132H mutation in glioma, with 50% mutant/wild type reads, confirming 
heterozygosity for this mutation.
SmMIP-based t/RNA-NGS has advantages over w/RNA-NGS. It yields workable data at 
a fraction of the cost of w/RNA-NGS, and smart positioning of extension and ligation 
target sequences allows the design of splice-variant-specific smMIPs. Furthermore, 
smMIP sets can be extended at any time with novel smMIPs of interest without 
affecting performance. Efficacy of different smMIPs that are designed to detect the 
same transcript is variable. As for now, it is difficult to discriminate between low 
intrinsic efficiency of a smMIP and low abundance of the target sequence (e.g. in case 
of pseudo-exons), and these issues should be resolved for individual genes. Related to 
this it must be realized that reliable detection of mutations or splice variants depends 
on the efficacy of smMIPs covering the area of interest. This may present a problem 
when trying to detect mutations in VHL using smMIPs 1, 8 or 10. A way of improvement 
could be to rebalance the smMIP concentrations in the capture pool for smMIPs 
having low capture efficiency. With the generation of a database containing t/RNA-NGS 
datasets from large numbers of cancers with the same smMIP panel it will become 
possible in the future to assign a value of relevance to individual smMIPs. Targeting 
of cancer-specific metabolic pathways is gaining importance in cancer research. Since 
decades glycolysis has been considered the predominant metabolic pathway in cancer, 
but it is increasingly clear that tumours can also thrive on other sources, such as amino 
acids, acetate and fatty acids. Identification of the fuel-processing pathways that 
represent metabolic Achilles heels in cancer is important to apply metabolic inhibitors 
in a personalized fashion. SmMIP-based transcript profiling may be a highly relevant 
alternative with added value in the field of cancer diagnostics as it can identify metabolic 
Achilles heels by simultaneously measuring relative gene expression levels and 
detecting variants. When combined with smMIP sets that detect actionable mutations 
in oncogenes or tumour suppressor genes, personalized treatment protocols may be 
optimized by including inhibitors of the most predominant metabolic pathways (e.g. 
3-bromopyruvate, dichloroacetate for glycolysis 283-285, 6-aminonicotinamide for the 
pentose phosphate pathway 249, epigallocathechin-3-gallate for glutaminolysis 286,287, 
metformin for mitochondrial oxidative phosphorylation 288-290, cerulenin for fatty acid 
oxidation and lipid synthesis 291).
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Figure S1. A) Western blot containing samples from SKRC7 and SKRC7-VHL-HA cell lines, probed 
with an antibody against g-tubulin (probed with a 680 nm fluorescent secondary antibody) and 
an antibody against HA (probed with an 800 nm fluorescent secondary antibody), to detect 
tagged VHL. The blot was stained in dual color for imaging in the Odyssee (Licor). To prevent 
confusion about the background signals between 30 and 37 kDa, we repeated the blot with the 
same samples, but stained for VHL only (B). 
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Oncogenic membrane receptor tyrosine kinases such as MET and EGFR, or auto-active 
variants thereof, are important targets for cancer precision therapy. Targeted inhibition 
of these oncogenic receptors however invariably leads to resistance, resulting from 
acquisition of resistance-inducing mutations or from selective outgrowth of a priori 
resistant tumour cells. Most applied molecular protocols cannot distinguish between 
intracellular and intercellular heterogeneity of oncogene (variant) expression, which 
may lead to misinterpretation of the molecular make-up of a cancer and suboptimal 
application of targeted therapies. We here combined two related techniques to allow 
semiquantitative and localized in situ detection of specific transcript splice variants 
using single molecule molecular inversion probe (smMIP)-based next-generation 
sequencing and padlock probe-based rolling circle amplification, respectively. We 
show highly specific padlock probe-based multiplex detection of MET, METΔ7-8 and 
METΔ14 transcripts, lacking exons 7-8 and exon 14 respectively, and of EGFR and the 
auto-active EGFRvIII, lacking exons 2-7. The combination of quantitative transcript 
variant detection with smMIPs and transcript localization using padlock probes can 
be used for detection of oncogenic transcripts on the single-cell level, allowing study 
of tumour heterogeneity. Visualization of tumour heterogeneity can shed light on the 
biology underlying drug resistance and potentially improve targeted therapeutics. 
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Introduction
Membrane receptor tyrosine kinases, e.g. EGFR, FGFR, IGF1-R, MET, AXL, KIT, 
RON, VEGFRs and PDGFRs 292, have become important targets for cancer precision 
therapy. Although inhibition of the oncogenic products of these genes frequently 
leads to initial responses, experience is that eventually treatment-resistant tumours 
develop. Treatment failure may result from intrinsic intra-tumoral heterogeneity or 
from acquisition of resistance-inducing mutations 141,293,294. An example of the latter 
is acquisition of EGFRT790M or EGFRC797S mutation in non-small cell lung cancers upon 
treatment with the EGFR tyrosine kinase inhibitor erlotinib 295,296. Novel precision 
medicines have been developed that specifically inhibit these mutant EGFR variants 
297. Formally however, it is unclear whether such aberrations are acquired de novo 
or whether a priori resistant cells pre-existed in the primary tumour, experiencing a 
growth advantage and eventually replacing the treatment-sensitive tumour bulk. This 
is a highly important question, since in the latter case patients should be treated with 
combination therapy comprising relevant tyrosine kinase inhibitors at start. Therefore, 
it is important to investigate heterogeneity of expression of tyrosine kinases, but also 
other oncogenes, in tumours in more detail. 
Molecular research as well as diagnostics of cancer currently consists of analysis of 
genomic DNA which is extracted from cancer tissues that also contain non-tumour 
cells. In these situations, it is impossible to assign wild-type alleles to cancer- or stromal 
cells, or to detect tumour heterogeneity. Examples of oncogenic receptors are the 
MET and EGFR oncogenes, of which different auto-active variants exist. The METΔ7-8 
variant results from a ~2Kb intragenic deletion which results in spliced mRNA lacking 
exons 7 and 8. This variant, that misses only 80 amino acids in the ectodomain, is 
expressed in 6% of high-grade gliomas, remains intracellularly and its activation is ligand 
independent 24. METΔ14 is a splice variant lacking exon 14, a result of exon-skipping point 
mutations in splice sites 298,299, and is hyperactive due to increased protein stability. 
METΔ14 is detected in 0.4% of glioma and 3-4% of non-small cell lung carcinoma (NSCLC) 
cases 20,298-300. Increased MET (variant) expression has been described for NSCLC under 
gefitinib treatment and may represent a rescue kinase for EGFR inhibition 301-304. 
A second example of oncogene aberration is EGFRvIII. Whereas EGFR is amplified in 
50% of glioblastomas, half of these events is accompanied by an intragenic deletion, 
resulting in EGFR transcripts lacking exons 2-7 298,305. Protein products of this transcript 
lack a large part of the extracellular domain and are auto-active. Because the EGFRvIII 
protein contains a neo-epitope at the exon 1-8 junction, it is tumour specific and 
therefore of considerable interest for targeted therapies 306,307. In glioblastoma, 
expression of this variant emerges after initial EGFR amplification and is heterogeneous, 
being more prominent in diffuse infiltrating areas of the brain 305. Importantly, this 
spatial heterogeneity cannot be inferred from genetic analysis. This highlights the 
need for expression analysis on the single-cell level. 
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In this study, we combine single molecule molecular inversion probe (smMIP) targeted 
transcriptome sequencing 308,309 (Figure 1) with in situ detection of transcript splice 
variants using padlock probe-based rolling circle amplification 310-314 (Figure 2). We show 
that we are able to specifically and semiquantitatively detect transcript variants in RNA 
samples from both cell lines and xenografts using smMIPs, and we demonstrate how in 
situ padlock probe rolling circle amplification adds essential information on transcript 
localization and tumour heterogeneity. 
Figure 1. Quantitative detection of transcript splice variants using smMIPs. A) Schematic over-
view of the method. mRNA is reverse transcribed into cDNA using random primers. SmMIP 
probes hybridize to the target region of interest, leaving a gap of ~112 nucleotides. The gap is 
filled by primer extension and ligation, whereafter all remaining linear smMIPs, RNA and cDNA 
are removed by exonuclease treatment. All circular smMIPs are PCR amplified using a unique 
barcoded reverse primer for each sample. Resulting reads are mapped against reference tran-
scriptomes, normalized to the total read count within a samples (FPM), and averaged per tran-
script variant. B) Design of smMIP probes. To determine the total expression of a gene, smMIPs 
were designed against shared parts of the transcriptome (upper panel). For specific detection 
of splice variants smMIPs were designed to target variant-specific exon-exon junctions (for ex-
ample the exon6-9 junction for METΔ7-8), either covering the junction with the gap or the ligation/
extension probe (lower panel left and right, respectively). Note that for graphical representa-
tion, the figure is not to scale.
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Materials and Methods
Cell lines and xenografts
Cell lines Hs746T and H596 were obtained from ATCC (Manassas, VA). Cell lines E98 
209, Hs746T, H596, U87-EV and U87-EGFRvIII (obtained from dr. Web Cavenee, Ludwig 
Cancer Inst., USA 315) were cultured at 37°C in the presence of 5% CO2 in Dulbecco’s 
Modified Eagle’s Medium (DMEM) containing 4.5 g/L glucose and 4mM L-glutamin 
(Lonza, Basel, Switzerland), 10% fetal calf serum (FCS, Gibco, Waltham, MA, USA) and 
40 µg/ml gentamycin (Centrafarm, Ettenleur, The Netherlands). The METΔ7-8-expressing 
astrocytoma cell line E98 and the EGFR-expressing astrocytoma line E468, as well as 
the generation of orthotopic xenografts thereof, has been described before 24,209.
Western blot
Cells were lysed in 1x RIPA buffer (Cell Signalling Technology, CST, Danvers, MA) 
with 1 mM phenylmethylsulfonyl fluoride (PMSF), according to manufacturer’s 
instructions. Protein lysates were subjected to electrophoresis on 10% SDS-PAGE 
gels and electroblotted onto nitrocellulose membranes (Whatman Optitran BA-S85, 
GE Healthcare, Little Chalfont, UK). After blocking aspecific binding sites in blocking 
buffer (1:1 PBS/Odyssey blocking buffer [LI-COR Biosciences, Lincoln, NE, USA]), blots 
were incubated o/n at 4°C with primary antibodies: rabbit-anti-MET (1:2500, CST, 
#8198), rabbit-anti-EGFR D38B1 (1:2000, CST, #4267) and mouse-anti-GAPDH (1:5000, 
Abcam, ab8245). Primary antibodies were detected with appropriate IRDye680- or 
IRDye800-conjugated secondary antibodies (Invitrogen Molecular Probes, Waltham, 
MA, USA) incubated 1 hr at RT shielded from light. Signals were visualized using the 
Odyssey imaging system (LI-COR Biosciences, Lincoln, NE, USA). 
PCR
RNA was isolated from cell lines and snap-frozen xenograft tissue using TRIzol 
reagent (Life Technologies, ThermoFisher Scientific, Waltham, MA, USA) and reverse 
transcribed with Superscript II (Invitrogen, ThermoFisher Scientific, Waltham, MA, 
USA) using random hexamer primers, according to the manufacturer’s instructions. 
RT-PCR was performed using Amplitaq Gold 360 mastermix (Applied Biosystems, 
Life Technologies), which for PCR on MET was supplemented with 1 mM MgCl2 and 
20 µg/ml BSA (both New England Biolabs, Ipswich, MA, USA). To distinguish METΔ7-8 
transcripts from their wild-type variant (METexon7-8wt), primers MET1997Fw (5’-
CTCCTTGGAAATGAGAGCTG-3’, forward, located in exon 6) and MET2393Rv (5’-
AGATGCTTGTCTCTCGGTTG-3’, reverse, located in exon 9) were used. This PCR 
results in a 397-bp amplicon for METexon7-8wt and a 157-bp product for METΔ7-8. To 
distinguish METΔ14 transcripts and their wild-type variant (METexon14wt) primers 
MET2982Fw (5’- CAGGATTGATTGCTGGTGTTGTCTC-3’, forward, located in exon 13) and 
MET3252Rv (5’- CGGCATGAACCGTTCTGAGATG-3’, reverse, located in exon 15) were 
used, resulting in a PCR product of 271 bp for METexon14wt and 130 bp for METΔ14. To 
detect EGFRwt transcripts primers EGFR819Fw (5’-GATATCACCATGCGACCCTCCGGG-
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3’, forward, located in exon 5) and EGFR1567Rv (5’-CGACTGCAAGAGAAAACTGA-
3’, reverse, located in exon 12) were used, resulting in a 749-bp product for EGFRwt. 
For detection of EGFRvIII transcripts in U87-EGFRvIII cells, primers EGFR258Fw (5’-
GATATCACCATGCGACCCTCCGGG-3’, forward, located in exon 1) and EGFR1567Rv (5’-
CGACTGCAAGAGAAAACTGA-3’, reverse, located in exon 12) were used, resulting in a 
529-bp product for EGFRvIII. PCR conditions were: initial denaturation of 3 min at 95°C, 
followed by 36 cycles of denaturation at 95°C, 30 s; annealing at 60°C, 30 s; elongation 
at 72°C, 30 s, and a final elongation step of 5 min at 72°C. 
smMIP targeted RNA sequencing
RNA from cell lines and snap-frozen xenograft tissue was isolated and converted to 
cDNA as described under ‘PCR’. The smMIP method and its application for targeted 
transcriptome sequencing has been described before 308,309 and is depicted in Figure 
1A. SmMIPs were designed against target regions of interest (UCSC human genome 
assembly hg19, and variant-specific FASTA sequences) with ligation and extension 
probes localized on different exons, depending on the splice variant to be detected, 
and leaving a gap of maximum 112 nt. SmMIPs were designed based on the MIPgen 
algorithm as described by Boyle et al. 275 and added to a large panel of previously 
designed smMIPs 309. The panel of phosphorylated smMIPs was hybridized to cDNA 
after which the gap was filled by primer extension and ligation. Non-reacted smMIPs and 
remaining RNA and cDNA were removed by exonuclease treatment, followed by PCR 
amplification of the circularized smMIP library using a unique barcoded reverse primer 
for each sample. After library pooling and purification using AMPureXP beads (Beckman 
Coulter Genomics, High Wycombe, UK) smMIP-PCR libraries were sequenced on the 
Illumina Nextseq platform (Illumina, San Diego, CA) at the Radboudumc sequencing 
facility. Reads were mapped against the reference transcripts (UCSC human genome 
assembly hg19 and variant-specific FASTA sequences) using the SeqNext module of 
JSI SequencePilot version 4.2.2 build 502 (JSI Medical Systems, Ettenheim, Germany). 
The random 8xN nucleotide tag flanking the ligation probe was used to reduce PCR 
amplicates to one consensus read originating from the same smMIP (unique read). 
Read counts for each smMIP were normalized to the total read count within a sample 
and multiplied by 106 (Fragments per Million, FPM). Individual transcript levels were 
expressed as mean FPM of all smMIPs targeting that transcript. 
SmMIPs were designed against transcript variants of MET (total MET, METΔ7-8, METΔ14) 
and EGFR (total EGFR, EGFRvIII). SmMIP sequences are depicted in Table 1. An example 
of smMIP design for total MET (transcript variant 2) and METΔ7-8 is depicted in Figure 1B. 
To determine the cumulated expression of all MET transcript variants, smMIPs were 
designed against shared parts of the transcripts (total MET). To enable detection of 
truncated transcripts, smMIPs were designed against splice variant-specific exon-exon 
junctions, either with the maximum 112 nt gap or the ligation/extension probe covering 
the exon-exon junction (exon 6-9 junction for METΔ7-8). SmMIPs were designed in a 
similar way for METΔ14, total EGFR and EGFRvIII. 
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Table 1. SmMIP nucleotide sequences. Ligation and extension probes are depicted in blue.
Padlock probe design
The protocol for padlock probe rolling circle amplification and the design of padlock 
probes with associated bridged nucleic acid (BNA) primers was adapted from 
Weibrecht et al. 314 and is summarized in Figure 2A and B. Wild-type transcripts were 
distinctively detected with padlock probes targeting ‘normal’ exon-exon junctions 
that are missing in the exon-deletion transcript variants. For specific detection of 
splice variants, padlock probes were designed to target the splice variant-specific MET 
exon-exon junctions 6-9 (for detection of METΔ7-8) and 13-15 (for detection of METΔ14) 
and EGFR exon-exon junction 1-8 (for detection of EGFRvIII, Figure 2B). To allow dual 
detection of splice variants together with their associated wild-type transcripts, specific 
sequences were included in the backbone of the padlock probe allowing detection 
via hybridization of complementary fluorescent probes. BNA primer, padlock probe 
and detection probe nucleotide sequences, as well as the nomenclature of probes 
and transcript variants used in this paper, are outlined in Table 2. Before use, padlock 
probes (IDT, Leuven, Belgium) were 5’-phosphorylated using 0.2 U/µl T4 PNK in 1x PNK 
buffer A (ThermoFisher Scientific, Waltham, MA, USA) according to manufacturer’s 
instructions. 
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Table 2. BNA primer, padlock probe and detection probe nucleotide sequences. BNA primer 
Bridged Nucleic Acids are depicted in bold. Padlock probe target-specific sequences are depicted 
in blue. Detection probe complementary sequences in the padlock probe are coloured green 
(wild-type) or magenta (mutant).
Padlock probe rolling circle amplification
The protocol for padlock probe rolling circle amplification is summarized in Figure 2A. 
For padlock assays on cell lines, cells were seeded on 8-well Lab-Tek II chamber slides 
(ThermoFisher Scientific, Waltham, MA, USA) and fixated the following day in 3.7% 
freshly prepared formaldehyde in DEPC-treated PBS (DEPC-PBS) for 30 min at room 
temperature. Fixated cells were washed twice with DEPC-PBS and dehydrated through 
an ethanol series (70%, 85% and 99.5%). Secure-seals (Grace Bio-Labs inc., Bend, Oregon, 
USA) with a volume of 50 µl (Ø 9 mm, 0.8 mm deep) were mounted on the Lab-Tek 
slides and cells were rehydrated by addition of DEPC-PBS-Tween (DEPC-PBS with 0.05% 
Tween-20). For tissue analyses, formalin-fixed paraffin-embedded (FFPE) sections of 
E98 xenografts (E98-FM, generated from the E98 cell line) and E468 xenografts were 
deparaffinized and fixated in 3.7% paraformaldehyde (PFA) in diethylpyrocarbonate 
(DEPC)-treated PBS. Tissue sections were permeabilized with pepsin (2 mg/ml in 0.1 
M HCl) and dehydrated through an ethanol series (70%, 85% and 99.5%). Secure-seals 
(Grace Bio-Labs inc., Bend, Oregon, USA) with a volume of 250 µl (Ø 20 mm, 0.8 mm 
deep) were mounted and cells were rehydrated with DEPC-PBS-Tween. All following 
incubation steps were performed within the secure seal chambers, incubated in a 
hybridizer (Dakocytomation, Glostrup, Denmark).
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Figure 2. In situ detection of whole-exon deletion splice variants using padlock probes. A) Sche-
matic overview of the method. mRNA is converted into localized cDNA molecules, which can 
be targeted through padlock probe hybridization and rolling circle amplification. Rolling circle 
products (RCPs) can then be detected with fluorescently labeled probes. Nucleic acid bridges 
in the BNA primer are depicted in green, padlock probe target sites are depicted in blue and 
padlock probe detection sites are depicted in red. B) Design of padlock probes targeting ME-
Texon7-8wt, METΔ7-8, METexon14wt, METΔ14, EGFRwt and EGFRvIII. For specific detection of tran-
script splice variants, padlock probes were designed to target the mutation-specific exon-exon 
junction (detected with magenta fluorescence). For distinctive detection of their associated 
wild-type variants, padlock probes were targeted at the exon(s) missing in the exon deletion 
transcripts (detected with green fluorescence). Note that for graphical representation, the fig-
ure is not to scale.
In situ reverse transcription was performed using BNA primers positioned within ≤ 1 nt 
from the 5’ end of the padlock probe target site (see Table 2 for nucleotide sequences). 
BNA primer hybridization and mRNA reverse transcription were performed o/n at 42°C 
using 200 nM of BNA primer (IDT, Leuven Belgium), 20 U/µl RevertAid H minus M-MuLV 
reverse transcriptase in 1x M-MuLV reaction buffer (ThermoFisher Scientific, Waltham, 
MA, USA), 1 U/µl RiboLock RNase Inhibitor (ThermoFisher Scientific, Waltham, MA, 
USA), 500µM dNTP and 0.2 µg/µl BSA (New England Biolabs, Ipswich, MA, USA). 
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Post-fixation was performed with 3.7% formaldehyde (5 min) or 3.7% PFA (45 min) for 
cells or tissues, respectively. FFPE tissues were subsequently treated with glycine (2 
g/100 ml in DEPC-PBS, 20 min RT) to decrease autofluorescence. Secure seal chambers 
were flushed with DEPC-PBS-Tween. Padlock probes (100 nM) were hybridized to the 
cDNA and ligated using 0.5 U/µl Ampligase in 1x Ampligase buffer (Epicentre, Madison, 
Wisconsin, USA) containing 0.4 U/µl RNase H (New England Biolabs, Ipswich, MA, 
USA), 1 U/µl RiboLock RNase Inhibitor, 0.2 µg/µl BSA, 50 mM KCl and 20% formamide 
(30 min 37°C, 30 min 45°C).
Rolling circle amplification of the ligated padlock probe was performed o/n at 37°C 
using Phi29 DNA polymerase (ThermoFisher Scientific, Waltham, MA, USA). Secure 
seal chambers were flushed with DEPC-PBS-Tween and Phi29 DNA polymerase was 
added at a concentration of 1 U/µl in 1x Phi29 DNA polymerase buffer (ThermoFisher 
Scientific, Waltham, MA, USA) with 1 U/µl RiboLock RNase Inhibitor, 250 µM dNTP, 0.2 
µg/µl BSA and 5% glycerol. After washing with DEPC-PBS-Tween, rolling circle products 
(RCPs) were visualized by hybridization to 100 nM of corresponding fluorescent 
detection probe (See Table 2; IDT, Leuven, Belgium) in 1x saline-sodium citrate (SSC) 
and 20% formamide (37°C, 30 min). The slides were dehydrated through an ethanol 
series (70%, 85% and 99.5%) and mounted with Vectashield (Vector Laboratories Inc., 
Burlingame, CA, USA) containing 375 ng/ml DAPI for nuclear counterstaining.
Slides were imaged using the Vectra (Caliper Life Sciences, Waltham, MA, USA). Slide 
analysis was performed with the Vectra Automated Quantitative Pathology Imaging 
System (Version 3.0.3, PerkinElmer Inc., Waltham, MA, USA) and inForm Advanced 
Image Analysis Software (Version 2.2.1, PerkinElmer Inc., Waltham, MA, USA). 
Contrast-enhancement was applied on the resulting images using GIMP version 2.8.20.
Results
To investigate whether padlock assays can be used for specific in situ detection of 
oncogene transcripts, we here examined expression of MET and EGFR and auto-active 
splice variants of these tyrosine kinases, in a cohort of cell lines and xenografts with 
defined EGFR and MET expression. To set up the technique we used cell lines E98 and 
its corresponding xenograft (E98-FM, METΔ7-8 amplification) 24, cell lines Hs746T (METΔ14, 
high expression), H596 (METΔ14, low expression), U87-EV (EGFRwt, low expression), 
U87-EGFRvIII (over-expression) 315, and xenograft E468 (EGFR amplification) 209. Relative 
protein expression levels of MET and EGFR in the different cell lines and xenografts are 
shown in Figure 3A (complete blots are shown in Supplementary Figure S1). By PCR 
analysis we confirmed the MET transcript status of E98, Hs746T and H596, and EGFR 
transcript mutation status of E468, U87-EV and U87-EGFRvIII (Figure 3B, complete gels 
are shown in Supplementary Figure S2). We semiquantitatively determined transcript 
variant-specific expression levels of MET and EGFR in all cell lines and xenografts using 
smMIPs (Figure 3C). 
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Figure 3. Expression levels and mutation status of MET and EGFR in relevant cell lines and 
xenografts. A) Left: western blot of cell lines E98, Hs746T and H596, U87-EV, U87-EGFRvIII, and 
xenografts E98-FM and E468, showing relative (total) MET and EGFR expression. Note that MET 
shows two proteins of different sizes, corresponding to the preform and the processed form 
of the protein (Navis et al., 2015, Acta Neuropathol.). B) Left: MET PCR on cell lines E98, Hs746T 
and H596 to confirm METΔ7-8 and METΔ14 mutation status. Right: EGFR PCR on cell lines U87-EV 
and U87-EGFRvIII, and xenograft E468, to confirm EGFRwt and EGFRvIII status. C) SmMIP target-
ed transcriptome profiling of MET (left) and EGFR (right) quantifies variant-specific expression 
levels in cell lines and xenografts. While E98 cells and xenografts express the METΔ7-8 variant, 
Hs746T and H596 predominantly express the METΔ14 variant. U87 cells express METwt transcripts. 
EGFRwt transcript expression is present in Hs746T, H596, U87 and E468 cells and xenografts, 
while the EGFRvIII variant is only present in the U87-EGFRvIII cell line.
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Figure 4. Single-probe in situ mutation detection of MET using padlock probe rolling circle 
amplification on cell lines. A) In situ detection of METexon7-8wt and METΔ7-8 transcripts in E98 
and Hs746T cells using padlock probes MET7-8 and MET6-9, respectively. METexon7-8wt transcripts 
are displayed as green RCPs, METΔ7-8 transcripts are displayed as magenta RCPs. Cell nuclei are 
shown in grey. Original magnification 40x. B) In situ detection of METexon14wt and METΔ14 tran-
scripts in E98, Hs746T and H596 cell lines using padlock probes MET14 and MET13-15, respectively. 
METexon14wt transcripts are displayed as green RCPs, METΔ14 transcripts are displayed as magen-
ta RCPs. Cell nuclei are shown in grey. Original magnification 40x.
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We first tested the specificity of the MET-targeting padlock probes on cell lines 
with known MET status. Single-probe assays with padlock probe MET7-8 resulted in 
fluorescent signal in Hs746T, but not in E98 cells. Conversely, single-probe assays 
with padlock probe MET6-9 resulted in fluorescent signal in E98, but not in Hs746T 
cells (Figure 4A). These results are in line with the fact that E98 cells exclusively 
express METΔ7-8, while Hs746T cells only express METexon7-8wt transcripts, confirming 
the specificity of MET7-8 and MET6-9 probes. Similarly, we performed single-probe 
padlock assays with the MET14 and MET13-15 probes on E98 cells in which no METΔ14 is 
expressed, and Hs746T and H596 cell lines, expressing METΔ14. As expected, in E98 cells 
METexon14wt transcripts were readily detected with probe MET14, while the assay was 
negative when performed with the MET13-15 probe (Figure 4B upper panel). Conversely, 
Hs746T and H596 cells were positive when assayed with the padlock MET13-15 probe, 
and negative with the MET14 probe (Figure 4B middle and lower panels). Numbers of 
fluorescent spots in H596 cells were lower than in Hs746T cells, in agreement with the 
lower levels of MET protein that we detected by western blot in these cell lines (Figure 
3A) and lower levels of MET transcript as detected by smMIP-sequencing (Figure 3C). 
Having confirmed the specificity of these probes, we subjected E98 and Hs746T cells to 
a combination of MET7-8 and MET6-9 probes, and MET14 and MET13-15 probes, respectively. 
This duo-probe padlock assay allows duplex detection of wild-type (detected in green) 
and mutant variants (detected in magenta) of the same RNA transcript simultaneously. 
The selectivity of the padlock probes was preserved when mutant-specific probes were 
applied together with their corresponding wild-type probe, and also the efficiency was 
not notably affected (Figure 5). 
Figure 5. Multi-plex in situ mutation detection of MET using padlock probe rolling circle am-
plification on cell lines. In situ duo-probe detection of METexon7-8wt and METΔ7-8 transcripts in 
E98 cells (left) and METexon14wt and METΔ14 transcripts in Hs746T cells (right) using padlock 
probes MET7-8 and MET6-9, and MET14 and MET13-15, respectively. METexon7-8wt and METexon14wt 
transcripts are displayed as green RCPs, METΔ7-8 and METΔ14 transcripts are displayed as magenta 
RCPs. Cell nuclei are shown in grey. Original magnification 40x.
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After successful and specific detection of MET splice variants in cell lines, we tested 
our duo-probe padlock assay on FFPE xenograft material. We subjected serial E98-FM 
FFPE tissue slides, carrying the METΔ7-8 mutation but with a wild type exon 14 allele, to 
duo-probe padlock assays using a combination of probes MET6-9 and MET7-8 (Figure 
6B), MET13-15 and MET14 (Figure 6C), or MET14 and MET6-9 (Figure 6D). H&E sections serial 
to the padlock assay tissues are depicted in Figure 6A. Both METΔ7-8 and METexon14wt 
transcripts were specifically detected in E98 xenograft tissue, without detection spots 
for METexon7-8wt or METΔ14 transcripts, respectively (Figure 6B, C). We could visualize 
different tumour areas with high and low expression of the targeted MET transcripts 
(Figure 6B and C, left and middle panels, respectively). Note that normal tissue 
(right part of right panels) was completely negative. A double-positive padlock assay 
targeting METexon14wt and METΔ7-8 on E98 xenograft tissue showed specific detection 
of both transcripts simultaneously (Figure 6D). Probe specificity is again highlighted 
at the tumour border (Figure 6D, right panel). Although both padlock probes were 
readily identified in these sections, co-localization was only occasionally observed (see 
Supplementary Figure S2, arrows). This is possibly due to the low sensitivity of the 
padlock probe assay. Of note, signals were slightly decreased in the double-positive 
assay as compared to the single-positive padlock assays. Although we could not 
quantify this, we attribute this to competition of padlock probes on the same transcript. 
Similar to the padlock assays targeting MET, we performed padlock assays targeting 
EGFRwt and EGFRvIII transcripts. We subjected U87-EV (EGFRwt) and U87-EGFRvIII 
overexpressing cell lines to a duplex assay to detect EGFRwt and EGFRvIII transcripts, 
using padlock probes EGFR2-3 (green) and EGFR1-8 (magenta), respectively. In U87-EV 
cells this assay resulted in fluorescent signal for EGFRwt, while EGFRvIII specific 
transcripts were abundantly detected in U87-EGFRvIII overexpressing cells (Figure 7A). 
In U87-EGFRvIII cells no EGFRwt signals were detected in the duplex assay, probably 
because of the low abundance of EGFRwt transcripts in these cells, compared to high 
overexpression of EGFRvIII transcripts. Note that the number of EGFRwt fluorescent 
spots in U87-EV cells is much lower than the number of EGFRvIII spots in U87-EGFRvIII 
cells, which corresponds to the difference in EGFR expression (Figure 3A and C). We 
also subjected EGFRwt expressing E468 xenograft tissue to a duplex EGFR padlock 
assay. Figure 7B shows specific detection of EGFRwt transcripts.
Figure 6. Multi-plex in situ mutation detection of MET using padlock probe rolling circle ampli-
fication on E98-FM FFPE xenograft tissue. A) Serial H&E stainings. B) In situ duo-probe detection 
of METexon7-8wt and METΔ7-8 transcripts using padlock probes MET7-8 and MET6-9, respectively. C) 
In situ duo-probe detection of METexon14wt and METΔ14 transcripts using padlock probes MET14 
and MET13-15, respectively. D) In situ duo-probe detection of METexon14wt and METΔ7-8 transcripts 
using padlock probes MET14 and MET6-9, respectively. Wild-type transcripts are displayed as green 
RCPs, mutant transcripts are displayed as magenta RCPs. Cell nuclei are shown in grey. Note 
that in all assays the tumour border emphasizes the specificity of the padlock probes, showing 
no fluorescent detection spots in normal brain tissue (right figures, original magnification 20x). 
Compare the left and middle panels for each assay, visualizing differences in transcript expres-
sion in different tumour areas. Inserts give a zoomed view of the underlying image. Original 
magnification 40x. (Next page)
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Figure 7. Multi-plex in situ mutation detection of EGFR using padlock probe rolling circle am-
plification on cell lines and E468 xenograft tissue. A) In situ duo-probe detection of EGFRwt and 
EGFRvIII transcripts using padlock probes EGFR2-3 and EGFR1-8, on U87-EV and U87-EGFRvIII cells 
(original magnification 40x). B) In situ duo-probe detection of EGFRwt and EGFRvIII transcripts 
using padlock probes EGFR2-3 and EGFR1-8, on E468 xenograft FFPE tissue (original magnification 
20x). EGFRwt transcripts are displayed as green RCPs, EGFRvIII transcripts are displayed as ma-
genta RCPs. Cell nuclei are shown in grey.
Discussion
To be able to investigate tumour heterogeneity with respect to oncogene expression, 
we applied padlock probe rolling circle amplification to identify EGFR, MET and the 
whole-exon deletion splice variants of these oncogenes that play a role in, among 
others, glioma and NSCLC 103,104,188,292,295,304. Simultaneous in situ detection of tyrosine 
kinase splice variants with their associated wild-type variants enables visualization 
of tumour heterogeneity in FFPE tissue sections, material which is routinely used in 
diagnostics and can be preserved for years. 
In recent years, articles have reported on the use of padlock probes for in situ analysis 
of single-nucleotide transcript variants 310,312 and fusion transcripts 311. Here, we adapted 
these protocols to allow in situ identification of whole-exon deletion splice variants. 
Probe specificity was validated in single-probe assays on cell lines with known MET or 
EGFR status, and was preserved in duplex padlock assays. As for now, a drawback is 
low sensitivity of padlock probe assays, possibly explaining the lack of co-localization 
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of MET14 and MET6-9 probes in Figure 6D. The distinction between intercellular 
and intracellular tumoral heterogeneity, with different oncogene variants being 
present within the same cell or with subclones of cells carrying different oncogene 
variants, respectively 139,141,293, can therefore not be made. This distinction is important 
since cells co-expressing different tyrosine kinases that initiate similar signalling 
pathways, will respond differently to drugs than cells expressing only the targeted 
kinase. Low sensitivity of padlock probe assays has been described before 310,312,313. 
However, the reason is not clear and may be related to any of the complex steps in 
the procedure, including fixation method/RNA quality, RNA secondary structures that 
hamper effective in situ reverse transcription, and the presence of single nucleotide 
polymorphisms (SNPs) impeding hybridisation of the BNA probe and the padlock 
probe. Improvement of sensitivity of the method is necessary to detect co-expression 
of different transcripts in one cancer cell. However, the high specificity of the padlock 
assay will allow the investigation of intra-tumoral, intercellular heterogeneity of splice 
variant transcript expression. To allow successful padlock assays on clinical tissue, the 
essentiality of RNA integrity probably requires that tumour tissue is fixated shortly 
after surgery or biopsy in proper preservatives.
For smMIP-based targeted RNA sequencing we have observed a variance in efficacy 
between different smMIPs targeting the same transcript. We have reported that 
the average of five smMIPs targeting one transcript gives a reliable estimate of the 
expression level of a transcript 309. Because padlock assays rely on the hybridisation of 
one individual probe for each transcript variant, these are not suitable for quantification 
of transcript (variant) expression levels. In situ rolling circle amplification using padlock 
probes does allow visualization of intercellular heterogeneity within tumour tissues. 
In contrast, smMIP-based targeted RNA sequencing allows quantitative and specific 
detection of splice variants, but does not enable visualization of tumour heterogeneity 
and localization of specific transcripts. The combination of both techniques possibly 
allows differentiation between intrinsic and acquired transcript expression (induced 
tumour heterogeneity), and between intrinsic and acquired treatment resistance 
development. This is an interesting aspect for future studies and may give more insight 
into tumour resistance biology. This potentially has implications for targeted therapy, 
because patients with pre-existent resistant tumour clones may benefit significantly 
from combination therapies at start. 
In conclusion, we here show the high value of combining two molecular inversion 
probe techniques. Using smMIP targeted transcriptomics we can quantitatively 
measure transcript variant-specific gene expression. Additionally, padlock probe 
rolling circle amplification enables specific and local visualization of transcript variants 
in situ, however with low efficacy. The technique of smMIP-based RNA splice variant 
sequencing can be easily expanded with smMIP probes to detect other transcript 
variants, and can serve as an important tool for detection of molecular heterogeneity 
and investigation of the role of splice variants in therapy resistance. 
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Figure S1 (supplementary data to Figure 3). Expression levels and mutation status of MET and 
EGFR in relevant cell lines and xenografts. A) Western blot of cell lines E98, Hs746T and H596, 
U87-EV, U87-EGFRvIII, and xenografts E98-FM and E468, showing relative (total) EGFR (left) and 
MET (right) expression. B) Left: MET PCR on cell lines E98, Hs746T and H596 to confirm METΔ7-8 
and METΔ14 mutation status. Right: EGFR PCR on cell lines U87-EV and U87-EGFRvIII, and xeno-
graft E468, to confirm EGFRwt and EGFRvIII status. 
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Figure S2 (supplementary data to Figure 6D). Multi-plex in situ duo-probe detection of MET 
using padlock probe rolling circle amplification on E98-FM FFPE xenograft tissue. METexon14wt 
and METΔ7-8 transcripts are detected using padlock probes MET14 and MET6-9, respectively. Wild-
type transcripts are displayed as green RCPs, mutant transcripts are displayed as magenta RCPs. 
Cell nuclei are shown in grey (original magnification 20x). Note that occasionally co-localization 
of both transcripts was observed (arrows).
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Many biology-based precision drugs are available that neutralize aberrant molecular 
pathways in cancer. Molecular heterogeneity and the lack of reliable companion 
diagnostic biomarkers for many drugs makes targeted treatment of cancer inaccurate 
for many individuals. Identifying actionable hyperactive biological pathways in 
individual cancers may improve this situation.
To achieve this, we applied a novel targeted RNA next-generation sequencing (t/
RNA-NGS) technique to surgically obtained glioma tissues. The test combines mutation 
detection with analysis of biological pathway activities that are involved in tumour 
behaviour in many cancer types (e.g. tyrosine kinase signalling, angiogenesis signalling, 
immune response, metabolism), via quantitative measurement of transcript levels 
and splice variants of hundreds of genes. We here present proof of concept that the 
technique, which uses molecular inversion probes, generates a histology-independent 
molecular diagnosis and identifies classifiers that are strongly associated with 
conventional histopathology diagnoses and even with patient prognosis. The test not 
only confirmed known glioma-associated molecular aberrations but also identified 
aberrant expression levels of actionable genes and mutations that have so far been 
considered not to be associated with glioma, opening up the possibility of drug 
repurposing for individual patients. Its cost-effectiveness makes t/RNA-NGS to an 
attractive instrument to aid oncologists in therapy decision making. 
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Introduction
Many different cancer types share similar driver mutations. Examples are loss of 
function mutations in tumour suppressor genes (e.g. p53 and CDKN2A) and DNA repair 
proteins, leading to genetic instability and loss of cell cycle control) 316-318, and activating 
mutations, amplifications or fusion events in proto-oncogenes 319,320. Other shared 
features are related to micro-environmental effectors, such as altered metabolism as a 
result of hypoxia 35,321, induction of angiogenesis 70 and immune suppression 322. 
Additionally, aberrations exist that are tumour-type specific. Examples are expression 
of hormone receptors in cancers of prostate, ovary and breast 323,324; mutations 
affecting metabolism (isocitrate dehydrogenase mutations [p.IDH1-R132H] in glioma 
and acute myeloid leukaemia 211); and mutations affecting the PI3K and MAPK 
pathway (PIK3CA, p.KRAS-G12/G13 mutations in adenocarcinomas 325, p.BRAF-V600E 
in melanoma 326). Such specificity is however never absolute. As an example, IDH and 
BRAF mutations are sporadically found in other cancers too 327-329. Detection of such 
relatively rare, and therefore a priori unexpected mutations in individual patients could 
lead to repurposing of precision medicines in basket trials, in which precision drugs are 
administered to patients based on DNA profiling 157,176,330,331. 
A number of actionable biological pathways in cancer involve the products of 
genes that are not mutated, but epigenetically regulated, for example by altered 
transcription factor availability, repressor activity or gene methylation, 332,333. Activity 
of such pathways cannot be directly inferred from DNA analyses. Whole genome 
methylation analysis has robust diagnostic power 334 but does not allow analysis of 
activity of biological pathways, involved in cancer development and progression. 
An example is angiogenesis, initiated by hypoxia-inducible factor (HIF-1α)- induced 
expression of an abundance of growth factors and followed by extensive crosstalk 
between tumour cells, tip- and stalk endothelial cells and pericytes 335,336. DNA analysis 
also does not provide information on post-transcriptional events. For example, 
expression of alternative splice variants of vascular endothelial growth factor (VEGFA) 
has implications for the regulation of angiogenesis 337 and splice variants of receptor 
tyrosine kinases can lead to auto-active and oncogenic PI3K signalling (e.g. EGFRvIII 
and METΔ7-8 in glioma and METΔ14 in lung cancer 24,298,338,339). 
A comprehensive overview of gene expression levels and alternative splice variants 
can be obtained with whole RNA next-generation sequencing (w/RNA-NGS), provided 
sufficient coverage to detect alternative exon-exon boundaries. w/RNA-NGS is 
increasingly performed in a research setting but is cost-wise still not suitable for 
implementation in routine patient care. There is therefore a huge need for novel and 
cost-effective methods to obtain clinically actionable and reliable information for 
individual patients, to be able to implement personalized treatment approaches. 
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Due to its low incidence (6 per 100,000) and high molecular heterogeneity 340, glioma 
is a difficult tumour type to organize clinical trials with, although the molecular 
underpinnings of gliomagenesis and glioma progression are relatively well established 
211. In the absence of alternatives, treatment of its most malignant form, glioblastoma, 
is still confined to palliative surgery, followed by chemotherapy with temozolomide 
(TMZ) and radiotherapy 341 which extents median life expectancy with only few months. 
Surgical cure for this tumour type is not possible due to its diffuse infiltrative nature 
342. Glioma is therefore one of the most challenging tumours for which new treatment 
strategies are urgently needed. 
We here analysed test and validation cohorts of in total 103 surgically derived brain 
tumours with quantitative targeted RNA next-generation sequencing (t/RNA-NGS) 
309,343-345. The technique uses single molecule molecular inversion probes (smMIPs) and 
sensitively and quantitatively measures expression levels of and mutations in actionable 
genes. We show that t/RNA-NGS provides a histology-independent molecular diagnosis 
and identifies classifier transcripts that are closely associated with histopathological 
diagnosis and prognosis. By measuring hyperactivity of cancer-related pathways the 
test may also stratify individual patients for treatment with appropriate medicine.
Materials and Methods
Patients
The study described here was performed with brain tumour tissue from newly 
diagnosed patients who were operated for a glioma between 2013 and 2018 (N=103). 
The cohort was separated in a experimental cohort (N=75, tumours that were operated 
between 2013 and 2017) and an independent validation set of 28 tumours (operated in 
2017 and 2018). Researchers were blinded to histopathology and clinical outcome. The 
study protocol was approved by the Ethical Committee for Human Experimentation 
of the Radboudumc. All patients signed informed consent. Directly after surgery, 
tissue samples were snap frozen in liquid nitrogen and stored at -80oC until further 
processing. In retrospect, patient characteristics were extracted from Radboudumc 
electronic patient files (EPIC) and documented in the electronic data capture system 
CASTOR. Histopathology and molecular diagnoses were extracted from the Dutch 
Pathology archive PALGA and summarized in 
RNA preparation and cDNA synthesis
Cryosections of 10 µm were cut for RNA isolation using TRIzol (ThermoFisher Scientific, 
Waltham, MA). For every sample a 4 µm serial section was stained with H&E to estimate 
percentage tumour area by an experienced neuropathologist (BK). RNA was reverse 
transcribed into cDNA using random hexamer primers and Superscript II (Invitrogen, 
CA) according to standard protocols. In parallel, tissue was processed to formalin-fixed 
paraffin-embedded (FFPE) tissue blocks for routine diagnosis. Samples from 2014 
onwards were also subjected to genetic analysis using targeted DNA next-generation 
sequencing 176. 
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t/RNA-NGS with smMIPs
All enzymes were from NEB (Ipswich, MA) unless stated otherwise. The procedure 
of smMIP-based targeted RNA next-generation sequencing (t/RNA-NGS) to detect 
expression of metabolic genes has been described before 309,344-346. SmMIPs were 
designed by an adjusted version of the MIPgen algorithm 276 and were ordered from 
Integrated DNA Technologies (Leuven, Belgium). The set of smMIP probes used in 309 
was expanded with probes for detection of regions of interest (ROI) in novel transcripts 
of interest that play a role in a wide variety of cancer types. Furthermore, smMIP 
probes were included for specific detection of splice variants by placing extension 
and ligation probes on neighbouring exons, e.g. probes on exons 1/8 of Epidermal 
Growth Factor Receptor (EGFR) for detection of EGFRvIII 344. Probes for detection of 
Vascular Endothelial Growth Factor (VEGF) isoforms 121, 165 and 189 were designed 
with extension and ligation probes in exons 5/8, 5/7 and 5/6, respectively. Additional 
smMIPs were included that were directed against shared exons of transcript variants. 
For transcripts in which relevant mutations can be expected, smMIPs were selected 
with extension and ligation probes flanking the respective ROI. At least 5 smMIPs 
were used for each transcript of interest, evenly distributed along the transcript. 
cDNA was subjected to smMIP capture as described in 309,343. In short, a mixture of 
936 phosphorylated smMIPs was hybridized to 15-50 ng of cDNA. After overnight 
hybridization and enzymatic gap-filling (KlenTaq polymerase, Epicentre, Madison, WI) 
and ligation (Ampligase, Epicentre) circular smMIPs are formed, the number of which 
is linearly related to the number of RNA molecules present in the original sample. 
After treatment with exonuclease to remove cDNA and linear smMIPs, the libraries of 
circular smMIPs were subjected to PCR with a unique barcoded primer set per sample. 
The PCR products of the expected length of 266 bp were purified with Ampure beads 
(Beckmann Coulter Genomics, High Wycombe, UK) and quantified on a TapeStation 
2200 (Agilent Technologies, Santa Clara, CA). PCR libraries were sequenced on the 
Illumina Nextseq platform (Illumina, San Diego, CA) at the Radboudumc sequencing 
facility (output 2x151 bases). The barcode in the PCR primers allows for pooling of 
multiple samples into one sequencing library, followed by demultiplexing of reads, 
generating for all individual samples a FASTQ file.
Data processing
For each patient sample, all reads in the FASTQ file were mapped against reference 
transcripts (UCSC human genome assembly hg19) using the SeqNext module of JSI 
SequencePilot version 4.2.2 build 502 (JSI Medical Systems, Ettenheim, Germany). 
In all smMIP molecules a unique random 8N sequence is included (unique molecular 
identifier or UMI), allowing to assign all identical sequencing reads to one originating 
circularized (unique) smMIP. This excludes PCR amplification bias and makes the assay 
quantitative. Number of unique reads for each individual smMIP in a sample were 
normalized to the total of unique reads in that sample and expressed as fragment per 
million (FPM). Mean FPM values from all smMIPs covering different ROIs in the same 
transcript were considered to represent gene expression levels in the tumour sample. 
Using the base calling algorithm of SeqNext a list of single nucleotide variations and 
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insertions and deletions was generated for each sample. An in–house developed 
Python script (version 3.7) allowed direct coupling of gene expression values and 
mutation status of individual cancer samples.
Data analysis and statistics
Unsupervised hierarchical cluster analysis with the gene expression data was performed 
using R programming (version 3.4.3). Mean FPM values were log-transformed (after 
addition of 0.01 to prevent log0 transformation). Manhattan distance between 
gene expression profiles were calculated using the group average method for 
agglomerative clustering (Unweighted Pair Group Method with Arithmetic Mean) 347. 
Other packages were heatmap.Plus (http://www.sciviews.org/SciViews-R.) and plyr 
(http://www.jstatsoft.org/v40/i01/). The Wilcoxon Mann-Whitney U test was used to 
find differentially expressed genes between clusters. Associations of mutations with 
clusters were calculated using Fisher’s exact test. Multiple testing corrections were 
done using Benjamini Hochberg (FDR<0.05). Kaplan-Meier survival curves of 75 brain 
cancer patients in the test cohort were generated using Graphpad Prism, version 5.03. 
Patients who were still alive at the date of analysis or were lost to follow-up, were 
censored in the survival data. P-values were calculated using the Log-Rank test. All 
p-values are indicated as *(p<0.05), ** (p<0.01), *** (p<0.001), **** (p<0.0001), unless 
specified otherwise. Survival analysis of the 28 patients in the validation cohort could 
not be performed due to short follow-up time. 
Immunohistochemistry
Immunohistochemistry (IHC) was performed on 4 µm sections of FFPE tissue or 
on frozen sections, adjacent to those used for t/RNA-NGS. Frozen sections were 
air dried and fixed with 4% paraformaldehyde (PFA) solution for 20 min at room 
temperature before staining. After appropriate epitope retrieval (for FFPE sections), 
antibodies rabbit-anti-Prostate-Specific Membrane Antigen (PSMA; Abcam; ab133579), 
rabbit-anti-Carbonic Anhydrase 12 (CAXII; Sigma Life Sciences; HPA008773), 
mouse-anti-androgen receptor (AR; Santa Cruz; sc-7305), rabbit-anti-MET (Cell 
Signaling Technologies; #8198), and rabbit-anti-EGFR (Cell Signaling Technologies; 
#4267) were used. Sections were incubated with primary antibody in normal antibody 
diluent (Immunologic, Duiven, The Netherlands) overnight at 4oC. Primary antibody 
detection was done using BrightVision polyHRP-anti-rabbit IgG (Immunologic, Duiven, 
The Netherlands), or BrightVision polyHRP-anti-mouse/rabbit/rat IgG (Immunologic) 
for AR staining. Sections were counterstained with haematoxylin and mounted with 
Quick-D mounting medium (Klinipath, Duiven, The Netherlands). As control staining, 
secondary antibody-only stainings were performed. 
Whole transcriptome RNA-NGS (w/RNA-NGS)
Total RNA was isolated using the Qiagen AllPrep DNA/RNA Mini Kit following the 
manufacturer’s protocol for animal tissues (Qiagen, Hilden, Germany). RNA sequencing 
libraries were prepared from 16 gliomas using the KAPA RNA HyperPrep Kit with 
RiboErase (HMR; KAPA Biosystems, Wilmington, MA) following the manufacturer’s 
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protocol. Briefly, 100ng of total RNA was used to generate libraries, which were 
fragmented for 8 minutes at 94°C. Adapter stock concentration used was 750 nM and 
libraries were amplified for 11 cycles. Duplex “Y” adapter sequences with molecular 
barcodes were generated by IDT (Integrated DNA Technologies, Skokie, Illinois). Final 
libraries were quantified on a High Sensitivity Bioanalyzer chip (Agilent, Santa Clara, 
CA) and sequenced at 1.4pM with 10% PhiX on the Illumina NextSeq 550 Sequencer 
(Illumina, San Diego, CA). Raw FASTQ files were mapped to the human genome (hg19) 
with STAR (v2.5.3) aligner 348. Mapped reads were filtered and deduplicated using 
sambamba v0.6.6 and feature quantification was performed using featureCounts 
v1.5.0-p1 against the RefSeq database (downloaded from the UCSC genome browser 
on 01/05/2017). Gene and exon-level fragments per kilobase per million mapped reads 
(FPKMs) were calculated using a custom python script.
Results
t/RNA-NGS profiles have prognostic value
To investigate the prognostic value of t/RNA-NGS, we profiled a experimental set of 75 
brain tumours, including 69 grade II-IV diffuse gliomas and 6 brain lesions that upon 
routine histopathology were diagnosed as an ependymoma (N=1), one dysembryoplastic 
neuroepithelial tumour (DNET), one pleomorphic xanthoastrocytoma, a variant 
glioma, a brain metastasis of lung adenocarcinoma and a lymphoproliferative disorder 
(LPD; Table 1). Annotated unique smMIP counts for each tumour sample ranged from 
275,000 to 1,111,000 (not shown). Hierarchical unsupervised agglomerative clustering 
of the gene expression data of the grade II-IV gliomas (excluding the 6 rare cancers) 
resulted in 3 main clusters A, B and C, comprising of 26, 38 and 5 tumours, respectively 
(Figure 1). 
In a next step we performed a Wilcoxon Mann-Whitney U test to find genes that were 
differentially expressed between clusters A and B; A and C; and B and C. A total of 
83 genes were differentially expressed between clusters A and B with p<0.05 and 
False Discovery Rate (FDR) <0.05 (Table S1A). Among these were transcripts encoding 
transporters and enzymes involved in metabolism, as described before 346. Membrane 
receptor tyrosine kinases (RTKs) NTRK2, ERBB3, ERBB4 were higher expressed in 
cluster B with average fold changes (FC) of 3.5, 4.8 and 5.2 respectively, while cluster 
A was characterized by significantly higher expression levels of EGFRvIII (FC=250) 
and VEGFA isoforms VEGFA-121, VEGFA-165 and VEGFA-189 (all with FC>11, Table S1A). 
Between cluster B and C 69 genes were differentially expressed (Table S1B). Cluster A 
and C significantly differed with respect to expression levels of 9 genes (Table S1C). The 
functional significance of these differences was not subject of further investigation in 
this study.
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Figure 1. Agglomerative clustering of t/RNA-NGS profiles of 69 grade II-IV gliomas. Clustering 
was based on expression levels of 145 genes of interest. Gene expression levels (in FPM) were 
transformed to a z-score for each individual transcript. After generating the dendrogram and 
heatmap using the average clustering method in R, histopathology results and mutation status 
were added in retrospect (legend and upper annotation bars). Cluster A and C strongly correlate 
with a wild-type IDH status, while cluster B is strongly associated with the IDH1R132H mutation 
(see also Supplementary Table S3). IDH2 mutations (R172K, R172M, and R172W) are annotated as 
IDH2-MT (black in the annotation bar) and all co-clustered with the IDH1R132H mutation. IDH1-oth-
er refers to variants other than the IDH1R132H (see Table 1). 
We then coupled the profiles to survival data. As shown in Figure 2A, cluster B gene 
expression profiles of gliomas were associated with good prognosis (median survival, 
defined as time between surgery and death, >6 years; exact value could not be 
calculated for available follow-up time) whereas gene expression profiles in cluster A 
and C were associated with median survival of 467 and 135 days, respectively. Results 
were highly significant between clusters A and B (p<0.0001), A and C (p=0.0078), 
and C and B (p<0.0001). A Kaplan-Meier curve with survival data including also the 
non-glioma patients is presented in Supplementary Figure S1.
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Figure 2. Kaplan-Meier analyses of unsupervised clusters. A) For patients in clusters A (N=26) 
and C (N=5) median survival was 467 days and 135 days, respectively. For cluster B (N=38) the 
follow-up period was too short to determine median survival. Survival of patients in cluster B 
was significantly better than of clusters A and C (both p<0.0001). Survival in cluster A was signifi-
cantly better than C (P=0.008). B) Oligodendroglioma patients in cluster B (diagnosed according 
to WHO 2016 classification, and treated with PCV) performed better than astrocytoma patients 
in this cluster (all treated with TMZ) (p=0.04). Two patients (N16-06 and N16-10) were excluded 
from analysis because no survival data was present.
Mutation analysis 
We next investigated whether we could identify nucleotide variations that significantly 
associate with the subgroups. To this end we included all identified sequence variants 
of potential clinical significance with a coverage of >10% of the unique reads. This 
analysis revealed that the well-known hotspot mutation in the metabolic enzyme 
isocitrate dehydrogenase 1 (p.IDH1-R132H) 211 was significantly associated with cluster 
B (p<3x10-5 when compared to cluster A, see Supplementary Table S2). Additionally, 
a duplication in succinate dehydrogenase A (SDHA) of unknown significance was 
strongly associated with group B (p=3x10-5). The test also identified known oncogenic 
mutations in mitochondrial IDH2 in four patients (two p.R172K, one p.R172C and one 
p.R172M mutation, Table 1). Gene expression profiles from these gliomas co-clustered 
with those of the p.IDH1-R132H gliomas in cluster B (Figure 1, black in IDH-status 
annotation bar). All IDH1R132 and IDH2R172 mutations were in retrospect confirmed by 
routine genetic analyses (not shown). As described before, also other variants of IDH1 
(p.V178I, p.Y183C) were identified by the assay 346 (Table 1). 
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Table 1. Summary of characteristics of glioma samples. Histological type, WHO grade, and 
percentage tumor cells were confirmed by a trained neuropathologist (B.K.). IDH-mutational 
status was derived from the t/RNA-NGS data. All IDH1R132H/IDH2 mutations were validated by 
routine diagnostic genetic analysis with the ‘Radboud Cancer Hotspot Gene panel’.
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Abbreviations. DNET, Dysembryoplastic neuroepithelial tumor; F, Female; IDH, Isocitrate 
Dehydrogenase; LPD, Lymphoproliferative disorder; M, male; IDH-WT, IDH wild-type; WHO, 
World Health Organization. * Data not available; ** Non-glioma, no WHO-grade.
We then analysed the profiles in relation to survival with treatment and histopathology 
as additional parameters. Retrospective analysis of histopathology and clinical 
follow-up data revealed that all patients in clusters A and C received temozolomide 
(TMZ) and/or radiotherapy upon signs of tumour progression after surgery, 
suggesting that the differences in survival were not related to treatment. We therefore 
concentrated on patients in cluster B who were treated with TMZ (N=9, astrocytomas), 
procarbazine/lomustine/vincristine (PCV) chemotherapy (N=6, all 1p/19q co-deleted 
oligodendrogliomas), both adjuvant therapies (N=3), or did not receive additional 
treatment (N=19). Of 2 patients adjuvant therapy status was unknown (N=2). As shown 
in Figure 2B, outcome for oligodendroglioma patients treated with PCV was better 
than for astrocytoma patients treated with TMZ (p=0.04). 
Whereas group B was dominated by IDH-mutated gliomas, this group also contained 
6 IDH wild-type glioblastomas. Comparison of gene expression profiles of these 
gliomas with those of cluster A revealed that expression levels of all VEGF isoforms 
were significantly lower in the group B IDHwt gliomas (Supplementary Table S3). This 
suggests that these 6 tumours grouped with the IDHmut gliomas based on the lack of 
an angiogenic response. 
t/RNA-NGS based molecular diagnosis
To investigate whether t/RNA-NGS profiles are associated with histopathology 
diagnoses, we performed a group-based analysis according to the WHO 2016 grading 
system 349 and compared grade II/III astrocytomas (N=12), grade II/III oligodendrogliomas 
(N=19) and glioblastomas (N=38). Wilcoxon Mann-Whitney U tests identified 79 genes 
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that were differentially expressed between diffuse grade II/III oligodendrogliomas and 
glioblastomas (Table S4A). In the top 5 of differentially expressed genes were LDHA 
and BCAT1, genes that are known to be hypermethylated in low grade, IDHmut gliomas 
343,350. Expression levels of 50 genes were significantly different between grade II/III 
astrocytomas and glioblastomas (Table S4B), whereas expression levels of only 1 gene 
(ALK) differed significantly between astrocytomas and oligodendrogliomas (Table 
S4C). As expected, both oligodendrogliomas and astrocytomas were distinguished 
from glioblastomas by the p.IDH1-R132H mutation. EGFRvIII was expressed in 30% of 
glioblastomas (N=13; mean FPM=550, range 6-1450; Figure 3A) and never in grade II/
III gliomas, in good agreement with literature 351. Expression of wild-type EGFR was 
found among all gliomas, but was more prominent in glioblastomas than in grade II/
III gliomas (mean FPM=612 vs. 126; p=0.0061). Levels of EGFR and MET expression in 
glioblastomas were inversely correlated (Spearman R=-0.59, p<0.0001; Figure 3B). Not 
surprising given the strong association of IDH1 mutations and grade II/III gliomas with 
cluster B of Figure 1, the supervised histopathology-based analysis again identified 
ERBB3, ERBB4 and TRKB (the product of NTRK2) as potentially targetable proteins in 
grade II/III gliomas (Figure 3C). 
Figure 3. Actionable gene expression in grade II/III astrocytomas, oligodendrogliomas and glio-
blastoma. A) EGFRvIII was detected at significant levels in 30% of glioblastomas (GB, red) but not 
in grade II/III astrocytomas (A) and oligodendrogliomas (O) (note the log scale of the Y-axis, 
expression <5 FPM was considered EGFRvIII-negative). B) Wild-type EGFR expression is inversely 
correlated with expression of MET in glioblastoma (Spearman R=-0.59; p<0.0001). C) Mean ex-
pression of ErbB3, ErbB4, and NTRK2 in GB (red) and grade II/III O/A (blue). Error bars represent 
the standard deviation. 
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Carbonic anhydrase 12 is a poor prognostic factor
To investigate whether prognostic factors other than IDH1 mutations can be identified 
by t/RNA-NGS, we performed subgroup analysis on tumour profiles from IDHwt patients 
with survival <14 months and >14 months (the median overall survival time of this 
group of patients). A Fisher’s exact test on the sequence variations in these groups 
identified two different splice isoforms of CAXII: a full-length variant 1 (CAXIIv1), and a 
variant 2 (CAXIIv2) that lacks exon 9. Expression levels of CAXIIv1 were associated with 
poor survival (Figure 4A). Detection of this variant was based on one smMIP with both 
exon 8-9 and exon 8-10 boundaries in its ROI. This smMIP can detect both isoforms due 
to the small size of exon 9 of 33 nucleotides. Interestingly, CAXIIv1 was never detected 
in IDHmut gliomas. CAXIIv1 expression values higher than 50 FPM translated in poor 
prognosis as shown by Kaplan-Meier analysis (272 vs.1002 days from surgery to death, 
p=0.0137; Figure 4B).
Figure 4. Expression of CAXII is a poor prognostic factor. A) CAXIIv1 expression levels in the 
positive patient samples included in panel A. Expression >50 FPM is a poor prognostic survival 
marker. B) Kaplan-Meier curve of IDHWT gliomas, grouped based on CAXIIv1 expression. 
Validation of t/RNA-NGS data
We have previously shown that the quality of t/RNA-NGS data correlates well with 
w/RNA-NGS 309. All IDH1 and IDH2 mutations that were found with regular molecular 
screening, were verified by t/RNA-NGS 343. Interestingly, the broad set-up of our t/
RNA-NGS assay allowed the frequent detection of androgen receptor (AR) in gliomas 
at relatively high levels. To confirm and validate these and other findings on the 
proteome level we performed immunohistochemical analyses for EGFR, MET, CAXII 
and AR on a number of tumours with low or high FPM values for the corresponding 
genes. Transcript levels for EGFR, MET, CAXII, and AR correlated with protein levels 
(Figure 5). In one case we found that EGFR-transcript levels from frozen tumour tissue 
did not match with protein levels in FFPE blocks. This discrepancy could be attributed 
to tumour heterogeneity since the FFPE block contained both EGFR-positive and 
negative areas (Figure 5A). 
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Figure 5. Immunohistochemical staining of EGFR, MET, CA12, AR, and PSMA. A, B) EGFR staining 
of tumour N15-12 (negative in the smMIP assay) was negative in the frozen section, but partly 
positive in the FFPE section, indicating intratumoural heterogeneity of EGFR expression. High 
EGFR gene expression in tumour N16-13 was consistent with protein expression. IHC staining for 
MET (C), CA12 (D), and AR (E) of tumour samples with low (upper panels) and high (lower pan-
els) expression levels of MET, CA12 and AR respectively in the t/RNA-NGS assay. Expression levels 
in FPM are stated with the sample name. F) Staining for PSMA showed endothelial staining in gli-
omas with high PSMA (FOLH1) FPM values, as indicated with the yellow arrowheads in the lower 
panel. In gliomas with low expression (N14-05), no staining was observed (red arrowheads in up-
per panel point at blood vessels). Original magnification for upper panel in A, 5x. For lower panel 
of A and other panels, magnification is 10x. Yellow annotated bar for 5x 500µm, for 10x 200µm.
We also detected prominent expression of FOLH1, the gene encoding prostate specific 
membrane antigen (PSMA), in approximately 70% of the gliomas. To validate this 
finding, we performed IHC analysis for PSMA on a number of tumours with either low 
or high FOLH1 FPM values. IHC revealed expression of PSMA on the blood vessels of 
tumours with high FOLH1 FPM values (Figure 5F). 
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Actionable markers in individual brain cancers
We then investigated whether t/RNA-NGS can stratify patient tumours based 
on relatively high expression of actionable targets (arbitrarily defined as >2-fold 
expression compared to the mean of all gliomas). Results of a selection of tyrosine 
kinases (EGFR, MET, ALK, AXL, KIT, RET, ROS1) for 12 gliomas are presented in Figure 6A. 
In only one tumour high expression levels of CD2, CD3, CD4, CD8, CTLA4 and PD-1 were 
found, suggesting an inflammatory phenotype (not shown). Many mutations were 
detected in the assay that are described as somatic mutations in the Cosmic database 
352. Potentially interesting mutations that we found (based on FATHMM score) included 
p.RET-S1002R, p.EGFR-G719D, p.EGFR-A289D, PTEN mutations ad TP53 mutations (not 
shown). 
Figure 6. Actionable markers in brain tumours. A) Overview of expression of potentially ac-
tionable targets in a subset of patients, expressed as fold change compared to the mean of 
the entire group. For clarity only tyrosine kinases are shown for a small selection of patients. B) 
Comparative analysis of a primary pleomorphous xantoastrocytoma and its recurrence 4 years 
later. C) Selection of actionable targets in sample N13-05, a metastasis of a lung cancer. Note 
high expression levels of the macrophage receptor RON, MET and CTLA4. Also VEGF isoforms 
121 and 189 are detected. 
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In the pleomorphic xanthoastrocyoma (PXA) in our test cohort a BRAFV600E mutation 
was found which was confirmed via genetic testing (Table 1). This mutation has been 
described before in PXA 353. These are mostly slow growing, low-grade gliomas but 
some patients will undergo malignant progression. Mutations in BRAF have been 
identified as poor prognostic factors for this tumour type 354,355. Interestingly, patient 
14-03 was operated for a recurrent tumour 4 years later (sample 18-13 in the validation 
cohort). Samples 14-03 and 18-13 were therefore re-analysed with t/RNA-NGS in 
the same sequencing run. The recurrent tumour showed a 70-80-fold increase of 
expression of transcription factors ASCL1 and HOXA1 and tyrosine kinases FGFR3, 
HER3, HER4 and MET (Figure 6B). Another interesting finding was high expression of 
oestrogen receptor 2 (ESR2) in the recurrent, but not the primary tumour. Whereas 
the p.BRAF-V600E mutation was retained, the recurrent tumour showed an additional 
p.NF1-E1571* nonsense mutation (not shown). This mutation has been described as 
pathogenic in the Cosmic database 352 (FATHMM score=0.99).
Other observations that were of potential clinical relevance were that the brain 
metastasis of lung carcinoma expressed relatively high levels of MET, RON and CTLA4 
(Figure 6C). This may suggest sensitivity to the MET/RON inhibitor BMS777607/
ASLAN002, combined with immune checkpoint inhibition 356. The ependymoma 
showed high levels of EGFRvIII (not shown). One glioblastoma expressed the MET∆7-8 
variant that we described previously 24. In the DNET, considered as a benign grade I 
tumour, we found high expression levels of ERBB3, FGFR2, FOLH1 and AXL. 
Validation cohort 
To validate these results, we next performed t/RNA-NGS on an independent validation 
cohort of 26 analysable glioma samples. p.IDH1-R132H mutations were found in 7 
samples, all diagnosed as grade II/III astrocytomas and oligodendrogliomas (Table 1). 
Differentially expressed genes between IDHmut and IDHwt gliomas in the experimental 
cohort were confirmed in the validation cohort (Supplementary Table S5). EGFRvIII 
expression was found in 4 of 19 (21%) of IDHwt glioblastomas and not in p.IDH1-R132H 
cancers, confirming results in the test cohort. Thus, the test is robust and yields 
batch-independent clinically relevant information. Survival data in the validation set 
could not be interpreted due to short time of follow-up.
Discussion 
We here describe the clinical application of a relatively novel and cost-effective 
multiplex next generation RNA sequencing assay for cancer pathway profiling. The 
assay generates expression profiles and sequence information of genes that have 
been identified by literature surveys as potentially important for diagnosis, prognosis 
and response to precision medicines in a variety of cancer types. We previously 
demonstrated that the test allows analysis of metabolism by measuring relative 
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expression levels of metabolic enzymes 343,345. To analyse clinically actionable pathways, 
we expanded the assay with smMIPs to quantify expression levels of and detect 
mutations in the involved genes. Analysis of the cohort of 103 brain cancers, of which 
97 well characterized gliomas, allowed robust group-based analysis, and confirmed 
high inter tumour molecular heterogeneity with respect to tyrosine kinase expression. 
Indeed, the biology in individual gliomas that drives progression is mostly a black box. 
Therefore, in the routine clinical setting molecular genetics is increasingly implemented 
as add-on to histopathology to aid the diagnostic process, but influence on therapeutic 
decision making is limited. Biomarkers that influence clinical management include IDH 
mutations, combined with loss of chromosome arms 1p and 19q, leading to a diagnosis 
of oligodendroglioma that responds well to PCV, whereas methylation of the MGMT 
promoter in glioblastoma predicts a better response to TMZ 357-359. EGFR status is 
also determined, amplification of which, in combination with the EGFR mutation, is 
associated with glioblastoma 360. We here show that a single t/RNA-NGS test gives 
the same genetic information that can be derived from DNA analysis, but additionally 
provides information on gene activity from mutated but also non-mutated alleles. 
Thus, RNA-profiling is better suited than DNA-profiling to draw conclusions on activity 
of biological pathways, and thus may be more reliable as a guide to personalized 
treatment plans 361,362. It must be noted that for this study we isolated RNA from tumour 
tissue, snap-frozen directly after surgery. Although t/RNA-NGS can also be performed 
on RNA isolated from FFPE tissue, we found that whereas the quality of t/RNA-NGS 
data is good if tissue is formalin-fixed directly after surgery, it decreases in case of large 
time lags between surgery and formalin fixation (data not shown). 
Tumours with overexpression of a targetable tyrosine kinase will be resistant to 
the corresponding inhibitor if other kinases are present that converge on the same 
signalling pathways 363. Insight in the entire repertoire of expressed tyrosine kinases, 
downstream signalling intermediates and counteracting phosphatases may therefore 
predict intrinsic resistance or rapid development thereof 177,364,365. t/RNA-NGS provides 
such insight for individual glioma patients, and even can identify gene activities 
that have so far been associated with other cancer types, opening new avenues for 
targeted therapy. For example, expression of the prostate cancer marker PSMA 
on microvasculature of glioblastoma as we show here, may provide opportunities 
for tumour-vascular targeting 366-368. Of interest, it was reported before that high 
expression levels of AR in glioblastoma translates into sensitivity to the AR antagonist 
enzalutamide 369. Notably, our data also confirmed the identification of CAXIIv1 as a 
marker of poor prognosis in glioblastoma patients 370. CAXII is a transmembrane enzyme 
that is involved in intracellular pH homeostasis and extracellular acidification, providing 
a biological explanation for the association with poor survival 371. Overexpression 
of CAXIIv1, but not CAXIIv2, in cell models leads to acidification of the extracellular 
milieu, whereas overexpression of CAXIIv2 leads to increased oxygen consumption 
(manuscript in preparation). Because CAXII is expressed at low levels in normal brain, 
it is an interesting therapeutic target for the group of CAXII-positive glioblastomas 372. 
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In conclusion we here present a novel t/RNA-NGS ‘one size fits all’ assay that can 
provide a molecular diagnosis and prognosis for glioma and other cancers, as well 
as generate a list of (actionable) gene expression levels and mutations for individual 
cancers. The work described in this manuscript was performed with RNA, isolated 
from optimally biobanked tissue. The small size of the RNA regions of interest (150 
bases) that is required for successful smMIP capture, however also allows testing 
of RNA isolated from formalin fixed, paraffin embedded tissue blocks, provided 
that autolysis is prevented by proper and rapid processing. The low costs and high 
throughput capacity of the assay (up to 400 samples can be processed simultaneously 
due to barcoding) makes it highly interesting to further analyse biobanked tissues in 
future studies and identify classifier profiles that can predict prognosis and response 
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Figure S1. Kaplan-Meier analysis of unsupervised clusters of the entire cohort. Indicated in the 
figure are (a) ependymoma, (b) lung metastasis, (c) DNET, (d) LPD, and (e) variant glioma.
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Table S1A: Differential gene expression in cluster A vs. B. A total of 83 genes were differentially 
expressed between the two clusters. Only genes that were significantly different are shown. 
Mean gene expression values (FPM) values for the clusters are given. For significance: A 
Wilcoxon-Mann-Whitney test with multiple testing correction was performed. Values are 
significant when the p-value is lower than the False Discovery Rate (FDR).  The cut-off for the 
FDR was <0.05.
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Table S1B: Differential gene expression in cluster B vs. C. A total of 69 genes were differentially 
expressed between the two clusters. Only genes that were significantly different are shown. 
Mean gene expression values (FPM) values for the clusters are given.  For significance: A 
Wilcoxon-Mann-Whitney test with multiple testing correction was performed. Values are 
significant when the p-value is lower than the False Discovery Rate (FDR).  The cut-off for the 
FDR was <0.05.
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Table S1C: Differential gene expression in cluster A vs. C. A total of 9 genes were differentially ex-
pressed between the two clusters. Only genes that were significantly different are shown. Mean 
gene expression values (FPM) values for the clusters are given.  For significance: A Wilcoxon-
Mann-Whitney test with multiple testing correction was performed. Values are significant when 
the p-value is lower than the False Discovery Rate (FDR).  The cut-off for the FDR was <0.05.
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Table S2: Mutation detection in glioma samples. A Fisher’s exact test was performed to identify 
genetic mutations that distinguish the clusters A, B, and C as defined in Figure 1. Mutations that 
were present in at least 10 percent of the unique reads were tested for significance. There were 
no significant differences between cluster A vs. C. The cut-off for the FDR was set at 0.01. Genes 
shown here were significantly different between clusters.
Table S3: Differential gene expression in IDHwt gliomas from cluster B vs cluster A. A total of 4 
genes were differentially expressed between the cluster A and the IDHwt gliomas that grouped in 
cluster B. Only genes that were significantly different are shown. Mean gene expression values 
(FPM) values for the clusters are given. For significance: A Wilcoxon-Mann-Whitney test with 
multiple testing correction was performed. Values are significant when the p-value is lower than 
the False Discovery Rate (FDR). The cut-off for the FDR was <0.05. 
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Table S4A: Differential gene expression in oligodendroglioma (O) vs. glioblastoma (G). A total 
of 79 genes were differentially expressed between the two histological types. Only genes that 
were significantly different are shown. Mean gene expression values (FPM) values for the histo-
logical type are given.  For significance: A Wilcoxon-Mann-Whitney test with multiple testing cor-
rection was performed. Values are significant when the p-value is lower than the False Discovery 
Rate (FDR).  The cut-off for the FDR was <0.05.
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Table S4B: Differential gene expression in astrocytomas (A) vs. glioblastoma (G). A total of 50 
genes were differentially expressed between the two histological types. Only genes that were 
significantly different are shown. Mean gene expression values (FPM) values for the histological 
type are given.  For significance: A Wilcoxon-Mann-Whitney test with multiple testing correction 
was performed. Values are significant when the p-value is lower than the False Discovery Rate 
(FDR).  The cut-off for the FDR was <0.05.
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Table S4C: Differential gene expression in astrocytomas (A) vs. oligodendroglioma (O). One 
gene was differentially expressed between the two histological types. Only genes that were 
significantly different are shown. Mean gene expression values (FPM) values for the histological 
type are given.  For significance: A Wilcoxon-Mann-Whitney test with multiple testing correction 
was performed. Values are significant when the p-value is lower than the False Discovery Rate 
(FDR).  The cut-off for the FDR was <0.05.
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Table S5. Analysis of validation cohort. Shown are fold changes of gene expression values, 
calculated by dividing mean FPM values of each transcript in IDH-WT tumours by that in IDH 
mutant tumours, both in the experimental cohort and validation cohort. FC, fold change.
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Clear cell renal cell carcinoma (ccRCC) comprises more than 80% of all renal cancers and 
when metastasized leads to a 5-year survival rate of only 10%. The high rate of therapy 
failure and resistance development calls for reliable methods that provide information 
on the actionable biological pathways and predict optimal treatment protocols for 
individual patients. We here applied targeted RNA sequencing (t/RNA-NGS) using 
single molecule Molecular Inversion Probes on tumour nephrectomy samples of 
five ccRCC patients, comparing tumour with healthy kidney tissues. Transcriptome 
profiling focused on expression of genes with involvement in ccRCC biology that can 
be targeted with clinically available drugs. Results confirm high expression of vascular 
endothelial growth factor-A (VEGFA) in tumour tissue relative to healthy-appearing 
kidney, in line with the angiogenic nature of ccRCC. PDGFRα and KIT, targets of the 
multi-kinase inhibitor sunitinib which is one of the current choices of first-line drug 
in metastasized ccRCC patients, were expressed at relatively low levels in tumour 
tissues, whereas significantly increased in normal kidney. Of all measured druggable 
tyrosine kinases, MET, AXL or EGFR were expressed at higher levels in tumours than in 
normal kidney tissues, although intertumoral differences were observed. Using cancer 
cell lines, we show that t/RNA-NGS gene expression profiles can be used to predict in 
vitro sensitivity to targeted drugs.
In conclusion, t/RNA-NGS analysis may provide insights into the (druggable) molecular 
make-up of individual renal cancers, and may guide personalized therapy of renal cell 
cancers. 
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Introduction
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma, 
comprising more than 80% of all renal cancers 373. Upon first diagnosis, 30-40% of 
patients have disseminated disease 374. Patients with metastasized ccRCC (m-ccRCC) 
respond poorly to chemotherapy or radiotherapy. While the prognosis for these 
patients has improved with the introduction of targeted therapies, side-effects and 
intrinsic or acquired resistance still lead to a 5-year survival rate of only 10% 375. 
In more than 80% of ccRCCs the von Hippel-Lindau gene (VHL) is mutated or silenced 
by promoter methylation, leading to dysfunctional VHL protein and subsequent 
accumulation of the transcription factor Hypoxia Inducible Factor 1 (HIF1α) 376. This 
leads to a state of pseudohypoxia, characterized by expression of HIF-target genes 
that are responsible for stimulation of angiogenesis and cell survival 266,376-379. Based 
on this molecular insight angiogenesis inhibitors have been implemented as targeted 
agents for progressive ccRCC patients 380. One of the current choices for first-line 
treatment is sunitinib, a tyrosine kinase inhibitor (TKI) with activity against vascular 
endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor 
receptor β (PDGFRβ) but also receptor tyrosine kinases PDGFRα, KIT, FLT3, RET and 
CSF1R. Twenty percent of ccRCC patients with metastasized disease does not respond 
to this treatment, whereas another 30% develops resistance within 12 months 118. These 
patients are treated in second-line with other TKIs such as cabozantinib (targeting 
VEGFRs, MET, AXL, RET, KIT, FLT3), mTOR inhibitors, or immune checkpoint inhibitors 
381-383. Rationale for treatment with these drugs comes from clinical trials, but therapy 
decision making in general does not include the molecular characteristics of an 
individual tumour. The high rate of non-responders and occurrence of serious side 
effects call for novel methods to determine optimal treatment protocols for individual 
m-ccRCC patients. 
HIF1 hyperactivity also induces a shift in metabolism 309,384,385. Instead of shuffling 
glucose-derived pyruvate to the mitochondrial tricarboxylic acid (TCA) cycle, ccRCC 
cells convert pyruvate into lactate to accommodate their energy demand. The 
increased glucose uptake that accompanies this glycolysis also leads to increased 
activity of the pentose phosphate pathway (PPP), an important producer of 
nucleotides and reductive power. These metabolic alterations are strongly associated 
with disease progression and patient survival 267,384. Altered metabolism may therefore 
be an appropriate therapeutic target for m-ccRCC, but carries a risk of side-effects in 
healthy tissues 386. We hypothesized that concomitant inhibition of tumour cell tyrosine 
kinases, angiogenesis and metabolism may have additive or even synergistic effects, 
and may allow dose reduction to minimize effects on healthy tissues.
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Here, we determined expression levels of potentially actionable genes in clinical 
ccRCCs and in RCC cell lines using targeted RNA next-generation sequencing (t/
RNA-NGS) 309,344, and show that from the transcriptional profiles potentially effective 
treatment combinations can be inferred.
Materials and Methods 
Patient material
Use of patient tissues for this study was approved by the local committee of 
the Radboudumc and involved informed consent. All methods were performed 
in accordance with the guidelines for use of human tissue of the Radboudumc. 
Immediately after tumour nephrectomy, one 1 cm3 of healthy-appearing renal 
tissue (referred to as healthy tissue) and three tumour tissue fragments (T1-3) from 
different parts of the tumour were collected and snap-frozen in liquid nitrogen. Tissue 
samples were anonymized to the researchers. All tumours were identified as ccRCC by 
standard histopathology. Of all tissue samples H&E stainings were performed on 4 µm 
cryosections to estimate tumour cell percentage.
Cell culture
VHL-defective cell lines SKRC7 and SKRC17 are derived from a primary human ccRCC 
and a soft tissue metastasis of ccRCC, respectively 273. Both cell lines were cultured in 
RPMI 1640 medium (Lonza Group, Switzerland) supplemented with 10% fetal calf serum 
(FCS; Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 40 µg/ml gentamycin 
(Centrafarm, Etten-Leur, The Netherlands) at 37°C in a 5% CO2 environment. The 
patient-derived astrocytoma cell line E98 has been described before 24 and was cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4.5 g/L glucose and 4 mM 
L-glutamin (Lonza, Basel, Switzerland), supplemented with 10% FCS (Gibco, Waltham, 
MA, USA) and 40 µg/ml gentamycin (Centrafarm, Ettenleur, The Netherlands) at 37°C 
in the presence of 5% CO2.
Targeted RNA sequencing
RNA was isolated from 10 µm cryosections using TRIzol reagent (ThermoFisher Scientific, 
Waltham, MA, USA) and reverse transcribed with Superscript II (ThermoFisher Scientific) 
using random hexamer primers, according to the manufacturer’s instructions. Targeted 
RNA sequencing using smMIPs has been described before 308,309. In short, smMIPs 
were designed against target regions of interest (UCSC human genome assembly 
hg19 and splice-variant specific FASTA sequences) based on the MIPgen algorithm 
as described by Boyle et al. 275, including a random octanucleotide unique molecule 
identifier (UMI). SmMIPs were phosphorylated using T4 polynucleotide kinase as 
described 309. The panel of transcripts of interest as presented in 309 was expanded 
with new cancer-related transcripts (Supplementary Table S1). Phosphorylated 
smMIPs (898 smMIPs, together targeting 150 transcripts) were hybridized to 50 ng 
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of cDNA, followed by enzymatic gap-fill by primer extension and ligation. Exonuclease 
treatment, PCR amplification and library pooling and purification were performed as 
described 309. smMIP-PCR libraries were sequenced on the Illumina Nextseq platform 
(Illumina, San Diego, CA) at the Radboudumc sequencing facility. Reads were mapped 
against reference transcripts (UCSC human genome assembly hg19 and variant-specific 
FASTA sequences) using the SeqNext module of JSI SequencePilot version 4.2.2 build 
502 (JSI Medical Systems, Ettenheim, Germany). The UMI was used to reduce all 
identical PCR amplification products to one consensus read originating from the same 
smMIP (unique read). Unique read counts for each smMIP were normalized to the 
total unique read count within a sample and multiplied by 106 (Fragments per Million, 
FPM). Individual transcript levels were expressed as mean FPM of all smMIPs targeting 
that transcript. Variant calling was performed within SeqNext, excluding all variants 
with a coverage of <10% variant reads.
Western blot
Cryosections of normal kidney and matched tumour tissues were lysed in 1x RIPA 
buffer (Cell Signaling Technology, CST, Danvers, MA) supplemented with 1 mM 
phenylmethylsulfonyl fluoride (PMSF), according to manufacturer’s instructions. Cell 
lines were seeded in 6-well plates and allowed to adhere. E98, SKRC7 and SKRC17 cells 
at ~80% confluence were treated with MET inhibitors Compound A (targeting MET; 
Amgen, Thousand Oaks, CA, USA 207,387), cabozantinib (targeting MET, VEGFR, RET, 
AXL, KIT, FLT3; Exelixis, San Francisco, CA, USA 177,203,212) or DMSO vehicle for 20 min. 
Subsequently, SKRC7 cells were stimulated with HGF for 10 min. After treatment, cells 
were washed twice with ice-cold PBS and lysed in 1x RIPA buffer. 
Cell lysates were subjected to electrophoresis on 10% SDS-PAGE gels and electroblotted 
onto nitrocellulose membranes (Whatman Optitran BA-S85, GE Healthcare, Little 
Chalfont, UK). Following blocking of aspecific binding sites in blocking buffer (1:1 
PBS/Odyssey blocking buffer [LI-COR Biosciences, Lincoln, NE, USA]), blots were 
incubated o/n at 4°C with primary antibodies: rabbit-anti-MET (1:2500, CST, #8198), 
rabbit-anti-P-MET Tyr1234/Tyr1235 (1:2500, CST, #3077), rabbit-anti-P-ERK1/2 Thr202/
Tyr204 (p44/p42, 1:500, CST, #4376), rabbit-anti-P-AKT S473 (1:2500, CST, #4060), 
rabbit-anti-CAIX (1:1000, Epitomics, #3829B), goat-anti-γ-tubulin C-20 (1:5000, Santa 
crus, #sc-7396) and mouse-anti-GAPDH (1:10000, Abcam, ab8245). Primary antibodies 
were detected with appropriate IRDye680- or IRDye800-conjugated secondary 
antibodies (Invitrogen Molecular Probes, Waltham, MA, USA) incubated 1 hr at RT 
shielded from light. Signals were visualized using the Odyssey imaging system (LI-COR 
Biosciences, Lincoln, NE, USA). 
Cell proliferation assays
Cells were seeded in 96-well plates (2,000 and 20,000 cells/well for SKRC7/SKRC17 
and E98 cells, respectively). The next day increasing concentrations of Compound A, 
cabozantinib, gefitinib (targeting EGFR; Axon Medchem, Groningen, The Netherlands) 
or 6-aminonicotinamide (6AN, targeting glucose-6-phosphate dehydrogenase (G6PD); 
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Sigma-Aldrich, St. Louis, MO, USA) were added to the medium. For monotherapy 
assays with Compound A and cabozantinib metabolic activity of cells was measured 
four days later by incubation with 0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) in PBS (Sigma-Aldrich, St. Louis, MO, USA). After 3.5 
hr incubation at 37°C formazan crystals were dissolved in DMSO and optical densities 
were measured at 560 nm. Alternatively, for combination therapies total protein 
content was measured four days after start of treatment. Cells were washed with PBS 
and fixed overnight with 10% (w/v) trichloroacetic acid at 4°C. Total cellular protein was 
stained with 0.5% (w/v) sulfurhodamine B (SRB, Sigma-Aldrich, St. Louis, MO, USA) in 
1% acetic acid. After 20 min wells were washed 4 times with 1% acetic acid to remove 
unbound dye and dried at 60°C. Protein-bound SRB was solubilised using 150 µl 1 mM 
Tris-HCl (pH=10) and optical densities were measured at 560 nm.
Synergy of drug combinations was assessed by calculation of the combination index 
(CoI) and dose reduction index (DRI) using CompuSyn software (ComboSyn, Inc.), 
according to the manufacturer’s instructions 388,389. Increasing concentrations of 
Compound A and cabozantinib were combined with gefitinib and 6AN in a constant 
ratio. Levels of synergy were calculated using the fraction affected (FA-) value, and 
classified as follows: CoI=0.1-0.3 strong synergism, CoI=0.3-0.7 synergism, CoI=0.7-0.85 
moderate synergism, CoI=0.85-0.9 slight synergism, CoI=0.9-1.1 additive, CoI=1.1-1.2 
slight antagonism, CoI=1.2-1.45 moderate antagonism, CoI=1.45-3.3 antagonism. The 
DRI denotes an indication for the fold of dose-reduction allowed for each drug due to 
synergism when compared with the dose of each drug alone. 
Statistical analysis
Statistical analyses were performed in R (version 3.4.3). Mean FPM values were log2 
transformed (after addition of 0.01 to prevent log(0) transformation errors) and 
clustered in an unsupervised manner using the Manhattan distance and Average 
(Unweighted Pair Group Method with Arithmetic Mean, UPGMA) clustering method, 
and translated into a heatmap. A Wilcoxon Mann-Whitney U test was performed to find 
differentially expressed genes between clusters (p<0.05). Multiple testing corrections 
were done using Benjamini Hochberg (FDR<0.01). 
Results
From 5 tumour nephrectomies, one biopsy of healthy kidney tissue and three matched 
tumour biopsies were collected for t/RNA-NGS. H&E staining of all tumour samples 
confirmed ccRCC diagnosis. Normal-appearing kidney tissues, taken at distance of 
the tumour, were free of cancer cells (Figure 1). The mean unique read count of t/
RNA-NGS per sample was >106, which is sufficient to generate reliable expression and 
mutation data. Unsupervised hierarchical clustering of gene expression levels (given 
as Fragments per Million, FPM) of all 20 samples as obtained with t/RNA-NGS resulted 
in two main clusters A and B, comprising all healthy kidney tissues and all tumour 
tissues, respectively (Figure 2). Tumour biopsies from patients B, D and E clustered 
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together in subgroups, showing that inter-tumour variability for these patients was 
higher than intra-tumour heterogeneity. For patients A and C, one of the three tumour 
samples grouped separately from the other two. 
Figure 1. H&E stainings of tissues biopsies from ccRCC patients A-E. For each patient one 
healthy-appearing kidney sample and three tumour biopsies (T1-T3) are included. Original mag-
nification 20x.
We then performed a Wilcoxon Mann-Whitney U test to compare gene expression 
profiles in cluster A versus cluster B. Expression of 44 transcripts differed significantly 
between both clusters (Table 1). Expression levels and fold changes of all genes of 
which expression did not significantly differ are outlined in Supplementary Table 
S2. Differential gene expression was observed for genes associated with glucose 
import and glycolysis (high in cluster B, ccRCC tissues), and genes encoding TCA 
cycle enzymes, glutamine/glutamate metabolism and lipid synthesis (low in cluster 
B; Figure 3). HIF1 target genes carbonic anhydrase IX (CAIX) and the pro-angiogenic 
VEGFA isoform VEGFA-165 were significantly associated with cluster B. CAIX levels of all 
tissue biopsies are presented in Figure 4A. CAIX transcript expression correlated well 
with protein levels (representative examples shown in Figure 4B). Transcript levels of 
tyrosine kinase receptors ERBB4, PDGFRA, ERBB2, RET, KIT, NTRK1, MST1R (RON) and 
NTRK2 were significantly decreased, while expression of the tyrosine kinase receptor 
MET was significantly increased in cluster B compared to cluster A (Table 1).
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Figure 2. t/RNA-NGS of ccRCC and healthy kidney tissue. Tissues originate from five ccRCC pa-
tients, one healthy-appearing kidney sample and three tumour biopsies each. Heatmap containing 
152 genes, generated by unsupervised hierarchical clustering using the Manhattan distance and 
Average clustering method. Two head clusters are generated: cluster a contains all healthy kidney 
tissues, while cluster b consists of the tumour biopsies from all five ccRCC patients. The three 
tumour biopsies from patients B, D and E cluster together in a subcluster, while patients A and C 
both have one tumour sample that groups separately from the other two. (Previous page)
Figure 3. Metabolic transcript expression changes in ccRCC tissue compared to healthy kidney 
tissue. Mean FPM values of cluster a (healthy-appearing kidney tissues) were compared with 
mean FPM values of cluster b (tumour biopsies) using the fold change of (cluster b/a) or -1/(clus-
ter b/a). For visuality, transcripts with a fold change of >1.5 or <-1.5 (see Table 1 and Supplementa-
ry Table S2) are coloured in green and red, respectively. Transcripts marked with a * are changed 
significantly, as determined with a Wilcoxon Mann-Whitney U test and Benjamini Hochberg cor-
rection for multiple testing (p<0.05, FDR<0.05) (see Table 1 and Supplementary Table S2).
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Table 1. Differential gene expression in cluster A vs. cluster B. Expression of 44 genes differed 
significantly between cluster a and cluster b. Fold changes of cluster b/cluster a are indicated. 
Significance was determined using a Wilcoxon Mann-Whitney U test with Benjamini Hochberg 
correction for multiple testing (p<0.05, FDR<0.01). Note that for significance, the p-value must 
not exceed the FDR. Fold changes are calculated as (cluster b/a), or -1/(cluster b/a) to prevent 
fold changes >0 and <1. FC, fold change.
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Variant calling of the t/RNA-NGS datasets revealed mutations in the VHL gene in tumour 
samples of four of the patients, which were not present in matched healthy kidney 
tissue, identifying these as somatic mutations. Three patients had VHL STOP mutations 
whereas in patient C the known pathogenic VHL p.L118P mutation was detected in 
one tissue biopsy, in 29% of the reads (Table 2). The coverage of the corresponding 
c.353T locus in this sample was 22 unique reads as compared with 7 and 18 unique read 
counts in the other two biopsies of the same tumour, in which the mutation was not 
called. This suggests intra-tumour heterogeneity of this pathogenic variant, although 
low coverage may also cause a false-negative result. 
Figure 4. CAIX expression in ccRCC. A) CAIX FPM values in each individual tissue biopsy of ccRCC 
patients A-E. CAIX expression is absent in healthy kidney tissues, while elevated in ccRCC tissues. 
B) CAIX transcript expression levels correlate well with protein levels, as shown for three repre-
sentative patients. γ-tubulin was used as a loading control. Presented blots are cropped. 
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Table 2. VHL mutations in ccRCC. Different VHL mutations with variable coverage levels were 
detected in four of the five ccRCC patients, with VHL STOP mutations in three of the patients.
We then focussed on the relative expression levels of tyrosine kinases that are 
potential targets for available precision medicines. VEGFA and the pro-angiogenic 
isoforms VEGFA-121, VEGFA-165 and VEGFA-189 were highly expressed in all cancers, 
although there was interpatient heterogeneity with respect to VEGFR2 expression 
levels (Figure 5A and B). Of note, PDGFRA and KIT were expressed at relatively low 
levels in tumour tissue and higher in healthy kidney tissue (Figure 5). Among other 
targetable tyrosine kinases AXL, MET and EGFR were expressed at high levels in some, 
but not all, tumour samples (Figure 5C). Expression of cytotoxic T-cell marker CTLA4 
varied widely between patients, whereas expression of PD-1 (PDCD1) was uniformly 
low and tumour cell marker PD-L1 (CD274) was only moderately expressed (Figure 5D). 
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Figure 5. Possible targets for individualized targeted therapeutics. Expression levels are shown 
in FPM. FPM levels of the three tumour biopsies for each patient are averaged, error bars rep-
resenting the level of intratumour heterogeneity. Expression of A) VEGF-A variants, B) sunitinib 
target genes, C) other targetable receptor tyrosine kinases, D) immune checkpoints in ccRCC 
patients A-E. Intertumour heterogeneity is visualized. Data represent mean ± SD.
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Figure 6. Targeted therapy prediction based on t/RNA-NGS. A) Heatmap showing expression 
levels (FPM) of 136 genes in E98, SKRC7 and SKRC17 cell lines. B) E98, SKRC7 and SKRC17 cells 
were treated for 20 min with Compound A or cabozantinib. SKRC7 cells were stimulated with 
HGF for 10 min subsequently. Phosphorylation levels of MET (Tyr1234/Tyr1235), AKT (Ser473) 
and ERK1/2 (Thr202/Tyr204) were monitored by western blot, with GAPDH as a loading control. 
Presented blots are cropped. C) MTT proliferation assays of E98, SKRC7 and SKRC17 treated with 
Compound A or cabozantinib. Both compounds show high efficacy in E98, but less in SKRC7 and 
SKRC17 cells. Data represent mean ± SD (N=4). D) FPM expression levels of a selection of tyro-
sine kinases in E98, SKRC7 and SKRC17. While E98 shows high expression of only the tyrosine 
kinase MET, SKRC cell lines also have considerable expression of AXL, EGFR, FGFR1 and FGFR2, 
tyrosine kinases that may be responsible for resistance to MET inhibition in these cells. Data 
represent mean ± SD (N=2).
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To test the hypothesis that t/RNA-NGS datasets can be used to guide targeted 
therapy we performed smMIP-based targeted RNA sequencing on patient-derived 
renal carcinoma cell lines SKRC7 and SKRC17 (Figure 6A). These cell lines express 
MET transcript and protein at levels comparable to the E98 astrocytoma cell line 24 
(Figure 6A, B) , which is very well characterized by our group 24,177,387 and was used 
as a positive control. MET phosphorylation in SKRC17 cells did not require addition of 
exogenous HGF, possibly a result of endogenous production of HGF (as determined by 
w/RNA-NGS, not shown). E98 cells were sensitive to MET inhibition by the multi-kinase 
inhibitor cabozantinib and mono-inhibitor Compound A as shown by decreased 
levels of phosphorylated MET 177,387. The same effects on pMET were observed in 
SKRC7 and SKRC17 cells. However, whereas in E98 cells decreased inhibition of MET 
phosphorylation coincided with decreased levels of pAKT and pERK, effects on 
pAKT were only minor in SKRC17 and pERK levels were unchanged in both cell lines 
(Figure 6B). In E98 cells inhibition of MET by Compound A or cabozantinib translated 
to decreased proliferation rates, but this was not the situation in SKRC7 and SKRC17 
cells (Figure 6C). A possible explanation is expression of additional membrane tyrosine 
kinases AXL, EGFR and FGFR1/2 that signal via similar pathways as MET. These kinases 
are not expressed by E98 and may provide compensation pathways for MET inhibition 
(Figure 6A and D). 
Table 3. Combination index (CI) and dose reduction index (DRI) values for the combination 
therapies as indicated, in SKRC7 and SKRC17 cell lines. The FA-values represent the fraction of 
cell viability affected by treatment. CI and DRI values are given for FA values of 0.5, 0.75 and 0.9.
Considering the expression of potential rescue kinases in SKRC7 and SKRC17 cells and 
the known interplay of MET and EGFR in therapy resistance 363, we tested combinations 
of the MET inhibitors Compound A and cabozantinib with the EGFR inhibitor gefitinib 
on SKRC7 and SKRC17 cell viability. Gefitinib induced moderate levels of synergy 
when combined with the MET inhibitor Compound A in SKRC17, but not SKRC7 cells. 
The combination of the MET/AXL/VEGFR2 inhibitor cabozantinib with gefitinib acted 
synergistically in SKRC7, but less so in SKRC17 cells (Figure 7 and Table 3). 
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Figure 7. Combination therapy of MET inhibitors Compound A and cabozantinib with an EGFR 
inhibitor (gefitinib) or G6PD inhibitor (6AN) in A) SKRC7 and B) SKRC17 cell lines. Drug effects 
were tested using SRB assays. The FA-value represents the fraction of cell viability affected by 
therapy. Points on the graph axes represent the dose of the monotherapy (drug A or B, as indi-
cated in the figure head of each isobologram) necessary to generate the given FA-value. The line 
connecting the x- and y-axis represents an additive effect (CoI=1) of the combination at the given 
FA-value. Points below or above the line represent synergism (CI<1.0) or antagonism (CI>1.0), 
respectively (N=2). (Previous page)
Because activity of TKIs does not only depend on expression levels of tyrosine kinases, 
but also on the expression levels and activities of the counteracting phosphatases 
390, reliable prediction of therapeutic efficacy of drug combinations is highly complex. 
Given the characteristic metabolic alterations induced in ccRCC, we next investigated 
the effect of combination therapy of Compound A or cabozantinib with metabolic 
inhibition by 6AN, an inhibitor of the rate-limiting PPP intermediate G6PD (FPM 
945.06 and 1241.78 in SKRC7 and SKRC17, respectively). In SKRC7 cells, combination 
of Compound A with 6AN induced moderate levels of synergism. Surprisingly, the 
combination of 6AN with cabozantinib was antagonistic in SKRC7 cells. However, 
combination of 6AN with Compound A or cabozantinib induced strong synergy in 
SKRC17 cells (Figure 7 and Table 3). All dose reduction indexes (DRI) for synergistic or 
additive drug combinations were favourable (Table 3).
Discussion
Patients with m-ccRCC are treated by first-line anti-angiogenesis therapy upon signs 
of tumour progression and immune checkpoint or alternative TKIs in second-line 380. 
However, these therapies do not take into account the molecular characteristics of the 
individual tumour. Using t/RNA-NGS we here show that whereas the five ccRCCs in our 
study share the metabolic reprogramming characteristic for this cancer, expression 
of targetable tyrosine kinases is heterogeneous between tumours. Remarkably, 
PDGFRα and KIT are expressed at much higher levels in the normal kidney than in the 
tumour cells, showing that targeting of ccRCC by sunitinib is not as cancer-specific as 
desirable, which may explain observed sunitinib-induced toxicity. Because t/RNA-NGS 
allows a comprehensive overview of all druggable tyrosine kinases in a tumour, it may 
allow more rational therapy decision making than is currently possible. Interestingly, 
we found significantly elevated tyrosine kinase receptor MET levels in ccRCC tissues 
compared to healthy kidney tissue, in agreement with in vitro studies and ccRCC tissue 
analyses demonstrating upregulation of MET induced by inactivation of VHL 391,392. 
There are multiple options for first-line TKI treatment including sunitinib, pazopanib 
and sorafenib, all having a different target spectrum. Recently, also cabozantinib 
has been approved for first-line therapy of advanced RCC. Considering the high MET 
expression in our subset of untreated ccRCC patients, MET inhibitors cabozantinib 
177,203,212 or Compound A 207,387 may be well suited for first-line treatment in this patient 
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group. Furthermore, MET upregulation has been associated with the development 
of resistance to VEGFR inhibition 393. Multi-kinase inhibition of MET, AXL and VEGFR2 
by cabozantinib may therefore particularly be effective in ccRCCs with elevated 
expression levels of MET and AXL, to simultaneously interfere with development of 
therapy resistance. On the other hand, angiogenic ccRCCs that overexpress EGFR 
may benefit better from the EGFR/VEGFR2 inhibitor vandetanib. It is important to 
realize that transcriptome data do not always correlate with protein expression, and 
therefore proof of concept for transcription-based therapy prediction has to come from 
retrospective studies in which t/RNA-NGS profiles are analysed with computational 
biology methods in relation to treatment and clinical outcome.
Dysfunctional VHL due to mutations or promoter hypermethylation are known 
drivers of ccRCC, causing accumulation of HIF1 and its target genes 266,376-379. In all five 
patients we confirmed VHL-associated metabolic alterations, notably upregulation 
of expression of genes involved in glycolysis and a decrease of expression levels of 
genes involved in the TCA cycle 384,385,394. In line with previous studies 395-397 expression 
of FBP1 was significantly decreased. FBP1 loss has been reported as a second unique 
feature of RCC and a mediator of HIF1-induced metabolic changes 398,399. Nonetheless, 
VHL mutations were detected in only four of the five ccRCC patients, and not in each 
of three biopsies. Low unique read coverage of transcript locations corresponding to 
a mutation may cause false-negative variant calling. Moreover, it has recently been 
suggested that a range of four to eight biopsies is required to capture the majority 
of driver events (>75%) in ccRCC 400, therefore sampling may also explain variability in 
mutation detection. Another possible explanation for failure to detect aberrant VHL is 
promoter hypermethylation, which was outside the scope of this study. 
While other studies have demonstrated increased expression of genes involved in PPP, 
glutamine metabolism and fatty acid synthesis 267,384, we found a significantly decreased 
expression of most enzymes involved in glutamine/glutamate metabolism and fatty acid 
synthesis in ccRCC tissues compared to healthy kidney tissue. Whereas dual activation 
of HIF2 and MYC induces glutamine-dependent lipogenesis in RCC 384,401-403, levels of 
both HIF2 and MYC expression in these five ccRCC patients were unaltered, possibly 
explaining the absence of increased glutamine synthesis. Moreover, the presence of 
metabolic shifts depends on aggressiveness of the tumour. Low expression levels of 
GPI and G6PD, which were unaltered in tumour compared with healthy tissue, have 
been associated with better patient survival 249. The low disease stage of these five 
ccRCC patients possibly implies that they do not have high metastatic capacity, which 
may explain why enzymes in abovementioned pathways are not elevated. 
Our in vitro data show that expression of therapy targets cannot always be translated 
to therapy response. Our data suggests that analysis involving the presence of direct 
therapy targets combined with the expression of genes in possible resistance pathways 
may allow prediction of therapy response. For example, MET and EGFR are well-known 
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to cause mutual cross-resistance to targeted therapy in different cancer types 303,404-409. 
Combined inhibition of MET and EGFR in vitro in SKRC7 and SKRC17 cell lines showed 
additive and moderately synergistic effects, but with positive DRI values, suggesting 
that in combination therapy the doses of each drug may be decreased to reduce drug 
toxicity. The very high DRI values of Compound A and cabozantinib in SKRC17 indicate 
that the dosages of these drugs could be dramatically decreased to achieve the 
therapeutic effect of the combination treatment with gefitinib, although this should 
be confirmed by similar in vitro and additional in vivo studies. Excessive toxicity has 
shown to complicate drug combination therapies in patients, but some clinical trials 
have also reported promising results 410-413. Better prediction for selected application 
of targeted (combination) therapies is essential to design treatment strategies with 
maximal efficacy and minimal toxicity
Transcript expression level-based combination therapy of MET tyrosine kinase 
inhibition with 6AN, a metabolic inhibitor against G6PD, did show strong synergism 
and positive DRI indexes in SKRC17 and may therefore be an interesting opportunity 
for new therapies. In SKRC7 the combination of 6AN with cabozantinib was however 
antagonistic, suggesting this combination of drugs may activate compensation 
pathways in these cells. Whereas SKRC7 and SKRC17 are derived from a primary 
human ccRCC and a soft tissue metastasis of ccRCC, respectively, here combination 
treatment involving PPP targeting seems most interesting in m-ccRCC cells. These data 
mark the complexity of tumour biology and the need for cautiousness with targeted 
therapeutics. 
Currently, ccRCC patients are offered first-line therapy based on clinical characteristics, 
and molecular characteristics are not included in the clinical management. Our data 
demonstrate the prominent inter-tumour variability that exists between ccRCC 
patients, and highlights the need for individual tumour profiling and personalized 
therapy. Moreover, t/RNA-NGS may allow repurposing of drugs that have been 
approved for other cancers but not (yet) for ccRCC. 
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Table S1. Transcripts for smMIP design. SmMIPs were designed against the antisense strand of 
predicted transcripts (UCSC human genome assembly hg19 and splice variant specific FASTA 
sequences). The genes listed are newly added to the panel published in De Bitter et al., 2017 
(Sci. Rep.).
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Table S2. Gene expression in cluster a vs. cluster b (non-significant). Fold changes of cluster b/
cluster a are indicated. Significance was determined using a Wilcoxon Mann-Whitney U test with 
Benjamini Hochberg correction for multiple testing (p<0.05, FDR<0.01). Note that for signifi-
cance, the p-value must not exceed the FDR. Significant differential gene expression in cluster a 
vs. cluster b is shown in Table 1. Fold changes are calculated as (cluster b/a), or -1/(cluster b/a) to 
prevent fold changes >0 and <1. FC, fold change.
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There is a great medical need for robust and reliable stratification methods to predict 
response of lung cancer patients to precision medicines. Comprehensive RNA-based 
analysis of pathways that are involved in tumour initiation and progression may be 
helpful to guide treatment decisions. Here, targeted RNA next-generation sequencing 
(t/RNA-NGS) using single molecule molecular inversion probes (smMIPs) was applied 
to 94 stage I-IV lung cancers and normal lung tissues, to quantify expression levels 
of and detect mutations in ~350 potentially relevant genes. Computational biology 
was applied to the output, to find classifiers that predict histopathology and clinical 
outcome.
Analysis of t/RNA-NGS datasets generated histology-independent molecular diagnoses 
and gave a comprehensive overview of relevant biological pathways in individual 
cancers. t/RNA-NGS yielded mutation information largely consistent with genetic 
analyses, but conversely, not all genetically identified mutations were detected by 
t/RNA-NGS. Based on overexpression of targetable genes in individual tumours the 
results suggested that for ~50% of patients personalized treatment with inhibitors of 
ALK, BRAFV600E, EGFR, KIT, MET, MEK or immune checkpoint inhibitors could have been 
potential alternative options. 
t/RNA-NGS may be an appropriate methodology to get a comprehensive overview of 
actionable biology in cancer tissues. The low costs and high specificity and sensitivity 
of t/RNA-NGS may allow stratification of patients for targeted treatment with precision 
medicines. Clinical trials should be started to reveal the value of t/RNA-NGS-based 
mapping of actionable biology for personalized medicine.
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Introduction
Non-small cell lung cancer (NSCLC) comprises 80-85% of all lung cancers, the major 
histological subtypes being squamous cell carcinoma (SCC) and adenocarcinoma 
(AdCa) 414-418. Patients with local disease (stage I-III) are treated by (potentially curative) 
surgery and (chemo-)radiotherapy. This group has a 50-90% chance of recurrent 
disease with dismal prognosis 419. If at first diagnosis disease has disseminated beyond 
the lymph nodes, surgery or radiotherapy is futile and patients will be treated with 
systemic treatment or, increasingly, first-line precision medicine. In the latter case 
treatment strategy is dictated by molecular analysis of biopsies. 
In the last twenty years many of the genetic alterations that are involved in the 
formation and progression of NSCLC have been elucidated 420-422. These include 
amplification and activating mutations in the membrane tyrosine kinase receptors 
EGFR and MET 423-425, rearrangements of RET, ROS1, NTRK2 and ALK 422,426,427 and 
activating mutations in downstream signalling molecules KRAS and BRAF. Patients 
in whom these aberrations are identified through analysis of tumour DNA (20-25% of 
all NSCLC patients 422) are eligible for targeted treatment with precision medicines 
that are designed to block activation of these proteins (e.g. erlotinib or gefitinib for 
EGFR-amplified cancer, osimertinib for cancers with EGFRT790M, crizotinib and entrectinib 
for ALK- and NTRK2-rearranged tumours respectively, foretinib for MET-amplified 
NSCLC, dabrafenib for NSCLC with BRAFV600E and MEK inhibitors for KRAS-mutated 
cancers). However, there are also situations in which aberrant biological pathways are 
not related to genetic aberrations, but rather to expression of actionable genes that 
are regulated by transcription factors, e.g. under conditions of hypoxia. A noteworthy 
example is expression of vascular endothelial growth factor (notably the VEGFA-165 
isoform) by tumour cells and its receptors VEGFR1/2 and neuropilins (NRP) in vascular 
cells, the combination of which induces an angiogenic response under conditions of 
high angiopoietin 2 (ANGPT2) 428-430. 
It is therefore of high importance to map all potentially involved tumour-promoting 
pathways, in addition to the relevant genetic mutations, in individual cancers. A 
well-known example is tumours with activating mutations in BRAF or KRAS, that will not 
respond to medicines that block upstream tyrosine kinases 431. Furthermore, tumours 
can escape therapy effects by acquisition of resistance mutations (e.g. EGFRT790M, 
inducing resistance to erlotinib 432), by induced expression of rescue tyrosine kinases 
363,433 or by upregulation of endogenous inhibitors of phosphatases 434. Additionally, 
reliable predictive biomarkers do not exist for inhibitors of complex pathways such 
as angiogenesis and immune response that involve non-variant genes expressed by 
stromal cells. Indeed, immune checkpoint inhibitors, nowadays probably the most 
promising class of drugs for treatment of multiple tumour types, lead to durable 
responses in only small subgroups of patients 435. Histopathological characteristics are 
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also included in therapy decision making, as AdCas and SCCs respond differently to 
precision medicines 436-441. The molecular backgrounds of these differential sensitivities 
are not known.
Clearly, there is a great need for novel methods that allow appropriate patient 
stratification to fulfil the promise of personalized treatment with precision medicine. 
Based on the finding that classifiers can be derived from RNA analysis 442 we here 
applied a recently developed quantitative method of targeted RNA next-generation 
sequencing (t/RNA-NGS) based on single molecule molecular inversion probes 
(smMIPs). t/RNA-NGS yields comprehensive information on sequence and activity of 
genes potentially involved in cancer development and progression (including cancer 
cells and stromal cells) 309,344,345. We show that t/RNA-NGS allows the establishment of 
a molecular diagnosis based on information of expression levels and mutation status 
of genes and biological pathways that are targetable with currently available precision 
medicines. Our results suggest that t/RNA-NGS may be helpful to stratify NSCLC 
patients for personalized precision medicines.
Materials and Methods
Patient material
A cohort of surgically obtained NSCLC tissues (N=81) and histologically normal-appearing 
lung samples (from here referred to as normal lung tissue; N=13), collected between 
2002 and 2008, was available for this study 415,443. Histopathology and clinical 
characteristics of tissues and patients are summarized in Table S1. NSCLC tissues 
consisted of AdCas (N=40), SCCs (N=33) and a group of ‘others’ including large-cell 
carcinoma (N=4), large-cell neuroendocrine carcinoma (N=1), pleiomorphic carcinoma 
(N=1), mixed large-cell carcinoma (N=1) and adenosquamous carcinoma (N=1).
From all tissues, biopsies were frozen in liquid nitrogen and stored at -80°C, in addition 
to standard processing for histopathology and immunohistochemistry as described 
before 443. The study was approved by the regional institutional ethical review board 
for human experimentation and involved signed informed consent. RNA from frozen 
tumour sections was subjected to quantitative RT-PCR (qPCR) with primers to detect 
expression levels of DLL4, GLUT-1, Notch, MCT4, MYC and CAIX. qPCR was performed 
on a CFX96 real-time PCR detection system (Bio-Rad Laboratories Inc, Richmond, CA) 
using SYBR Green as described 443,444. 
Targeted RNA sequencing
SmMIPs to sequence regions of interest (ROI) in selected transcripts were designed 
based on the MIPgen algorithm as described by Boyle et al. 275. Routinely, for each 
transcript ~5 smMIPs were selected that were evenly distributed over that transcript 
and flanked ROIs known to potentially carry relevant mutations, or containing 
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alternative exon-exon junctions 344. UCSC human genome assembly hg19 and splice 
variant-specific FASTA sequences were used as references. Transcripts of interest 
have been described before 309,344-346,363 and included tumour suppressors, oncogenes, 
transcription factors, metabolism-associated genes, immune-related genes, receptor 
tyrosine kinases and downstream signalling intermediates, phosphatases, cell cycle 
checkpoint genes and angiogenesis factors. An equimolar pool of 1956 smMIPs 
(Integrated DNA Technologies, Belgium, 100 μM per smMIP) was phosphorylated 
using T4-polynucleotide kinase (New England Biolabs, Ipswich MA, USA), according to 
the manufacturer’s guidelines.
Frozen tissue sections were lysed in TRIzol reagent for RNA isolation via standard 
protocols (ThermoFisher Scientific, Waltham, MA, USA). Total RNA was processed 
to cDNA using reverse transcriptase (Superscript II, ThermoFisher Scientific) and 
random hexamer primers. SmMIP capture on 15-50 ng cDNA was performed using 
the Microlab STAR automated liquid handling workstation (Hamilton, Reno, Nevada, 
USA). After enzymatic circularization by primer extension and ligation, non-circularized 
smMIPs and remaining RNA and cDNA were removed by exonuclease treatment. 
PCR amplification of the circularized smMIP pool was performed using the Microlab 
STARlet automated liquid handling workstation (Hamilton), with a primer set including 
a unique barcoded reverse primer for each sample. Two μl of PCR product from all 
samples were pooled using the Microlab STAR and amplicons of the expected size 
of 266 bp were purified with AMPureXP beads (Beckman Coulter Genomics, High 
Wycombe, UK). After quality control on a TapeStation 2200 (Agilent Technologies, 
Santa Clara, CA, USA) and quantification using Qubit (Life Technologies, ThermoFisher 
Scientific, Waltham, MA USA), a 4 nM library was sequenced on the Illumina Nextseq 
platform (Illumina, San Diego, CA) at the Radboudumc sequencing facility. The SeqNext 
module of JSI SequencePilot version 4.2.2, build 502 (JSI Medical Systems, Ettenheim, 
Germany) was used to count reads after mapping against reference transcripts (UCSC 
human genome assembly hg19 and variant-specific FASTA sequences). Based on the 
8*N unique molecule identifier (UMI) that is included in all smMIPs and co-amplified 
during PCR, all identical PCR products were reduced to one consensus read (unique 
read). Unique read counts for each smMIP in a sample were divided by the total of 
unique read counts in that sample and multiplied by 106 (Fragments per Million, FPM). 
Individual transcript levels were expressed as mean FPM of all smMIPs targeting 
that transcript. Variant calling was performed with a dedicated SeqNext feature. For 
analysis we excluded variants with a coverage of <10% variant reads. Known single 
nucleotide polymorphisms (SNPs) were filtered from the variant list by comparison 
with the gNomad database. For each sample, gene expression levels were coupled 
to mutations using an in-house developed Python script. FATHMM scores for the 
resulting individual mutations were extracted from the Cosmic database.
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Statistical analyses of t/RNA-NGS data were performed in R (version 3.4.3). First, 
mean FPM values were log2 transformed (after addition of 0.01 to prevent log(0) 
transformation errors) and subjected to agglomerative clustering using the Manhattan 
distance and Ward.D2 method. Clusters were visualized in a heatmap using ClustVis. 
A Wilcoxon Mann-Whitney U test was performed to investigate differential gene 
expression between normal lung tissue, AdCas and SCCs. Multiple testing corrections 
were done using Benjamini-Hochberg (FDR<0.01).
To investigate the potential of applying t/RNA-NGS in the field of personalized medicine, 
we next investigated patterns of actionable genes in individual tumour samples. For 
each transcript the mean expression level in normal lung tissue (mean FPM normal) 
was calculated. Fold changes in transcript expression for individual tumour samples 
were calculated by                             . All statistically significant fold-changes of >1.5 were 
considered as potentially relevant. Validation of significant differences was done using 
The Cancer Genome Atlas (TCGA) database.
Results
t/RNA-NGS output correlates with qPCR and immunohistochemistry 
The 94 samples included in this study had a mean unique read count of 713,893 
(13,228-1,169,743). We have previously shown that t/RNA-NGS analysis produces 
output of similar quality as w/RNA-NGS data 309. In a study published in 2012, a largely 
overlapping cohort of patient tissues as we used here was extensively analysed 
for expression of genes with an involvement in glycolysis (glucose transporters, 
monocarboxylate transporters), differentiation (NOTCH1/3, Delta-like ligand 4 [DLL4]) 
and transcription (MYC) using qPCR 443,444. To establish the quantitative value of t/
RNA-NGS in this complex set of tissues, we calculated correlation coefficients between 
expression levels as determined by t/RNA-NGS and qPCR. We found good Spearman 
correlation scores between t/RNA-NGS and qPCR (Figure 1).
Unsupervised hierarchical clustering
Unsupervised clustering analysis of all tissues based on t/RNA-NGS gene expression 
profiles resulted in separation of normal lung tissues and cancers (Figure 2). One SCC 
clustered with the normal tissues (cluster B), whereas two additional clusters were 
formed that were dominated by SCCs (cluster A) and AdCas (cluster C). The tumours 
classified as ‘other’ clustered predominantly with the SCC group. 
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Figure 1. Correlation between t/RNA-NGS and qPCR data. t/RNA-NGS values for each transcript 
are expressed as fragment per million (FPM) on the Y-axis. X-axes represent log ∆CT values (34). 
t/RNA-NGS-based expression values correlated well with qPCR as established by Spearman r 
values. 
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Figure 2. Dendrogram and heatmap visualization of t/RNA-NGS data from 94 lung tissues. The 
heatmap was generated by unsupervised hierarchical clustering using the Manhattan distance 
and Ward.D2 clustering method and contains 353 genes. Three main clusters can be distin-
guished: cluster A containing mainly SCCs, cluster B consisting of predominantly normal lung 
tissues and cluster C containing mainly AdCas. 
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Differential gene expression: normal lung tissue versus lung carcinoma
The good gene expression-based separation between normal lung tissues and 
cancers prompted us to investigate differential gene expression between normal 
lung tissues and all cancers in a supervised analysis. 142 genes in our panel were 
differentially expressed with a factor >1.5 with statistical significance (p<0.05, 
FDR<0.01; Supplementary Table S2). Genes that were overexpressed in cancers 
included genes involved in glycolysis (CAIX, SLC2A1, GPI, ENO1, ALDOA, PDK1, PGK1, 
LDHA), TCA cycle (PC), DNA damage repair (RAD54L, BRCA1, BIRC5, BRIP1), transcription 
regulation (TOP2A, EZH2), cell proliferation (CDK1, PCNA, TUBB), differentiation (ZIC1) 
and detoxification (NQO1). Expression of telomerase (TERT) was never detected in 
normal tissues, whereas low TERT levels were observed in a subset of cancers (not 
shown). Interestingly, in this group-based analysis many genes that are considered 
targets for precision medicine were expressed at significantly lower levels in cancer 
than in normal lung tissues. These included VEGFR2/KDR, the VEGFA-189 isoform, AXL, 
ERBB4, FGFR1/2/4, NTRK3 and ROS1 (Supplementary Table S2).
 
Differential gene expression: adenocarcinoma versus squamous cell cancer 
Clinical and transcriptional differences between lung SCCs and AdCas have been 
described in literature 416-418. Supervised analysis of t/RNA-NGS-based gene expression 
in AdCa and SCC revealed that 103 genes were differentially expressed genes with fold 
change <-1.5 or >1.5 (p<0.05, FDR<0.01; Supplementary Table S3). Genes involved in 
angiogenesis (VEGFR2/KDR, DLL4, NRP1, FLT-1, VEGF, PDGFRβ) were expressed at higher 
levels in AdCa (Figure 3A), in line with the relatively high vascular density in this subtype 
(Figure 3B). Differential expression of metabolic genes suggested that, in comparison 
to SCC, AdCas depended more on gluconeogenesis (FBP1), the TCA cycle (MPC1, ACO2, 
IDH2/3, OGDH, SDHB, FH), glutamine metabolism (GLS) and lipogenesis (GLS, ACO1, 
ACSS2, ACACB, FASN). In line with a lower vascular density in SCC, glycolysis was the 
more predominant pathway in this group 445 as suggested by higher expression levels 
of glycolytic genes SLC2A1, GPI and SLC16A1 (Figure 3C). Mining of the TCGA database 
(TCGA_LUAD_2016) using lung cancer explorer 446 confirmed higher angiogenic activity 
in AdCas, and higher glycolytic activity in the SCCs (Figure 4). 
Other interesting findings were the significantly higher expression levels in AdCas of 
S100B, CD2, CD3, CD4, CD8, CTLA4 and PD-1, suggesting increased immune cell infiltration 
in AdCas compared to SCCs (Supplementary Table S3 and Figure 5A). ErbB2, ErbB3 and 
ErbB4 and ROS1 were higher expressed in AdCas (Figure 5B), in line with a previous 
report 417, whereas expression of NTRK2, the gene encoding the targetable tyrosine 
kinase TRKB, was 28-fold higher in SCCs than in AdCas (Supplementary Table S3 and 
Figure 5B). 
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Figure 3. t/RNA-NGS identifies activity of angiogenesis and metabolic pathways. A) Expression 
levels of genes (FPM) involved in angiogenesis, in squamous cell cancers and adenocarcinomas 
(all significant by p<0.05, FDR<0.01). B) Vascular density, expressed as the number of vascular 
structures per mm2 tumor area. ***, p<0.0001. Vessel densities were determined before in 
Meijer et al., 2012, Lung Cancer. C) Metabolic differences between squamous cell cancers and 
adenocarcinomas as determined by t/RNA-NGS. Colours indicate significantly differentially 
expressed genes (p<0.05, FDR<0.01). 
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Figure 4. TCGA analysis of angiogenic and glycolytic genes in squamous cell cancers and ade-
nocarcinomas. TCGA analysis confirmed higher expression levels of angiogenesis-related genes 
in AdCas, and of genes involved in glycolysis in SCCs.
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Figure 5. Targetable gene expression in squamous cell cancers and adenocarcinomas as deter-
mined by t/RNA-NGS. A) Expression of genes involved in immune response. B) Expression of 
other targetable genes. All differences between squamous cell cancers and adenocarcinomas 
are significant (p<0.05, FDR<0.01).
Figure 6. Distribution of actionable targets in individual NSCLCs. For 90% of the patients action-
able targets could be detected. 
Actionable targets in individual cancers
Group-based statistical analyses as described above give a good general overview of 
biology in (subgroups of) NSCLCs. Given the high genetic heterogeneity in cancer, 
from a patients’ perspective it is important to investigate expression of actionable 
genes in individual samples. We therefore calculated the fold overexpression for 
each transcript per individual cancer sample, relative to the mean expression value in 
normal lung tissues. Using this approach an individual profile was obtained for each 
tumour. High expression of ALK (>4-fold compared to normal tissues) was observed 
in 30 tumours whereas EGFR, MET and RET were overexpressed in seven, nine and 
19 tumours, respectively. METΔ14 was detected in one tumour. NTRK2 overexpression 
was found in 21 SCCs. Only in nine tumours (10%) of the cohort no actionable tyrosine 
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kinases were detected. In three of these, overexpression of immune cell-related 
transcripts was detected. Figure 6 visualizes differential overexpression of genes in 
subsets of patients. Intriguingly, except for one tumour we never found significant 
co-overexpression of VEGFA and its receptor KDR/VEGFR2 (not shown). This indicates 
that angiogenesis is not an appropriate actionable pathway for the majority of lung 
cancers.
Mutation detection
A prerequisite during smMIP design was that t/RNA-NGS should provide information 
on mutations in expressed alleles that may have impact on tumour progression 
and treatment response. t/RNA-NGS identified many mutations of potential clinical 
relevance. Supplementary Table S4 summarizes some of these. In tumour 024 we 
detected a heterozygous BRAFV600E mutation, co-occurring with PTEN loss-of-function 
mutations. KRASG12D/G12C tumour driver mutations were found in three NSCLCs and 
were confirmed by standard genetic analysis. Other mutations that were detected by 
t/RNA-NGS and confirmed by genetic analysis were in TP53, KIT, PIK3CA and CTNNB1. 
Three samples contained RET-S1002R mutations, MET-R988C mutations were found 
in two samples and EGFR mutations in another two tumours. A number of tumours 
expressed mutated PMS2 and MSH2/6 alleles that are associated with Lynch syndrome 
and may be involved in genetic instability 447. In one tumour we found co-expression of 
mutated alleles of tumour suppressor genes pRB and TP53. 
Noteworthy, in eight cases we found that TP53 mutations that were identified by DNA 
analyses were not recovered by t/RNA-NGS analysis. Because sequencing depth of the 
corresponding loci were high (22-50 unique reads) this strongly suggests that these 
mutated alleles were not expressed (Supplementary Table S4). 
Discussion
To get a comprehensive overview of ‘actionable’ biology, we here analysed activity of 
biological pathways including metabolism, growth factor signalling, tyrosine kinases 
and phosphatases, DNA repair, cell cycle, angiogenesis and immune response in a 
cohort of lung cancers. Comparison with qPCR data, immunohistochemistry and in 
silico analyses of TCGA datasets confirmed that t/RNA-NGS generates functional data. 
We here used t/RNA-NGS that has some important advantages over whole RNA/NGS. 
Firstly, the technique allows sensitive and highly specific detection of alternative 
splice variants such as METΔ7/8 24 and METΔ14 298, two targetable MET variants that have 
increased activity compared to wild-type MET. Similarly, the technique quantitatively 
detects VEGFA splice variants that have different receptor binding characteristics and 
angiogenic potential 429. Secondly, because the technique focuses on detection of 
transcripts of potential interest only, multivariate analysis of results is less complex 
than analysis of w/RNA-NGS datasets that can contain tens of thousands of transcripts. 
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Thirdly, because the assay uses barcode technology it can be applied for hundreds of 
samples in one next-generation sequencing run, greatly reducing sequencing costs per 
sample and allowing comparative analyses without batch-effects.
Our data show that analysis of smMIP-based t/RNA-NGS datasets can generate a 
histology-independent molecular diagnosis which not only can confirm standard 
histopathology, but also provides important actionable information on the activity of 
oncobiology pathways, such as high rates of glycolysis in SCC relative to AdCa, and 
higher rates of angiogenesis, aerobic mitochondrial metabolism and inflammation 
in AdCa relative to SCC 416-418. Moreover, t/RNA-NGS confirmed known associations 
of specific tyrosine kinases with AdCa 417 and of NTRK2 with SCC. Finally, t/RNA-NGS 
yielded information on a large number of gene mutations that have been identified 
before as somatic mutations 352.
Although group-based analyses are interesting to elucidate biological principles, they 
are less relevant for the individual patient. To guide precision therapy, genetic testing 
is nowadays increasingly applied in clinical practice but this approach has not yet led 
to dramatic improvements 362. This may relate to the fact that precision medicines 
are often applied after pre-treatment with chemotherapy or radiotherapy, increasing 
genetic heterogeneity and allowing tumour subclones to quickly adapt to precision 
medicine 363. Additionally, as we show here mutated alleles may be silent in which 
case they should be considered non-actionable. Quantitative detection of mutations 
in expressed alleles will therefore be more informative than DNA-analysis alone. A 
final argument for RNA analysis as a method to rationally steer treatment decisions, is 
that activity measurements of biological pathways such as angiogenesis and immune 
suppression cannot be done through DNA analysis. The value of indirect methods such 
as mutational burden as a predictive biomarker for response to immune checkpoint 
inhibitors, still needs to be established.
An intrinsic problem of t/RNA-NGS is that RNA levels in a cell are subject to regulation. 
Detection of mutations in expressed alleles requires that the locus of interest is 
sequenced with sufficient depth, which may be a problem for low abundant transcripts. 
This problem can be solved by increasing sequencing depth and by rebalancing 
mutation-detecting smMIPs in the smMIP pool. Such optimizations should be guided 
by specific clinical questions.
Detection of fusion genes (e.g. ALK, RET, ROS1, NTRK2) in NSCLC is becoming increasingly 
important for clinical decision making. In this study we did not focus on detection of 
fusion events. Since smMIPs with extension and ligation probes in neighbouring exons 
can specifically quantify alternative splice variants, smMIPs with extension and ligation 
probes on 5’- and 3’-fusion partners will similarly be able to detect fusion genes on the 
RNA level. These efforts are ongoing.
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An open question that remains from this study is which level of overexpression of 
targetable genes is clinically actionable. Prospectively collecting cancer t/RNA-NGS 
profiles and corresponding clinical metadata from clinical trials, followed by analyses 
of datasets from responders and non-responders to a drug, will be required to answer 
this question.
In conclusion, we present an effective method of t/RNA-NGS using smMIPs that shows 
that actionable targets and mutations are identified in a large proportion of lung cancer 
patients. Thus, t/RNA-NGS could help in stratifying patients for appropriate targeted 
drugs. Proof of concept for this should come from large prospective studies. 
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Table S1. Clinicopathological characteristics of lung carcinoma tissues. Characteristics separat-
ed per histopathological subtype are indicated.
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Table S2. Differential gene expression in normal lung tissue versus lung carcinoma. All 
cancer tissues are included in the analysis (n=81). Gene expression differences as tested with a 
Wilcoxon Mann-Whitney U test and Benjamini-Hochberg correction for multiple testing (p<0.05, 
FDR<0.01). Note that for significance, the p-value must not exceed the FDR. Fold changes (FC) 
are calculated as cancer/normal, or -1/(cancer/normal) to prevent fold changes >0 and <1.
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Table S3. Differential gene expression in SCC versus AdCa. Gene expression differences as 
tested with a Wilcoxon Mann-Whitney U test and Benjamini-Hochberg correction for multiple 
testing (p<0.05, FDR<0.01). Note that for significance, the p-value must not exceed the FDR. 
Fold changes (FC) are calculated as AdCa/SCC, or -1/(AdCa/SCC) to prevent fold changes >0 and 
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Table S4: Overview of mutations found in regular genetic analysis and t/RNA-NGS. Note that 
genetic testing was performed in 2014 and does not include all markers that are currently tested. 
t/RNA-NGS data were analysed with respect to genetic analysis (‘confirmed’: confirms genetic 
data, ‘new’: mutations not found in genetic data).
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Nearly all cervical cancers are initiated by a persistent infection with one of the high-risk 
human papillomaviruses (high-risk HPV). High-risk HPV DNA testing is highly sensitive 
but cannot distinguish between active, productive infections and dormant infections 
or merely deposited virus. A solution for this shortcoming may be the detection of 
transcriptional activity of viral oncogenes instead of mere presence of high-risk HPVs. 
In this study, fresh-frozen cervical tissues (N=22) were subjected to high-risk HPV DNA 
detection using the Line Probe Assay and to targeted RNA next-generation sequencing 
using single molecule molecular inversion probes. Targeted RNA sequencing was 
applied for 1) RNA-based genotyping of high-risk HPV, giving information on specific 
HPV-subtype 2) discrimination of E2, E6 and E7 transcripts and 3) discovery of possible 
non-HPV cancer biomarkers. Data were analysed using computational biology. 
Targeted RNA sequencing enabled reliable genotyping of high-risk HPV subtypes 
and allowed quantitative detection of E2, E6 and E7 viral gene expression, thereby 
discriminating cervical lesions from normal cervical tissues. Moreover, targeted RNA 
sequencing identified possible cervical cancer biomarkers other than high-risk HPV. 
Interestingly, targeted RNA sequencing also provided high-quality transcription 
profiles from cervical scrape samples, even after one week of dry storage or storage in 
Preservcyt fixative. This proof of concept study shows that targeted RNA sequencing 
can be used for high-risk HPV genotyping and simultaneous detection of high-risk HPV 
gene activity. Future studies are warranted to investigate the potential of targeted 
RNA sequencing for risk assessment for development of cervical lesions, based on 
molecular analysis of cervical scrapes.
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Introduction 
Cervical cancer is the fourth most frequent cancer in women worldwide, with 
approximately half a million new cases each year of whom ~50% are lethal 448. Nearly 
all cervical cancers are associated with infection with one of 14 high-risk human 
papillomaviruses (high-risk HPV), subtypes HPV16 and HPV18 being responsible for 
~70% of cases 448,449. Persistent infection with high-risk HPV is considered a necessary 
cause for the development of squamous cell carcinoma (SCC) of the cervix, while 
cervical adenocarcinomas (AdCa) are often, but not always, HPV-related 449-453. 
The life-time risk for women to acquire an HPV infection is approximately 80%, but 
by far the majority of infections are cleared within two years. In approximately 
10% of women the infection persists 448,454,455. These cases may be associated with 
development of low-grade lesions (cervical intraepithelial neoplasia), most of which 
however regress within a year. Only a minority of all persistent high-risk HPV infections 
becomes a transforming infection that may progressively develop into high-grade 
cervical intraepithelial neoplasia and cancer, a process that may take years 456. The risk 
of developing high grade cervical intraepithelial neoplasia is higher after infection with 
HPV16/18 than with one of the other high-risk HPV subtypes 457. Since high-risk HPV 
DNA testing cannot distinguish between transient and clinically relevant, transforming 
infections, methods to enable risk prediction in high-risk HPV DNA-positive tissues are 
needed. 
In its episomal form HPV infections are characterized by expression of the early gene 
E2, a repressor of the oncogenes E6 and E7. Integration of high-risk HPV in the host 
genome is thought to be an important step in the oncogenesis of cervical cancer 458,459, 
as it leads to reduced E2 expression and activation of the E6 and E7 oncogenes 460,461. 
E6 and E7 gene products are primarily responsible for oncogenic transformation by 
interference with p53 and pRb proteins, disrupting DNA repair regulation and cell 
cycle checkpoints 459,462-469. Overexpression of E6 and E7 oncogenes can therefore 
be used to identify transforming infections, whereas levels of E2 expression may 
provide additional information on viral integration state 453. To obtain a comprehensive 
understanding of cervical carcinogenesis in clinical samples, methods for simultaneous 
detection of E2, E6 and E7 transcripts of all high-risk HPV subtypes are therefore 
needed and multiple tests for HPV E6/E7 mRNA detection are now available 470,471. The 
slow development from initial high-risk HPV infection to cervical cancer makes it likely 
that gradual accumulation of tumorigenic events in cervical intraepithelial neoplasia is 
required for progression to cancer. 472. Mapping of these events will further contribute 
to our knowledge of cancer biology in the cervix.
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The aims of this study were therefore to 1) investigate the value of targeted RNA 
next-generation sequencing for high-risk HPV genotyping and oncogene activity 
monitoring in cervical tissues, 2) identify possible biomarkers other than high-risk HPV 
that may distinguish normal cervical tissue from cervical cancer, and 3) determine the 
quality of targeted RNA sequencing data originating from cervical scrape samples, 




In this prospective single-centre study frozen cervical tissue samples were included 
from 22 non-pregnant Dutch women, presenting at the Department of Obstetrics and 
Gynecology of the Radboudumc for surgery of the uterus and/or cervix for different 
clinical indications. Punch biopsies from cervical tissue were taken during surgery or 
after extirpation. Tissues were snap frozen in liquid nitrogen and stored at -80°C until 
RNA isolation. H&E stainings were performed on 4 µm cryosections and reviewed 
by a pathologist (JB, Table 1). Based on histopathology, which was concordant with 
clinical patient diagnosis, tissues were classified as normal cervix tissue (N=4, N1-4) or 
cervical cancer (N=18, composed of 15 SCCs [SCC1-15] and 3 AdCas [AdCa1-3]). Evalyn 
Brush (Rovers Medical Devices B.V., Oss, Netherlands) cervicovaginal samples were 
collected in triplicate from two healthy women and either stored dry or in Preservcyt 
solution (Hologic, Marlborough, MA, USA) for different time spans (dry: 1h, 1 week; 
Preservcyt: 1hr, 24hrs, 1 week, 2 weeks). Written informed consent was obtained from 
all women in this study. The protocol was approved by the regional institutional review 
board (No. 2014-1295). All methods were performed in accordance with the guidelines 
for use of human tissue of the Radboudumc and the tissue samples were anonymized 
to the researchers. 
HPV genotyping
DNA was isolated from all tissues using MagNA Pure (Roche, Basel, Switzerland). The 
purified DNA was eluted in 50μl TE-buffer. For detection and genotyping of HPV, broad 
spectrum HPV amplification was performed using the short-PCR-fragment Line Probe 
Assay (SPF10-LiPA25; Labo Bio-medical Products B.V., Rijswijk, The Netherlands). This 
assay amplifies a small fragment of 65 bp from the L1 open reading frame and allows 
detection of a broad range of HPV genotypes with high analytical sensitivity 473.
Targeted RNA next-generation sequencing
Targeted RNA sequencing was performed essentially as described before 309, without 
prior knowledge on HPV status. RNA was isolated from 10 µm cryosections using TRIzol 
reagent (ThermoFisher Scientific, Waltham, MA, USA) and reverse transcribed with 
Superscript II (ThermoFisher Scientific) using random hexamer primers, according 
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to the manufacturer’s instructions. A previously described cohort of single molecule 
molecular inversion probes 309 was expanded with among others probes recognizing 
E2, E6 and E7 transcripts from high-risk HPV types 16, 18, 31, 33, 45 and 52. Single 
molecule molecular inversion probes to detect E2, E6 and E7 transcripts from HPV39 
and HPV56 were initially not included in the panel, but were added at a later stage to 
confirm Line Probe Assay results. Probe design was based on the MIPgen algorithm as 
described by Boyle et al. 275, and included a random octanucleotide unique molecule 
identifier (UMI). 
Table 1. Tissue samples with diagnosis and cancer grade. Diagnoses were based on 
histopathological review of the analysed biopsies and were concordant with clinical patient 
diagnosis. Differentiation grade is indicated where known. AdCa, adenocarcinoma; SCC, 
squamous cell carcinoma.
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All assay preparations were performed at 4oC. Single molecule molecular inversion 
probe pool preparation, capture and exonuclease treatment were performed using 
the Microlab STAR automated liquid handling workstation (Hamilton, Reno, Nevada, 
USA). Single molecule molecular inversion probes were pooled at 100 µM/probe (246 
transcripts, 1301 probes) and phosphorylated using T4 Polynucleotide Kinase (New 
England Biolabs, Ipswich, MA, USA) in T4 DNA ligase buffer (NEB) for 45 min at 37°C, 
followed by 20 min inactivation at 65°C. The capture reaction was performed using 
15-50 ng of cDNA and a 1 pM pool of phosphorylated probes. Capture and enzymatic 
circularization by primer extension and ligation were performed in a reaction mixture 
containing Ampligase buffer (Epicentre, Madison, WI, USA), dNTPs, Hemo KlenTaq 
enzyme (New England Biolabs, NEB, Ipswich, MA, USA) and DNA ligase (Ampligase, 
Epicentre) by incubation for 10 min at 95°C followed by 18 h at 60°C. Non-circularized 
single molecule molecular inversion probes and remaining RNA and cDNA were 
removed by exonuclease treatment as described 309. The pool of circularized probes 
was subjected to PCR amplification using the Microlab STARlet automated liquid 
handling workstation (Hamilton), with 2x iProof High-Fidelity DNA Polymerase 
master Mix (Bio-Rad, Hercules, CA) and a primer set including a unique barcoded 
reverse primer for each sample. Two μl of each sample was pooled using the Microlab 
STAR and 266 bp amplicons were purified using AMPureXP beads (Beckman Coulter 
Genomics, High Wycombe, UK). After quality control on a TapeStation 2200 (Agilent 
Technologies, Santa Clara, CA, USA) and quantification using Qubit (Life Technologies, 
ThermoFisher Scientific, Waltham, MA USA), a 4 nM library was sequenced on the 
Illumina Nextseq platform (Illumina, San Diego, CA) at the Radboudumc sequencing 
facility. Reads were mapped against reference transcripts (UCSC human genome 
assembly hg19 and variant-specific FASTA sequences) using the SeqNext module of 
JSI SequencePilot version 4.2.2 build 502 (JSI Medical Systems, Ettenheim, Germany). 
All identical PCR products were reduced to one consensus read (unique read) using 
the UMI. Unique read counts for each single molecule molecular inversion probe in a 
sample were divided by the total of unique read counts in that sample and multiplied 
by 106 (Fragments per Million, FPM). Individual transcript levels were expressed as 
mean FPM of all probes targeting that transcript. Less than 10 unique read counts for 
a high-risk HPV transcript were considered insignificant. Variant calling was performed 
within SeqNext, excluding all variants with a coverage of <10% variant reads.
Statistical analysis
Statistical analyses were performed in R (version 3.4.3). Mean FPM values were log2 
transformed (after addition of 0.01 to prevent log(0) transformation errors) and 
clustered in an unsupervised manner using the Manhattan distance and Ward.D2 
method, and translated into a heatmap using ClustVis. A Wilcoxon Mann-Whitney U 
test was performed to study differential gene expression between clusters. Multiple 
testing corrections were done using Benjamini Hochberg (FDR<0.01).
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Results 
High-risk HPV DNA vs. RNA detection
Line Probe Assay testing detected high-risk HPV DNA in 2 out of 4 normal cervix tissues, 
all 15 SCCs, and 2 of the 3 AdCa tissues (Figure 1A). Profiling the same set of tissues for HPV 
RNAs in the targeted RNA sequencing assay, blinded to the Line Probe Assay results, 
showed activity of viral oncogenes in all HPV DNA-positive SCC and AdCa samples. All 
genotypes identified by RNA sequencing were concordant with the outcome of the 
Line Probe Assay assay (Figure 1A). In two SCCs the Line Probe Assay detected HPV39 
and HPV56, two subtypes for which no single molecule molecular inversion probes 
were included in the original targeted RNA sequencing panel. Transcriptional activity 
of these subtypes was confirmed in an additional analysis (Figure 1A). In AdCa2 HPV16 
and HPV18 were detected by Line Probe Assay, but only HPV18 E6 and E7 oncogene 
activity was detected by targeted RNA sequencing. In SCC11 HPV16 and HPV39 DNA 
was detected, but only HPV39 E6 and E7 RNA was found. 
Samples that tested high-risk HPV-positive by Line Probe Assay analysis but were 
transcriptionally inactive by targeted RNA sequencing were normal cervical tissues 
(N=2). One AdCa tested negative in both DNA and RNA assays, in agreement with 
previous studies showing that cervical AdCas are not always caused by high-risk HPV 
infection 449-452.
High-risk HPV E2 vs. E6/E7 expression
We next studied whether we can distinguish E2 and E6/E7 viral gene expression, 
which may be used to discriminate transforming infections from clinically irrelevant 
infections. In all 17 high-risk HPV RNA-positive tissues oncogenes E6 and E7 were 
expressed (Figure 1A), with expression levels ranging from ~440-21,000 FPM (Figure 
1B). E6 expression exceeded E7 expression in 13/17 tissues (~75%). E2 expression was 
undetectable in 5 of the 17 samples (~30%), of which 4 were SCCs and 1 was AdCa. 
Co-expression of E2 (~740-23,700 FPM, Figure 1B), E6 and E7 was observed in the other 
12 tissues (~70%).
Non-HPV biomarkers of cervical cancer
To discover cervical cancer biomarkers other than high-risk HPV, we performed 
agglomerative unsupervised cluster analysis of all gene expression data excluding HPV 
(Figure 2). Normal cervical tissues and cancer tissues clustered together in separate 
groups. Within the cancer cluster, AdCas clustered together, including the HPV-negative 
AdCa3. SCC11, the only HPV39-positive SCC in the cohort, did not cluster with the other 
cervical cancers. We found no association of sample clusters with high-risk HPV E2 vs. 
E6/E7 expression levels.
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Figure 1. DNA vs. RNA detection of HPV. A) Presence of HPV DNA tested with LiPA versus pres-
ence of HPV RNA tested with t/RNA-NGS using smMIPs, separated for E2, E6 and E7, in frozen 
tissue samples of normal cervix tissue (N=4) and cervical cancer (N=18). t/RNA-NGS results are 
concordant with LiPA. All tissue samples that harboured HPV RNA expression had expression of 
the E6 and E7 oncogenes; expression of E2 was absent in five of the HPV-positive tissues. Note 
that in two tissues hrHPV subtypes (39, 56) were detected on the DNA level which were not 
included in the t/RNA-NGS panel but were confirmed in additional analyses. B) Mean FPM values 
of E2, E6 and E7 of the respective hrHPV RNA-based genotypes as shown in A).
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Figure 2. t/RNA-NGS of 22 gynaecological tissues. Samples include normal cervical tissue (N=4) 
and cervical cancer (N=18). Heatmap containing 219 genes, generated by unsupervised hierar-
chical clustering using the Manhattan distance and Ward.D2 clustering method. The heatmap 
can be separated in two groups: one containing all normal cervical tissues and one containing all 
cancer tissues except one SCC.
Statistical analysis revealed that 52 genes were differentially expressed between 
normal cervix and cervical cancer tissues with p<0.05 (Table 2, see Supplementary 
Table S1 for all transcripts in the analysis). Interestingly, many tyrosine kinases that 
are considered targets for precision medicines (FGFRs, PDGFRs, KDR, KIT, AXL, ERBB2, 
NTRK2) were expressed at lower levels in cancers than in normal cervix tissue, with the 
exception of the proto-oncogene MET. We previously observed a similar trend in renal 
cancer 345. In general, genes involved in glycolysis were expressed at higher levels in 
cancer tissues (HK2 [hexokinase 2)], PGK1 [phosphoglycerate kinase 1], ENO1 [enolase 
1], SLC16A3 [monocarboxylate transporter 4], CAIX [carbonic anhydrase 9]). These 
features are in accordance with the general concept that cancers experience hypoxia 
and shift energy production to glycolysis 474. Expression of the tumour suppressor 
gene PTEN was lower in the cancer cluster, as was expression of androgen receptor 
(AR). EpCAM (epithelial cell adhesion molecule) and the PSMA-coding gene FOLH1 were 
expressed at relatively high levels in the cancer group.
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Table 2. Gene expression in cervical cancer vs. normal cervix (p<0.05). Gene expression 
differences as tested with a Wilcoxon Mann-Whitney U test and Benjamini-Hochberg correction 
for multiple testing (p<0.05, FDR<0.01). Note that for significance, the p-value must not exceed 
the FDR. Fold changes were calculated as (cluster B/A) or -1/(cluster B/A) to prevent fold changes 
>0 and <1. Here, p<0.05 was considered relevant. FC, fold change. 
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In addition to gene expression, targeted RNA sequencing also allows for variant 
detection. The mismatch repair endonuclease PMS2 mutation c.187G>A (p.Val63Met, 
classified as confirmed somatic in five neoplasms in the liver in the COSMIC database 
352 and has a likely pathogenic CADD score of 18.5) was detected in 15/18 cancer tissues 
and in 1/4 normal cervix tissues (not shown). 
Targeted RNA sequencing on cervical scrape samples
In the context of nation-wide cervical cancer screening programs, cervical scrape 
samples are collected for cytology-based screening, which is increasingly preceded 
by molecular screening for the presence of high-risk HPV DNA. We therefore tested 
whether it is feasible to implement targeted RNA sequencing analysis on cervical 
scrape samples, collected under conditions that are relevant for population-based 
screening programs (with delays between scraping and analysis). Storage of scrape 
samples at room temperature for up to one week, either dry or in Preservcyt fixative, 
still allowed the generation of good-quality targeted RNA sequencing profiles (Figure 
3). After two weeks of Preservcyt fixation, quality of targeted RNA sequencing data 
(expressed as total unique reads obtained in a sample) decreased.
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Figure 3. Quality of targeted RNA sequencing data originating from cervical scrape samples. 
Data quality is expressed as percentage unique reads relative to 1 h sample preservation 
(100%). Up to 1 week of sample preservation either dry or in Preservcyt solution, targeted RNA 
sequencing generates good-quality transcription profiles from cervical scrapes (N=2). Total 
number of unique reads varied per sample (depending on amount of cells in the scrapes and 
transcriptional activity therein) and started at excellent values of 38,000 and 225,000 for both 
samples, respectively, at T=0.
Discussion
Infection of cervical tissues with high-risk HPV is not necessarily accompanied by 
oncogenic activity of high-risk HPV. This is a relevant observation because molecular 
testing for the presence of high-risk HPV DNA is increasingly implemented in 
population-based screening programs. High-risk HPV DNA screening is very sensitive 
(90-95% vs. 30-87% for cytology), objective and allows high-throughput testing 162,475,476 
but does not distinguish between deposited and dormant virus, transient infections 
and clinically relevant active and producing infections. Even with cytomorphology 
screening as triage test, this results in many unnecessary colposcopy referrals, 
overtreatment and follow-up. This problem may be solved by measuring transcripts 
from high-risk HPV E6 and E7 oncogenes in infected tissues 161,477-480. A number of 
studies have now shown the increased specificity of HPV-RNA testing compared to 
HPV-DNA testing 470,471,481.
The aim of this proof of concept study was to investigate the value of targeted RNA 
sequencing technology to detect high-risk HPV oncogene activity in well characterized 
gynaecological tissues. We previously showed that targeted RNA sequencing yields 
reliable quantitative gene expression data and mutation data 309,343-345. 
During integration into the host genome the reading frame of the early gene E2 is 
often disrupted 482, alleviating repression of the E6/E7 oncogenes. Concomitant 
measurement of E2, E6 and E7 transcripts may therefore provide information on 
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high-risk HPV integration status. Till now, comprehensive analysis of high-risk HPV 
transcripts required that for each tissue sample at least 44 RT-qPCR experiments 
should be performed (E2, E6 and E7 RT-qPCR for each of the 14 high-risk HPV subtypes, 
and a positive and negative control RT-qPCR) making such analyses labour-intensive. 
With targeted RNA sequencing, transcripts from the viral genes E2, E6 and E7 from 
all 14 high-risk HPV genotypes can be quantitatively detected in one go, whereas 
the sequence information concomitantly provides direct and reliable high-risk HPV 
subtype identification.
We observed E6/E7 gene expression in the absence of E2 in 30% of cases, suggesting 
HPV integration in the host genome. In the remaining cancers, E2 and E6/E7 genes 
were co-expressed. There are several possible explanations for this finding. E6/E7 
expression may have become independent of E2 repression, e.g. via methylation of 
the E2 binding sites 459,461,462,482,483, or analysed tissues may have been composed of 
mixed episomal and integrated viruses (either in the same cells or in different cell 
clones). Our data also demonstrate that multiple high-risk HPV types can be present 
in cancer tissues whereas only one of these subtypes is responsible for E6/7 oncogene 
expression. From this study we cannot conclude whether these cases concerned 
co-infected cells or multiple cell clones mono-infected by different high-risk HPV types.
Targeted RNA sequencing analysis has multiple other advantages compared to 
standard techniques. The test uses Illumina barcoding technology and therefore can 
be performed in parallel for as many samples as there are barcoded primers (currently 
386, but expandable), making the test high-throughput and highly cost-effective. A 
further important advantage is that the current test-format measures expression 
levels of a number of potentially cancer-associated genes and differentiation genes 
that are associated with normal physiology. This is highly relevant since host genes play 
an essential role not only in the development of cancer, but also in prevention thereof 
484. Analysing expression profiles of gynaecological tissues may therefore also allow 
for the identification of non-HPV-related cancers 449-452. This notion is strengthened by 
our finding that AdCa3 in our cohort is high-risk HPV-negative, but still groups with 
the two high-risk HPV-positive AdCas in unsupervised clustering analysis. Furthermore, 
supervised analysis of targeted RNA sequencing data from normal tissues and cancers 
identified a number of genes that are differentially expressed in cancers and normal 
tissues. Upregulated genes in cancers involved genes involved in metabolism and 
confirmed increased hypoxia in cancerous tissues. Other genes that were higher 
expressed in cancers were EpCAM and FOLH1, confirming previous reports 485,486 and 
the proto-oncogene MET. Relatively low expression levels of AR (androgen receptor) 
in cancer was also in accordance with previous reports 487,488 and illustrates that in 
cancers functions may be lost that are present in tissues with normal physiology. 
Further clinical research and computational biology on targeted RNA sequencing 
profiles from large numbers of samples in validation sets should confirm whether gene 
expression profiles can be further refined and translated into transcript classifiers that 
define a risk for cancer development.
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Of high interest, targeted RNA sequencing also allows to investigate potential 
associations of gene mutations with cervical cancer. Such profiles may be of additional 
importance for risk assessment of cervical biopsies. Our finding that mutations in 
the DNA repair protein PMS2 are associated with the cancers in our cohort suggests 
that PMS2 mutations may play a role in HPV-induced carcinogenesis, inducing genetic 
instability as a first step in the carcinogenic process. PMS2 mutations are common in 
Lynch syndrome and a recent publication showed a slightly increased risk of developing 
endometrial cancer in women with PMS2 mutations 489. Our results suggest that this 
PMS2 variant could possibly be a marker for cervical cancer. However, larger studies 
are needed to further investigate this. 
Whereas this proof of concept study was performed on surgically obtained tissues, 
we show here that targeted RNA sequencing also works for cervical scrapes, even 
scrapes that have been stored dry or in Preservcyt fixative at room temperature for up 
to a week. This is an important finding as it illustrates that targeted RNA sequencing 
may allow risk assessment of women for developing gynaecological cancers based on 
non-invasive analysis of scrapes. Including probes to detect somatic mutations such 
as recently identified 472 may further increase the value of such risk assessment. These 
studies are now ongoing.
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Supplementary material
Table S1. Gene expression in cluster A vs. cluster B (p>0.05). Statistical testing was performed 
using a Wilcoxon Mann-Whitney U test with Benjamini Hochberg correction for multiple testing 
(p<0.05, FDR<0.01). Note that for significance, the p-value must not exceed the FDR. Fold 
changes were calculated as (cluster B/A) or -1/(cluster B/A) to prevent fold changes >0 and <1.
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Radiotherapy is an important treatment modality of head and neck squamous cell 
carcinomas (HNSCC). Multiple links have been described between the metabolic 
activity of tumours and their clinical outcome. Here we test the hypothesis that 
metabolic features determine radiosensitivity, explaining the relationship between 
metabolism and clinical outcome. Radiosensitivity of 14 human HNSCC cell lines was 
determined using colony forming assays and the expression profile of approximately 
200 metabolic and cancer-related genes was generated using targeted RNA sequencing 
by single molecule molecular inversion probes. 
Correlation between radiosensitivity data and expression profiles yielded 18 genes 
associated with radiosensitivity or radioresistance, of which ATP citrate lyase 
(ACLY) was of particular interest. Pharmacological inhibition of ACLY caused an 
impairment of DNA damage repair, specifically homologous recombination, and lead 
to radiosensitization in HNSCC cell lines. Examination of a The Cancer Genome Atlas 
(TCGA) cohort of HNSCC patients revealed that high expression of ACLY was predictive 
for radiotherapy failure, as it was only associated with poor overall survival in patients 
who received radiotherapy (hazard ratio of 2.00, 95% CI: 1.12–3.55; p=0.0184). These 
data were further validated in an independent cohort of HNSCC patients treated 
with chemoradiation. Furthermore, patients with poor locoregional control after 
radiotherapy have significantly higher nuclear ACLY protein levels. Together, we here 
show that ACLY affects DNA damage repair, and is a predictive factor for radiotherapy 
outcome in HNSCC.
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Introduction
Head and neck squamous cell carcinomas (HNSCC) are malignancies of the epithelium 
lining the nasal and oral cavity as well as the pharynx, and annually affects 650,000 
people worldwide 490. Together with surgery and (concurrent) chemotherapy, 
radiotherapy (RT) is an essential part of standard treatment for patients with HNSCC. 
Although RT is generally highly effective, tumours recur in a substantial number of 
patients with advanced stage disease 491. In HNSCC originating in the oropharynx, the 
odds of treatment success are significantly affected by the human papillomavirus 
(HPV) status of the tumour. HPV-positive tumours constitute approximately 5%-60% 
of HNSCC cases, depending on the specific anatomical location 492. HPV positive 
oropharynx tumours have been shown to be significantly more radiosensitive, and 
this is reflected in the patient population where HPV-positive patients have a strikingly 
better prognosis, locoregional control, and five year survival 493-497. The mechanisms 
leading to radioresistance especially in HPV-negative patients have been extensively 
studied and have been attributed to DNA damage repair, cell cycle arrest, activation 
of oncogenes, microenvironmental changes, as well as changes in tumour metabolism 
498.
Malignant cells/tissues have been shown to have a significantly different metabolism 
than non-malignant tissues and this is considered to be one of the hallmarks of 
cancers 2. In addition, HNSCCs undergo extensive metabolic reprogramming upon 
malignant transformation, including others changes in oxidative phosphorylation, the 
tricarboxylic acid cycle, fatty acid metabolism and increase of glycolysis 499-501. These 
reports indicate that, overall, in cancer cells the utilisation of glucose and glutamine 
as a primary energy source is enhanced, matching the leading theory that cancer cells 
switch to aerobic glycolysis to generate sufficient macronutrients to allow for cellular 
growth and proliferation 499. 
Interestingly, metabolic reprogramming has previously been linked to changes in 
radiosensitivity, and has been shown to contribute to the development of radioresistant 
tumour cells. Increased aerobic glycolysis has been demonstrated to lead to elevated 
levels of lactate, pyruvate, and acetate, as well as changes in the redox state of cells. 
Overall, these changes affect the antioxidizing capacity of cells, enabling them to 
effectively scavenge DNA-damaging reactive oxygen species produced by ionising 
radiation 415.
In this study, we investigate the association between radiosensitivity and the 
metabolic gene profile in HNSCC. Hereto, we use a panel of HNSCC cell lines to identify 
clinically relevant metabolic transcripts that could confer radioresistance, irrespective 
of HPV status. We show that expression of ATP citrate lyase (ACLY), the enzyme 
converting citrate to oxaloacetate and acetyl-CoA, correlates with radioresistance in 
cell lines. Inhibition of ACLY led to impaired homologous recombination and increased 
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radiosensitivity, which is in line with a recently described role for ACLY in the DNA 
damage repair pathway 502. Furthermore, we show in two independent patient 
cohorts that patients who receive RT have a poorer prognosis in the case of high ACLY 
expression, and that nuclear ACLY may represent a novel target for radiosensitization 
in HNSCC. 
Materials and Methods
Cell lines, reagents, and irradiation
UT-SCC-5, UT-SCC-8, UT-SCC-9, UT-SCC-11, UT-SCC-15, UT-SCC-19A, UT-SCC-24A, 
UT-SCC-29, UT-SCC-38, UT-SCC-40, UT-SCC-45, FaDu (Kindly provided by Prof Grenman, 
University of Turku), UM-SCC-6, UM-SCC-47 (Kindly provided by Dr Carey, University 
of Pittsburgh), 93-VU-147T (Kindly provided by Dr Dorsman, Amsterdam University 
Medical Center), and UPCI:SCC-154 (DSMZ) were cultured in DMEM medium 
(Gibco) supplemented with 4.5 g/L glucose, GlutaMAX, 10% FBS, 100 u/mL penicillin/
streptomycin, non-essential amino acids (Gibco), HEPES (Gibco), and sodium pyruvate 
(Gibco). U2OS DRGFP cells (provided by Prof. Tim Humphrey, University of Oxford) 
were cultured in DMEM supplemented with 10% FCS and 5 mg/ml puromycin and 100 
U/ml penicillin/streptomycin. Cells were treated with 5 µM BMS303141 (Sigma-Aldrich, 
St. Louis, MO, USA) in DMSO or 10 µM C75 (Merck) in DMSO for 6 h prior to irradiation. 
Single dose irradiation was delivered using a 320 kV XRAD irradiator (RPS Services 
Limited, Surrey, UK) at a dose rate of 3.1 Gy/min. An overview of cell line characteristics 
and tissue origin can be found in Supplementary Table S1. 
Homologous recombination assay
U2OS DRGFP cells were plated in a 6 cm dish at a concentration of 2.5x105 cells per well 
and left to attach overnight. Cells were treated with an ACLY inhibitor (BMS303141, 
Selleckchem, Munich, Germany) or Rad51 inhibitor (B02, Calbiochem) for 6 hours and 
then transfected with 10 µg pCBASceI plasmid (Addgene #26477) using Lipofectamine 
3000 reagent for 24 h. Medium was refreshed after 24 h and cells were harvested by 
trypsinisation 48 h after transfection. The fraction GFP positive cells was determined 
by flow cytometry using a FACS Canto II (BD Biosciences, Franklin Lakes, NJ, USA).
Single molecule Molecular Inversion Probe sequencing
RNA was isolated from 14 cell lines using TRIzol reagent (ThermoFisher Scientific, 
Waltham, MA, USA) and reverse transcribed with Superscript II (ThermoFisher 
Scientific) using random hexamer primers, according to the manufacturer’s 
instructions. Targeted RNA sequencing using single molecule molecular inversion 
probes (smMIPs) has been described in detail before 308,309.
SmMIPs were designed against target regions of interest (UCSC human genome 
assembly hg19 and splice-variant specific FASTA sequences) based on the MIPgen 
algorithm as described by Boyle et al., including a random octanucleotide unique 
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molecule identifier 275. SmMIPs were pooled at 100 µM/smMIP (1078 smMIPs, ~200 
transcripts) and phosphorylated using T4 Polynucleotide Kinase (New England 
Biolabs, Ipswich, MA, USA) in T4 DNA ligase buffer (NEB) for 45 min at 37°C, followed 
by 20 min inactivation at 65°C. Phosphorylated smMIPs were hybridized to 50 ng of 
cDNA, followed by enzymatic gap-fill by primer extension and ligation in a reaction 
including Ampligase buffer (Epicentre, Madison, WI, USA), dNTPs, Hemo KlenTaq 
enzyme (New England Biolabs, NEB, Ipswich, MA, USA) and DNA ligase (Ampligase, 
Epicentre), incubated for 10 min at 95°C followed by 18 h at 60°C. Non-circularized 
smMIPs and remaining RNA and cDNA were removed by exonuclease treatment with 
10 U Exonuclease I and 50 U of Exonuclease III (both NEB) for 45 min at 37 °C, followed 
by heat inactivation (95 °C, 2 min). The circularized smMIP library was subjected to 
standard PCR with 2x iProof High-Fidelity DNA Polymerase master Mix (Bio-Rad, 
Hercules, CA) with a primer set containing a unique barcoded reverse primer for 
each sample. The pool was then purified using AMPureXP beads (Beckman Coulter 
Genomics, High Wycombe, UK) according to manufacturers’ instructions. smMIP-PCR 
libraries were sequenced on the Illumina Nextseq platform (Illumina, San Diego, CA, 
USA) at the Radboudumc sequencing facility. Reads were mapped against reference 
transcripts (UCSC human genome assembly hg19 and variant-specific FASTA sequences) 
using the SeqNext module of JSI SequencePilot version 4.2.2 build 502 (JSI Medical 
Systems, Ettenheim, Germany). The unique molecule identifier was used to reduce 
all identical PCR amplification products to one consensus read (unique read). Unique 
read counts for each smMIP were normalized to the total unique read count within a 
sample and multiplied by 106 (Fragments per Million, FPM). Individual transcript levels 
were expressed as mean FPM of all smMIPs targeting that transcript.
Colony forming assays
Cells were plated at a density of 150-19,200 cells/well in a 6-well polystyrene culture 
plate (Corning). Cells were incubated overnight, treated with BMS303141, C75, or a 
DMSO control for 6 h and irradiated while still in single-cell phase. Medium was 
refreshed 24 h after IR and cells were left to form colonies for 8-14 days. Colonies were 
fixed and stained by crystal violet staining (50% methanol, 20% ethanol, 30% water, 5 
mg/ml crystal violet). 
Radiosensitivity analysis and linear quadratic fitting 
Statistical analysis was carried out using Prism v8.01 (GraphPad). For colony survival 
assays the plating efficiency per condition was determined by dividing the total number 
of counted colonies by the total number of plated cells. Surviving fractions (SF) were 
calculated by dividing the plating efficiency of treated cells by the plating efficiency of 
the control cells. Data was fitted according to the linear quadratic model (LQ) using 
the formula SF = e^−(αD + βD2). The dose permitting a 37% clonogenic survival (D37) 
was used as a measure for cellular radiosensitivity and was calculated from the α and 
β generated by Prism LQ fitting. Sensitiser enhancement ratio (SER) was calculated 
as SER37 = D(without sensitiser)/D(with sensitiser) for the same biological effect at 
SF = 37%. 
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siRNA interference and real-time quantitative PCR (qPCR) 
siRNA mediated depletion was performed using the Lipofectamine RNAiMAX system 
(Invitrogen) according to the manufacturer’s instruction. Cells were transfected 
for 72 h with scrambled siRNA (SIC002 MISSION esiRNAm Sigma-Aldrich) or 
ACLY targeting pooled siRNA (EHU08192 1MISSION esiRNA, Sigma-Aldrich). RNA 
isolation and qPCR were performed as previously described [5]. HPRT forward: 
5’-TATTGTAATGACCAGTCAACAG-3’; HPRT reverse: 5’-AAGCTTGCTGGTGAAAAGGA-
3’; ACLY forward: 5’-TGCTCGATTATGCACTGGAAGT-3’; ACLY reverse: 5’-
ATGAACCCCATACTCCTTCCCAG-3’.
Immunofluorescence 
5 x 104 cells were plated in 8-well chamber slides (Nunc-Lab-Tek) and incubated 
overnight. Treatment with BMS303141/C75 was carried out and cells were irradiated 
with 2 Gy. Cells were fixed in 4% formaldehyde, permeabilized in 1% Triton-X in PBS 
and blocked in 2% bovine serum albumin in PBS-Tween (0.1%). Cells were subsequently 
stained with 1:1000 DAPI (Cell Biolabs) and 1:250 53BP1 (Novus NB100-305) primary 
antibody and 1:500 secondary Fab Cy3 antibody (Jackson ImmunoResearch, Ely, 
UK). Slides were mounted in fluoromount (Serva Electrophoresis GmbH, Heidelberg, 
Germany) and imaged on a Leica microscope. 
TCGA data extraction and selection criteria
Xena browser (https://xenabrowser.net/) was utilized to extract data from the HNSC 
TCGA dataset 503. From this dataset, radiotherapy status, sample type, time to event 
(death), event status, recurrence free survival, TNM status, and RNA sequencing 
expression data of genes of interest were extracted. Samples that were non-primary 
tumour (e.g. normal tissue or metastatic tissue) were excluded, as well as samples 
from patients with MX or M1 status of where radiotherapy status was unknown. Data 
was censored after 5 years follow-up. A total of 445 samples were selected for analysis, 
of which 288 patients received radiotherapy.
 
TCGA data analysis
Patient and gene expression data was analysed using SPSS v25.0.0.1 (IBM, Armonk, 
NY, USA). Optimal cut-off points for survival analysis were determined using the 
Cut-off Finder webtool (http://molpath.charite.de/cutoff/index.jsp). The optimal 
cut-off point for overall survival was determined as the highest or lowest hazard ratio 
that was significant (outside the 95% confidence interval) 504. Based on the optimized 
cut-off values for expression of the gene of interest, overall survival and recurrence 
free survival were evaluated using Kaplan-Meier analyses, and tested for statistical 
significance using the log-rank test. Hazard ratios were calculated between high and 
low expression groups using a Cox regression model. 
Validation dataset
As a validation cohort, we used clinical data and gene expression profiles of the 
Pramana HNSCC patient cohort 505. This cohort contained data of 91 HNSCC patients 
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who were all treated with cisplatin and radiotherapy. An extensive description of the 
patient cohort can be found in the original publication. 
Immunohistochemistry
Of a previously described cohort of HNSCC patients, 19 paraffin embedded biopsies 
were selected based on locoregional control; 9 biopsies of patients that had a poor 
locoregional outcome, and 10 biopsies of patients with favourable locoregional control 
(Supplementary Table S3) 506. Sections of 5 µM thickness were cut, deparaffinated and 
rehydrated. Sections were incubated in citrate buffer (Dako) at 96 °C for 30 min, cooled, 
and blocked using 5% normal donkey serum in primary antibody diluent (Bio-rad) at room 
temperature for 30 min. Total ACLY was stained using an ACLY antibody (HPA022434, 
Sigma-Aldrich) 1:25 at 4 °C overnight, followed by a 0.3% H2O2 peroxidase block and 
secondary antibody incubation with 1:200 F(ab) donkey anti rabbit Biotin (Jackson 
Immuno Research). Sections were then incubated in Vectastain avidin-biotin-complex 
reagent (Vector), rinsed with water, and incubated with diaminobenzidine (Vector). 
Afterwards, they were dehydrated and mounted in HistoChoice mounting medium. 
Images were acquired on a Leica DM 6000 microscope at 20x magnification. Scoring 
of nuclear or cytoplasmic staining of total ACLY was performed blindly by two 
independent researchers after a technician had randomised the images. 
Statistics
For in vitro assays, single variable comparisons between two groups were performed 
on the mean of three biological independent repeats using a two-tailed unpaired t-test 
with Welch’s correction. For experiments involving multiple variables, an ANOVA was 
performed, followed by Sidak’s correction for multiple testing. Testing of categorical 
variables was done using a Pearson’s χ2 test. Unless specified otherwise, error bars 
indicate the standard error of the mean of three biological replicates. Statistical 
significance is indicated as follows: * p<0.05, ** p<0.01; *** p<0.001. 
Results
Multiple metabolic genes associate with radioresistance and -sensitivity
To investigate the link between radiosensitivity and the metabolic gene profile, we 
first characterized the radiosensitivity of a panel of HNSCC cell lines. This panel of 14 
different HNSCC cell lines showed that there is a high variability in radiosensitivity 
between the lines (Figure 1A, B). Using a targeted sequencing approach by means 
of smMIPs for high-risk HPV types (HPV16, HPV18, HPV33, and HPV52) we validated 
the previously established HPV status in the cell lines (Supplementary Figure S1A). 
Using linear quadratic model fitting, the α and β, of each cell line were determined, 
which are the main parameters of intrinsic cellular radiosensitivity. Subsequently, 
the radiation dose permitting 37% survival (D37) was interpolated from the linear 
quadratic model (Supplementary Figure S1B). As expected, the D37 was significantly 
lower for HPV-positive HNSCC cell lines compared to HPV-negative HNSCC cell lines 
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(p=0.013; Supplementary Figure S1C), indicating that the HPV-positive cells were 
more sensitive to irradiation, confirming previous reports 493,497. We then performed 
smMIP sequencing for approximately 200 metabolic and cancer-related targets 
309,345 to investigate whether gene transcripts could be identified that correlate with 
radiosensitivity or radioresistance. When we compared the four most radioresistant 
and radiosensitive cell lines (UT-SCC-5, UT-SCC-15, UT-SCC-19A, UT-SCC-11 vs. UT-SCC-40, 
93-VU-147T, UM-SCC-47 and UT-SCC-45), we found that in the former expression levels 
of the tricarboxylic acid cycle, glutamine metabolism, and lipogenesis pathways were 
upregulated (Supplementary Figure S1D). Using a Spearman’s rank test to test for 
significant correlation between the D37 and gene transcripts, 18 targets were detected 
that significantly correlated with either radioresistance or radiosensitivity (Table 
1). Of these transcripts, 16 correlated positively with radioresistance, and two with 
radiosensitivity. 
Table 1. Genes significantly correlating with D37 values of 14 HNSCC cell lines. Spearman’s rho 
correlation was used to determine the strength of association. Shown are transcripts and their 
encoded proteins that are associated with radioresistance or -sensitivity.
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Figure 1. Characterization of 14 head and neck squamous cell carcinomas (HNSCC) cell lines. 
A) Schematic representation of the approach to determine radioresistance or -sensitivity 
associated metabolic transcripts. B) 10 HPV-negative (UT-SCC-5, 8, 11, 15, 19A, 24A, 29, 38, 40, 
and UM-SCC-6) and four HPV-positive (UT-SCC-45, UM-SCC-47, 93-VU-147T, and UPCI: SCC154) 
cell lines were exposed to 0, 2, 4, 6, or 8 Gy. Survival was determined by colony formation assay. 
Inhibition of ACLY affects DNA damage repair and radiosensitizes HNSCC cells
As the ATP citrate lyase (ACLY) enzyme has recently been implicated to play a role 
in the DNA damage repair pathway 502 and it is one of our top hits to correlate with 
radiosensitivity, we hypothesized that ACLY may be relevant for further study. There 
was no significant difference in ACLY expression levels between HPV-positive and 
HPV-negative HNSCC cells, suggesting that HPV status is not a confounding factor 
(p=0.09; Supplementary Figure S2). To investigate whether ACLY indeed affects DNA 
damage repair and subsequent radiosensitization of HNSCC cell lines, we depleted ACLY 
expression via siRNA in the most radioresistant cell line, UT-SCC-15. siRNA mediated 
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depletion of ACLY was confirmed 72 h after transfection (Supplementary Figure S3A) 
and radiosensitised UT-SCC-15 cells to irradiation (Figure S3B). To move towards a 
more clinically realistic setting, we opted to further validate this using pharmacological 
inhibition of ACLY using BMS303141. UM-SCC-6 and UT-SCC-5 cells were treated with 5 
µM BMS303141 for 6 h before irradiation, and thereafter colony survival was assessed as 
measure for radiosensitization. DNA damage repair was assessed by staining for 53BP1, 
an important repair factor which is rapidly recruited to sites of double-strand breaks 
507. BMS303141 treatment had a significant radiosensitizing effect on both UT-SCC-5 and 
UM-SCC-6 cells (sensitizer enhancement ratio at 37% survival (SER37)=1.29; p<0.001 and 
p=0.0068 respectively; Figure 2A, B). ACLY inhibition followed by 2 Gy ionizing radiation 
(IR) resulted in a significant defect in DNA damage repair, as shown by an increased 
number of residual 53BP1 foci 24 h post-IR (UT-SCC-5 p=0.0088; UM-SCC-6 p=0.0029; 
Figure 2C, D, Supplementary Figure S3C, D). We then determined whether the defect in 
DNA damage repair could be a consequence of defective homologous recombination 
using a GFP based reporter system 508. Pre-incubation with BMS303141 or B02, a Rad51 
inhibitor used as positive control of homologous recombination inhibition, resulted 
in a significant decrease of the GFP positive fraction (p=0.0036), indicating that 
ACLY inhibition repressed homologous recombination (Figure 2E, F). These data 
demonstrate that ACLY significantly influences DNA damage repair, which is in line 
with a previous report that explored the effect of ACLY-mediated histone acetylation 
on homologous recombination 502. To investigate whether other functions of ACLY 
distinct from homologous recombination repair can be involved, we inhibited fatty 
acid synthetase (FAS), responsible for the production of palmitate from acetyl-CoA 
and malonyl-CoA, with C75. Contrary to BMS303141, treatment with C75 did not lead to 
an increase of residual 53BP1 foci in UM-SCC-6 and UT-SCC-5 cells (UM-SCC-6 p=0.933; 
UT-SCC-5 p=0.195), nor did it cause radiosensitization (p=0.184; Supplementary Figure 
S3E-G), indicating that the radiosensitizing effect of ACLY inhibition is independent of 
fatty acid synthesis. 
Figure 2. Inhibition of ACLY exacerbates radiation induced DNA damage in HNSCC cells and im-
pairs homologous recombination. A,B) UM-SCC-6 (A) and UT-SCC-5 (B) cells were treated with 
5 µM BMS303141 for 6 h and irradiated with 2, 4, or 6 Gy. Survival was determined by colony for-
mation assay. C,D) Quantification of cells positive for 53BP1 foci (>5 53BP1 foci/nucleus in a single 
plane of view) in UM-SCC-6 (C) and UT-SCC-5 (D) cells. Shown are mean percentages of three 
biological replicates. Immunofluorescent representative images of examples of UM-SCC-6 or UT-
SCC-5 cells, 24 h post irradiation, with or without 5 µM BMS303141 pre-treatment. Nuclei in blue, 
53BP1 foci in red. E) Homologous recombination assay. U2OS cells have been stably transfected 
with a construct containing a GFP gene containing a I-SceI restriction site (SceGFP) as well as a 
stop codon at the same site. Upon transfection with an I-SceI encoded plasmid, a double strand 
break is induced at the I-SceI site. Repair of this break via homologous recombination occurs 
through utilization of the internal GFP (iGFP) fragment downstream of the SceGFP. Successful 
homologous recombination results in the restoration of a functional GFP gene. F) U2OS DRGFP 
cells were treated for 6 h with 5 µM BMS303141 or 5 µM BO2 (Rad51 inhibitor), and transfected 
with pCBASceI plasmid. 48 h post transfection, cells were harvested and the GFP positive fraction 
was determined using flow cytometry. Representative images from flow cytometry experiments 
are shown on the right, with DMSO Sce- as a negative control, and 5 µM B02 Sce+ as a positive 
control. In the graph, data are shown from two biological replicates. (Next page)
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High ACLY levels are associated with poor prognosis in HNSCC patients receiving 
radiotherapy
Next, we assessed whether ACLY expression levels were associated with HNSCC 
patients’ responses to RT, using an experimental and validation cohort. For the 
experimental cohort, we extracted gene expression data of 445 patients from the 
HNSCC TCGA dataset (Supplementary Table S2). To objectively stratify patients in 
two groups (low ACLY expression and high ACLY expression), we used Cut-off Finder 
504 to determine the optimal cut-off point in patients who did or did not receive RT. 
The optimal cut-off point was determined to be at 81.3% of the population, and was 
used in all subsequent analyses. Patients that were treated with RT and had high ACLY 
expression, had a significantly worse overall survival than patients with low ACLY 
expression (hazard ratio (HR)=2.00; 95% confidence interval (CI) 1.12-3.55; p=0.0184; 
Figure 3A). In contrast, ACLY expression did not correlate with the overall prognosis 
of patients that did not receive RT (HR=0.893; 95% CI 0.504-1.58; p=0.697; Figure 3B). 
Together, these results are in line with our preclinical data suggesting that patients 
with high ACLY expressing tumours have a superior DNA damage repair capacity, 
leading to radioresistance. Of note, ACLY expression did not affect the recurrence free 
survival, both in patients who did and who did not receive RT (RT+ HR=1.293; 95% CI 
0.684-2.45; p=0.389; RT- HR=0.804; 95% CI 0.320-2.02; p=0.660; Supplementary Figure 
S4A, B). Overall, no major differences were observed regarding TNM status in patients 
with high ACLY expression versus patients with low ACLY expression (Table 2). 
Table 2. Clinical characteristics of The Cancer Genome Atlas HNSCC cohort. Statistical 
significance between low versus high ACLY expression and RT+ and RT- patients was tested 
using a Chi-square test. * p<0.05, ** p<0.01; *** p<0.001.
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Figure 3. ACLY overexpression predicts poor response in RT treated HNSCC patients. A,B) Ka-
plan–Meier analysis of HNSCC patients that have high or low ACLY expression based on the 
optimal cut-off point. Shown are plots for overall survival of HNSCC patients that received ra-
diotherapy (A) and patients that did not (B). C) Kaplan–Meier analysis of HNSCC patients that 
have high or low ACLY expression based on the previously determined cut-off point. Shown is 
locoregional control of HNSCC patients that received chemoradiation therapy.
To validate that patients who received RT have a poorer prognosis when expressing 
high levels of ACLY, we tested an alternate HNSCC patient cohort 505. In this validation 
cohort 91 patients were included, all treated with a combination of cisplatin and RT 
(Supplementary Table S3). Like the TCGA HNSCC cohort, follow-up time was censored 
at five years. The same cut-off point as for the TCGA cohort was applied (e.g. 81.3%) 
and survival analysis was performed using Kaplan-Meier analyses. For this cohort, only 
locoregional control data was available. Again, patients who had a high ACLY expression 
had a significantly worse locoregional control than patients with low ACLY expression, 
confirming the results of the HNSCC TCGA cohort (HR=4.17; 95% CI 1.35-12.86; p=0.0130; 
Figure 3C). Taken together, this strongly suggests that HNSCC patients who receive RT 
have an overall worse prognosis when they express high levels of ACLY, and that ACLY 
expression is predictive for therapy outcome.
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Nuclear ACLY localisation is associated with locoregional control in HNSCC patients 
To further investigate the clinical impact of ACLY levels in more detail, we tested 
the levels of total ACLY protein in biopsies of HNSCC patients. 19 biopsies of HNSCC 
patients of a previously described cohort 506 were selected for analysis, based on the 
locoregional control; nine patients with poor locoregional control (locoregional event 
within 177 ± 36 days), and ten patients with good locoregional control (all minimal 
recurrence free survival of three years; Supplementary Table S4). We hypothesised that 
patients with a poor locoregional control had higher levels of ACLY than patients with a 
good locoregional control. Overall, ACLY expression seemed ubiquitously expressed in 
all patient samples, yet demonstrated a marked pattern in terms of cellular localisation 
(Figure 4A). Strikingly, patients with poor locoregional control had significantly higher 
levels of ACLY in the nucleus (p=0.037). In patients with good locoregional control, 
ACLY was almost unequivocally expressed in the cytoplasm, but not the nucleus 
(Figure 4B). This indicates that not only ACLY expression, but also its localisation could 
play a critical role in determining treatment response in HNSCC patients. 
Figure 4. Nuclear ACLY staining is associated with poor outcome in HNSCC patients. A) Immu-
nohistochemistry images showing total ACLY in HNSCC patient biopsy sections. The left pane 
corresponds to a representative section of a patient with poor locoregional control; the right 
pane to a patient with good locoregional control. Images are at 20× (top) or 60× (bottom) mag-
nification. B) χ2 test of patients with low vs. high regional control and nuclear or cytoplasmic 
staining. 
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Discussion
In this study, we have shown that a targeted RNA sequencing approach allowed to 
identify gene transcripts that are associated with radioresistance in HNSCC cell lines. 
One of the top hits, ACLY, correlated with radioresistance, and inhibition of ACLY resulted 
in impaired homologous recombination, leading to decreased DNA damage repair 
and radiosensitization. Furthermore, we demonstrated that high ACLY expression in 
patient cohorts corresponds to worse outcome, both for locoregional control as well 
as overall survival, and that nuclear ACLY is mainly found in HNSCC patients with poor 
outcome. It has previously been described that ACLY is overexpressed in malignant 
tissues as compared to normal tissues, which could provide for an optimal therapeutic 
window, yet the cause of overexpression of ACLY in HNSCC patients has not been 
investigated 509. Experiments performed in visceral adipose tissue suggest that ACLY 
levels could be elevated as a result of an hypoxic environment, and that ACLY could 
be a possible target gene of the hypoxia-inducible factor 1α (HIF-1α) 510. In that case, 
ACLY could correlate with the occurrence of hypoxic tumours, and the observed poor 
treatment response could be also partially attributed to the lack of oxygen required 
for effective irradiation. 
ACLY catalyses the production of acetyl-CoA and oxaloacetate from citrate and CoA, 
and thereby plays a crucial role in fatty acid synthesis and acetylation reactions 511. A 
number of mechanisms could be proposed for the DNA damage repair deficiency that 
was observed after ACLY inhibition. Inhibition of general fatty acid synthesis would 
deprive cells of the macronutrients required for cell proliferation, as well as fatty acids 
required to repair radiation-associated peroxidised lipids. Inhibition of FAS or FASN 
expression has been previously shown to sensitise prostate cancer and non-small cell 
lung cancer cells to irradiation 512,513 However, FAS inhibition did not result in an increase 
in DNA damage or radiosensitization in HNSCC cell lines. Interestingly, we now show 
that direct inhibition of ACLY results in impaired DNA repair within hours, specifically 
homologous recombination. Previously it has been demonstrated that nuclear ACLY 
promotes the cell’s choice for homologous recombination through elevated levels 
of acetylated histones at the site of double strand breaks 502. A shift in DNA damage 
repair to the virtually error-free homologous recombination pathway, rather than the 
more error-prone non-homologous end-joining, is likely to result in an improved DNA 
damage repair efficacy and thereby contributes to radioresistance. 
Additionally, we show that high ACLY expression is a prognostic factor for worse 
overall survival in a cohort of HNSCC patients. In line with its apparent role in DNA 
damage repair, high ACLY expression predicted worse outcome only in patients that 
received RT, but not in patients that did not, thus indicating that ACLY is a predictive 
biomarker for RT success, of which there is a critical need in HNSCC. In a validation 
cohort where all patients have been treated with chemoradiation (platinum-based 
chemotherapy and RT), better locoregional control was observed in patients who had 
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low ACLY expression levels. This further strengthens the notion that ACLY mediates 
radioresistance, and thus high levels of ACLY result in poor treatment success. 
Furthermore, while ACLY protein seemed ubiquitously expressed, ACLY localisation 
was strikingly different between patients with good versus poor locoregional control. 
Localisation in the nucleus was significantly associated with poor locoregional control, 
in line with data from an earlier report that demonstrates that, while acetyl-CoA is 
able to diffuse through nuclear pores, the activity between nuclear and cytoplasmic 
acetyl-CoA pools differs 514. Overall, this supports the hypothesis that nuclear-located 
ACLY facilitates the production of nuclear acetyl-CoA, which in turn affects the 
histone acetylation status of the chromatin, and thereby deters the cell’s choice for 
homologous recombination as the preferred pathway for DNA damage repair 502. 
As radiotherapy is an important treatment option in HNSCC, it is critical to elucidate 
the mechanisms that contribute to the development of radioresistance and to devise 
strategies for targeting this. It is becoming clear that metabolic reprogramming 
contributes to radioresistance, and affects treatment outcome. Here, we show that 
nuclear-located ACLY, an enzyme that catalyses the production of acetyl-CoA and 
oxaloacetate from citrate and CoA, correlates with radioresistance in HNSCC cell lines 
as well as different patient cohorts treated with (chemo)radiation, and demonstrate 
that ACLY directly affects DNA damage repair. 
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Supplementary material
Figure S1. Characterisation of HPV status, radiosensitivity and metabolic pathway expression of 
14 HNSCC cell lines. A) Expression of high-risk HPV genes E2, E6, and E7 was tested and pooled. 
14 HNSCC cell lines were tested for HPV16, HPV18, HPV33, and HPV52. Shown are fragments per 
million mapped fragments (FPM) for all high-risk HPV types for all cell lines. B) Radiosensitivity 
data of 14 HNSCC cell lines was fitted using the linear quadratic model. The dose permitting 37% 
survival (D37) was interpolated from this model using the generated α and β values. Shown are 
the α and β for each cell line, and the corresponding D37. C) D37 data were interpolated from 
survival curves in 1B using linear quadratic model fitting. D37 data are shown for 10 HPV-ve and 4 
HPV+ve cell lines respectively. Statistical test: two-sided t-test with Welch’s correction. D) Over-
view of metabolic pathway expression in four radioresistant vs. four radiosensitive HNSCC cell 
lines. Shown are genes that were enriched (red) or depleted (green) in radioresistant vs radio-
sensitive cells by at least a 1.5 fold change in either direction.
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Figure S2. ACLY expression does not differ between HPV+ and HPV- cell lines. Gene expression 
of ACLY was measured in 14 HNSCC cell lines using smMIPs. Comparison of ACLY expression 
between HPV+ and HPV- cell lines was done using an unpaired, two-sided t-test with Welch’s 
correction. FPM: fragments per million.
Figure S3. ACLY, but not FAS, inhibition leads residual DNA damage and radiosensitization. A) 
Depletion of ACLY expression in UT-SCC-15 cells was performed using 0.5 or 2.5µg pooled siRNA 
for 72 hours, followed by confirmation by RT-qPCR. Error bars indicate standard deviation of three 
technical replicates. B) ACLY was depleted in UT-SCC-15 cells using pooled ACLY siRNA for 72 hours. 
Subsequently, cells were plated for a colony forming assay and irradiated with the indicated 2, 4, 
6, or 8 Gy. Error bars indicate standard deviation of three technical replicates. C, D) UM-SCC-6 (A) 
and UT-SCC-5 (B) cells were treated with 5 µM BMS303141 or DMSO control for 6 hours and irradi-
ated with 2 Gy. 24 hours post-irradiation, quantification of 53BP1 foci was performed. Shown are 
percentages of cells containing a number of 53BP1 foci per nucleus. Bins indicate the following: 
0: 0-4 foci; 5: 5-9 foci etc. E, F) UM-SCC-6 (C) or UT-SCC-5 cells were treated with 10 µM 10 C75 or 
DMSO control for 6 hours and were irradiated with 2 Gy. Quantification of cells positive for 53BP1 
foci in UM-SCC-6 (C) and UT-SCC-5 (D) cells. Shown are mean percentages of three biological repli-
cates and indicates cells that are positive for 53BP1 (>5 53BP1 foci per nucleus) in a single plane of 
view. G) UT-SCC-5 cells were treated with 10 µM C75 or DMSO control for 6 hours and irradiated 
with 2, 4, or 6 Gy. Survival was determined by colony formation assay. Shown are mean values of 
two biological repeats with three technical replicates each. (Next page)
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Figure S4. ACLY is not associated with recurrence free survival outcome. A, B) Kaplan-Meier 
analysis of a TCGA cohort of HNSCC patients that have high or low ACLY expression based on the 
optimal cut-off point for overall survival. Shown are plots for recurrence free survival of HNSCC 
patients that received radiotherapy (A) and patients that did not (B).
Table S1. Cell line characteristics.
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Table S2. Clinical characteristics TCGA HNSCC cohort.
Table S3. Clinical characteristics of the patients selected from the HNSCC cohort previously 
described by Van der Heijden et al. Categorical values were tested using a Chi-squared test. 
Differences in age were tested by means of an independent t-test with Welch’s correction. Stars 
indicate statistically significant (p<0.05) differences.
Boek 1.indb   215 23-3-2020   11:50:45
542469-L-bw-vd Heuvel
Processed on: 24-3-2020 PDF page: 216
216
Chapter 9
Table S4. Clinical characteristics of the patients selected from the HNSCC cohort previously 
described by Liskamp et al. A selection of 10 patient with high locoregional control and 9 pa-
tients with poor locoregional control was made. Categorical values were tested using a Chi-
squared test. Differences in age were tested by means of an independent t-test with Welch’s 
correction. n.a.: not available. * p<0.05.
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Precision healthcare is an increasing field in oncology which aims to provide diagnoses, 
prognoses and therapy tailored to the individual patient. Currently, precision 
healthcare in clinical oncology practice is mainly executed on the level of genomics and 
through immunohistochemistry assays, which allow visualization of amongst others 
tumour heterogeneity and presence of immune checkpoints or pathogenic protein 
mutants, such as isocitrate dehydrogenase 1 (IDH1) R132H. In recent years also some 
transcriptomics assays have been introduced 515. Whereas some successes in cancer 
precision healthcare have been achieved 27,110,111,176,441,477,515-529, too often results have been 
disappointing 127-131,361,530. The degree of matching between tumour alterations (genomic 
or transcriptomic) and administered drugs has been correlated to treatment outcome 
531. In order to fully employ the potential of cancer precision healthcare we need an 
extensive understanding of cancer biology to 1) correlate molecular aberrations to 
cancer diagnosis and prognosis, 2) identify oncogenic addiction pathways and 3) 
predict response as well as resistance to targeted therapeutics. Efficient and reliable 
methods to map the molecular make-up of individual cancers are essential in this 
regard. Targeted RNA next-generation sequencing (t/RNA-NGS) using single molecule 
molecular inversion probes (smMIPs; Figure 1) may provide a method of easy and 
reliable tumour profiling to add in cancer precision healthcare. In this chapter, I will 
review the implications of the results presented in this thesis and discuss the challenges 
for clinical application of precision healthcare in oncology. 
Figure 1. Targeted RNA sequencing. Target mRNA (1) is reverse transcribed to cDNA using 
random hexamer primers (2). After capture of a smMIP to the target sequence, the transcript 
target region is copied into the smMIP probe (3). The two ends of the sequence are ligated to 
form a circular probe, and all remaining linear sequences are removed by exonuclease treatment 
(4). The smMIP library is PCR-amplified (5). PCR reads can be sequenced, using unique molecule 
identifiers to quantify the presence of the original target transcript.
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Diagnostic and prognostic cancer precision healthcare 
In diagnostic oncology, precision healthcare is currently guided by DNA or 
immunohistochemistry screening for pathogenic mutations in proto-oncogenes 
including BRCA1/2, BRAF, KRAS, EGFR and IDH1. Genomic screenings can be 
performed by Sanger sequencing of PCR amplicons 532, by using whole genome or 
exome sequencing or with the use of hotspot panels for next-generation sequencing 
(NGS), including single molecule molecular inversion probe (smMIP) sequencing 
157,176. In addition to serving as diagnostic biomarkers, genetic aberrations also confer 
prognostic information, such as the IDH1-R132H mutation in glioma which is associated 
with better patient prognosis 533-535. Whereas genetic aberrations are often tumour 
drivers 99, they are not necessarily essential in tumour progression. In Chapter 5, we 
investigated whether smMIP-based targeted RNA next-generation sequencing (t/
RNA-NGS) carries diagnostic or prognostic information by correlating the RNA profiles 
of a cohort of glioma tissues to routine histopathology-based diagnoses and patient 
survival. Using t/RNA-NGS we could confirm IDH1-R132H mutation status and, based on 
expression levels of a specified set of genes, we could 1) differentiate glioblastomas 
from astrocytomas and oligodendrogliomas, and 2) associate gene expression profiles 
with patient survival. Additionally, in Chapters 6, 7 and 8 we showed that t/RNA-NGS 
expression profiles can distinguish healthy kidney, lung or cervix tissues from renal 
cell carcinoma, lung carcinoma and cervical cancer, respectively. The successful 
discrimination of healthy and cancerous tissues in such small sample cohorts offers 
promise for application of t/RNA-NGS in larger settings, and possibly even in machine 
learning approaches where trained algorithms may provide patient diagnosis and 
predict prognosis or even treatment response 536-542. 
The best way of cancer therapy is prevention, for example by diagnosis in pre-cancerous 
stages. In current cervical cancer screening programs diagnostic precision healthcare is 
accomplished by screening for the presence of high-risk human papillomavirus (hrHPV) 
DNA in cervical scrapes. Nation-wide screening programs have significantly reduced 
the burden of cervical cancer in developed countries 543,544, but DNA-level hrHPV 
screening comes along with high numbers of overdiagnoses, unnecessary referrals 
and overtreatment of women 545,546. The reason for this is that hrHPV DNA screening 
cannot distinguish latent, clinically irrelevant hrHPV infections (healthy tissues) from 
active ones ([pre-]cancerous lesions), as hrHPV DNA is detected in both. Therefore, 
there is an essential need for more effective triage of hrHPV DNA-positive women. In 
Chapter 8, we performed a first proof-of-principle study to investigate the value of 
hrHPV RNA detection using smMIPs in distinguishing clinically relevant from irrelevant 
hrHPV infections. HrHPV RNA detection enabled correct identification of healthy 
cervical tissue and cervical cancer and moreover allowed discrimination of expression 
of different HPV oncogenes, which provides some information on the stage of a lesion 
and the chance of regression. Combining knowledge on the hrHPV transcriptome with 
that of the total tissue transcriptome might enable us to accurately predict whether 
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a lesion is in a progressive or regressive state. In this way, RNA profiling on cervical 
scrapes may allow a non-invasive risk assessment, identifying women who need 
immediate treatment and women who can safely return to the regular screening 
program. Accomplishing this would greatly reduce the anxiety imposed on women 
getting unnecessary follow-up, but would also reduce the costs for healthcare. To 
provide solid evidence, longitudinal studies applying hrHPV RNA-based detection 
in parallel with DNA-level screening on samples from the cervical cancer screening 
program are essential, and these are currently ongoing.
Therapeutic cancer precision healthcare
The main objective of therapeutic cancer precision medicine is to select patients who 
are most likely to benefit from a specific treatment, based on predictive biomarkers 
(companion diagnostics). Precision healthcare in cancer therapy has proven to be 
challenging. For a limited number of cancer types, patient subgroups have been 
identified bearing a specific genetic aberration which renders them sensitive to a 
targeted drug. The use of imatinib to treat patients with chronic myeloid leukaemia 
(CML) bearing a BCR-ABL fusion kinase is one of the first and most successful examples 
of this approach 547. In subsequent years, numerous targeted therapy applications have 
been discovered for patient subgroups in other cancers 23,103,104,106,107,548-554. Whereas 
targeted therapy based on genomic aberrations has shown exceptional responses 
in individual patients 555-557, the overall level of clinical benefit has been variable and 
often disappointing with only small subsets of patients showing partial and transient 
response 127-131,152,361,558-562. Possible explanations for this limited response include 
suboptimal companion diagnostics, cellular complexity and resistance development, 
which will be discussed further on in this chapter. Moreover, targeted drugs act on gene 
products, not genes themselves, making it more logical to find therapy predictions in 
analysis of RNA or proteins. The existing challenges of quantitative, high-throughput 
proteome analyses, including protein complexes and posttranslational modifications 
563,564, render the transcriptome a valuable intermediate.
A recent RNA interference study identified 769 genes differentially required for survival 
in subsets of cancer cell lines of different origin. The authors were able to generate 
predictive algorithmic models based on molecular features of the tumour for 289 of 
those ‘cancer cell dependencies’, which are possible targets for therapy. Only 18% of 
the predictive models was related to a genomic biomarker, such as a somatic mutation 
or copy number gain. In fact, in 82% of the predictive models the top biomarkers were 
based on gene expression levels 442. Likewise, a second study on sensitivity of cancer 
cell lines to small-molecule drugs found that cancer dependencies are most commonly 
predicted by RNA expression 565, illustrating the potential of transcriptomics in targeted 
therapy prediction. For this reason, gene expression levels should be included in 
precision healthcare decision making.
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Biomarker discovery and validation
The first step to therapeutic precision healthcare in oncology is discovery of predictive 
biomarkers or biomarker profiles that indicate hyperactivity of targetable biological 
pathways. As mentioned above, gene expression levels are promising for guidance 
of therapy prediction 442,565. To give an example, expression of angiogenesis genes 
such as vascular endothelial growth factor (VEGF) by tumour cells and its receptors 
by endothelial cells is influenced by tumour hypoxia and does not necessarily require a 
genetic aberration 566. Another example is given by Bubendorf et al., who described a 
cohort of non-small cell lung carcinoma (NSCLC) patients where MET gene amplification 
was present in only 4.6% of patients, but MET overexpression was found in 23.8% 22. 
Clearly, aberrant biology in cancer is not only related to genetic mutations but is also 
caused by aberrant gene regulation, in combination with post-transcriptionally and 
post-translationally regulated processes 567. Transcript-level biomarkers may therefore 
offer a more realistic view of a cancer’s real-time molecular make-up than do genomic 
biomarkers. The correlation between RNA and protein levels may vary per transcript 
and is dependent on many factors including protein and mRNA half-lives, cellular state, 
and cellular resources and feedback loops 568,569. Transcript-specific conversion factors 
are suggested to allow a more accurate prediction of protein levels deduced from 
RNA expression 570. For a selected set of genes, expression levels as determined with 
t/RNA-NGS correlated well with protein levels as shown in Chapters 3, 5 and 6 of this 
thesis. 
Unfortunately, of all candidate cancer biomarkers discovered only a minority eventually 
transitions to the clinic 571,572, due to the many hurdles in the phases from biomarker 
discovery until eventual clinical implementation. Many candidate biomarkers fail 
to be accurately validated, one of the reasons being suboptimal study design 573,574. 
Biomarker validation studies may profit from clear guidelines on set-up, analysis and 
reporting 575-578, harmonizing the way in which studies are performed and registered, 
thereby increasing quality and reliability of studies and predictive value of candidate 
biomarkers in early stages of discovery 571,574. 
Targeted drug development
In cancer precision therapy, treatment-predictive biomarkers and targeted cancer 
drugs go together. Optimally, biomarker discovery is therefore carried out either to 
support existing compounds or alongside new pharmaceuticals. There is an increasing 
armamentarium of targeted compounds, which are generally small-molecule drugs 
such as tyrosine kinase inhibitors (TKI), monoclonal antibodies or antibody-drug 
conjugates. 
Generally, targeted drugs are approved for the treatment of specific cancer types, 
without consideration of similar molecular aberrations in other cancers. The 
concept of drug repurposing aims at the reuse of existing approved drugs for new 
medical indications 579,580. Drug repurposing has the advantage of lower safety risks 
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and development costs and shorter implementation timelines 579,580. Repurposing 
has historically been mostly serendipitous, based on retrospective clinical and 
pharmacological analyses. Two famous examples of drug repurposing are thalidomide 
(originally indicated for morning sickness, repurposed for erythema nodosum leprosum 
and multiple myeloma) and aspirin (originally indicated for analgesia, repurposed for 
colorectal cancer and prevention of cardiovascular disease) 579,581,582. Successes as 
these have encouraged the development of more systematic approaches to identify 
repurposable drugs. These can be either computational, including pathway mapping, 
genetic association and structure-based prediction, or experimental, including binding 
assays and phenotypic screening 579. The Hartwig medical foundation started the 
first Dutch national DNA databank, collecting whole genome sequencing and clinical 
patient data to improve molecular knowledge of cancer and find new biomarkers for 
treatment and indications for drug repurposing 583. Considering the high potential of 
transcriptomics in targeted therapy prediction, transcriptomic associations may be 
used to identify repurposable drugs as well.
Therapy resistance
One major complication in the use of targeted therapeutics is the almost inevitable 
appearance of therapy resistance 26,126,134,139,302,404-406,408,584. Many cancers are characterized 
by genomic instability (especially after primary treatment with radio- or chemotherapy) 
and a multitude of cancer driver mutations, that activate multiple oncogenic signalling 
pathways. Anti-cancer therapies are well-known to change the molecular make-up of a 
tumour and gene expression profiles of tumour metastases often differ from those of 
the original tumour 585-587. Heterogeneity and plasticity are the cause of both intrinsic 
and acquired resistance 126,132,136,139,293,588,589, limiting the long-term success of targeted 
therapy. 
In Chapter 9 we investigated intrinsic resistance to radiotherapy in head and neck 
squamous cell carcinoma (HNSCC). HPV-negative HNSCCs are generally less sensitive 
to radiotherapy than HPV-positive HNSCCs, and the mechanisms behind this are 
suggested to include DNA damage repair and tumour metabolism 590-592. We propose ATP 
citrate lyase (ACLY) expression as a mediator of radioresistance through promotion of 
DNA damage repair. Combination of radiotherapy with ACLY inhibition impaired DNA 
damage repair and induced radiosensitization in HNSCC cell lines, offering a possible 
opportunity to overcome intrinsic therapy resistance. 
Due to the conserved receptor tyrosine kinase (RTK) catalytic domain many TKIs are 
multi-specific, having activity against multiple RTKs. Besides causing toxic side-effects, 
this multi-specificity may lead to off-target effects antagonizing drug efficacy. In Chapter 
2 and Navis et al. 2013 177 we compared the effectiveness of a multi-specific (cabozantinib) 
and a mono-specific (Compound A) MET inhibitor in an in vivo glioblastoma model. In 
the context of glioblastoma, the blood-brain barrier is often disrupted 177. Multi-specific 
targeting with cabozantinib restored the blood-brain barrier, possibly by concomitant 
inhibition of VEGFR2, thereby hampering delivery of the drug to the tumour 177,205,206,219. 
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Compound A in contrast did not restore the blood-brain barrier and showed superior 
effects on MET inhibition compared with cabozantinib. On the other hand, inhibition 
of angiogenesis in cancers located in tissues other than brain may improve drug 
delivery to the tumour by vessel normalization 61. In this context, or by dual targeting 
of two parallel signalling pathways that may effectuate mutual compensatory roads, 
multi-specific drugs may also have beneficial outcomes. It is clear that this depends 
not only on the characteristics of the tumour (primary or metastatic), but also on its 
localization. 
Although superior over multi-specific targeting, mono-specific targeting of MET still 
showed only limited survival benefit due to development of in vivo therapy resistance. 
Additionally, in Chapter 6 we show that MET targeting in renal carcinoma cell lines 
effectively blocks MET activation, however with limited effects on cell proliferation. 
Further transcriptomic analysis revealed high endogenous expression of multiple 
other RTKs (Chapter 6) or therapy-induced expression of rescue kinases (Chapter 2). 
Since most RTKs converge in the KRAS/PI3K signal transduction pathways, this finding 
possibly provides an explanation for intrinsic or acquired resistance. A well-known 
example of RTK crosstalk to effectuate therapy resistance is upregulation of MET upon 
EGFR inhibition, reported in amongst others gefitinib- or erlotinib-resistant NSCLC, 
glioblastoma and colorectal cancer 22,143,192,295,301,304,404,407,409,593. A second mechanism 
for resistance against EGFR inhibitors often seen in NSCLC is acquisition of the EGFR 
T790M mutation 136,142. Resistance induced by mutations of the target protein may 
be overcome by using second- or third-generation TKIs, such as osimertinib, that are 
selected for their potent inhibitory activity against EGFRT790M 102,134,142,594,595. 
As described before, heterogeneity in tumours is an enormous obstacle for effective 
targeted therapy. Blocking growth of one tumour subclone allows selective outgrowth 
of resistant subclones that were already present or induced by therapy. It is therefore 
important to not only identify biomarkers in a tumour, but also to know if this 
biomarker is homogeneously or heterogeneously expressed. To visualize intra-tumoral 
heterogeneity of actionable transcript expression, we used padlock probe rolling circle 
amplification in Chapter 4. However, the cost- and labour-intensive nature of this assay 
combined with low sensitivity prohibit it from being applied in general diagnostics. 
A second way of mapping the level of tumour heterogeneity is by evaluating gene 
expression profiles from multiple biopsies of the same tumour. We investigated 
tumour heterogeneity in clear cell renal cell carcinoma (ccRCC) in this manner in 
Chapter 6. Expression of targetable genes varied both within and between cancers, 
and analysis of multiple biopsies revealed that VHL mutations, which are considered 
oncogenic drivers, were not expressed at detectable levels throughout the entire 
tumour, a phenomenon that has been described before 140,400. To overcome therapy 
resistance, insight into all oncogenic addiction pathways in a tumour accompanied by 
adjusted treatment strategies is warranted.
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Given the genomic flexibility and complexity of many cancers, manipulation of the 
immune system by immune checkpoint blockade is a promising therapeutic area for 
tumour targeting, even though intrinsic and acquired resistance seems to complicate 
the efficacy of immune checkpoint blockade as well 133,596,597. Low mutational burden and 
low immune checkpoint expression, but also host factors such as gut microbiota and 
antibiotic use may result in primary resistance 137,166-175. Immune checkpoint inhibitors 
have demonstrated variable response rates that are usually not higher than 20-30% 
123,133, indicating the presence of resistance mechanisms in the other 70-80% of patients, 
but also cases of complete and durable response are reported 598-602. In agreement 
with these findings, our data present inter-patient variability in immune checkpoint 
gene expression in ccRCC, potentially explaining differences in response to immune 
checkpoint inhibition (Chapter 6). Acquired resistance may occur due to upregulation 
of PD-L1 expression, production of immunosuppressive cytokines or T-cell inhibitory 
receptors, or mutations in genes that regulate the response to immune checkpoint 
inhibitors 603-608. Further elucidation of the factors and mechanisms that regulate 
response to immune checkpoint blockade from the side of the host as well as the 
tumour may be accomplished by measuring expression levels of the involved genes 
in prospective clinical studies, and identifying classifiers for response or resistance 
to immune checkpoint inhibitors. Such biomarker identification will help to stratify 
patients who are predicted to respond to immunotherapy.
New treatment strategies to overcome resistance to targeted therapy
The heterogeneity and plasticity of tumours implies that therapeutic protocols should 
follow similar ‘evolutionary’ roads, which ideally anticipate on evolutionary trajectories 
of the tumour 588. Upregulation of parallel signalling pathways may be combated with 
adjusted targeted therapy. Alternatively, intermittent dosing of a drug may delay or 
oppose resistance development 609. There is also an opportunity for early combination 
therapies, based on prediction of resistance pathways, that might prevent the 
development of therapy resistance. However, early combination therapies are also 
associated with a risk of increased toxicity and could drive cancers towards alternative, 
possibly even more difficult to target resistance mechanisms. Therefore, additional 
research is needed to evaluate the specific vulnerabilities of therapy-resistant cancer 
cells and investigate opportunities to delay or prevent resistance development.
The almost inevitable development of resistance upon treatment with TKIs or 
monoclonal antibodies illustrates that cancer therapies should be directly cytotoxic, 
killing the tumour cells before they get the chance to develop resistance. For this 
purpose, targeted drugs may be coupled to cytotoxic agents, forming drug-drug or 
antibody-drug conjugates to improve efficacy. An example is the monoclonal antibody 
trastuzumab, which alone has shown great efficacy in HER2-overexpressing breast 
cancers 109-111, but its impact was greatly improved when the antibody was coupled to 
the toxic agent auristatin 112. The large size of full antibodies is, however, associated 
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with long circulation times and limited tissue penetration 610,611. To improve drug 
delivery systems much research is being performed on coupling of drugs to smaller 
antibody fragments or nanobodies 612-617. 
Biomarker detection and tumour monitoring
Considering the high plasticity of tumour cells, successful treatment with targeted 
drugs can only be achieved using up-to-date molecular target profiles. Effective 
detection methods are necessary that allow longitudinal monitoring of a cancer in 
order to tailor therapy. It is possible that only a small percentage of cancer cells harbour 
a resistance mechanism, or that only a small percentage of gene alleles per cell (in case 
of high gene amplification) carry a resistance-inducing mutation 618-620. Consequently, 
detection methods need to be 1) highly sensitive, and 2) non-invasive. 
Cancer monitoring can be performed through repeated biopsies. Obtaining biopsies 
can, however, be difficult and may be associated with complications. Moreover, 
biopsy analyses carry the risk of missing important molecular aberrations due to 
tumour heterogeneity. A relatively new and less invasive approach for evaluating 
the molecular make-up of a tumour is through liquid biopsy. Circulating tumour cells 
(CTCs) or circulating tumour DNA (ctDNA) present in blood plasma, or shed tumour 
cells or DNA in urine or saliva allow detection of cancer-related molecular alterations 
621-629. In CTCs and blood platelets RNA biomarkers have been successfully detected 
as well 542,630-634. Moreover, ctDNA-based profiling may capture tumour heterogeneity 
635,636 and alterations in molecular signature allow monitoring of tumour evolution and 
therapy response 633,637-643. Tissue and liquid biopsies can also be applied in single-cell 
RNA sequencing approaches, which will allow a better understanding of amongst 
others tumour evolution, immune invasion, cancer heterogeneity and resistance 
development 644-647. The ability of smMIP-based sequencing to detect low-abundance 
transcripts and low-frequency mutations 176,272,308 makes it a promising method for 
cancer detection and tumour monitoring. Additional studies to test the application of 
t/RNA-NGS for this purpose are warranted and are currently in progress.
Patient stratification and clinical trials
Medical care has long been guided by population-based studies based on cancer 
type, in which inter-patient variability and site of metastatic deposits are not taken 
into account. Many clinical trials have failed because of too much generalisation. To 
determine the value of cancer precision drugs, modified trial designs are essential.
Molecular tumour profiling has facilitated the establishment of so-called ‘basket’ and 
‘umbrella’ trials. Unlike conventional clinical trials, enrolment of patients in these 
trials is not solely based on tumour histology, but rather on particular molecular 
aberrations that may predict response to specific targeted agents 125,648. Schwaederle 
et al. performed a meta-analysis of 346 phase 1 trials published in 2011-2013 that 
included detection of response signals, comparing patient outcome between 
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targeted single-drug studies with and without a biomarker-based selection strategy. 
The majority of included targeted drug trials (~75%) in this meta-analysis did not 
include biomarker-based patient selection. Patients who did receive biomarker-based 
treatment had significantly higher median response rates (complete or partial) and 
progression-free survival than those who did not. In fact, targeted agents applied 
without a biomarker-based selection showed response rates comparable with those 
for cytotoxic agents such as chemotherapy 649. A meta-analysis on phase 2 clinical 
trials even demonstrated significantly poorer outcomes for targeted drugs without 
biomarker-based patient selection, compared with cytotoxic agents 559. A third 
meta-analysis on clinical trials leading to FDA approval also correlated biomarker 
selection strategies to better patient outcome 650. These and other studies 558,560,651-656 
illustrate the importance of predictive biomarkers and patient selection for molecularly 
targeted drugs. 
The first randomized clinical precision medicine trial was the SHIVA study, performed 
in 2012-2014 657. In this trial, off-label use of molecularly targeted agents, selected based 
on genomic tumour profiling, was tested against conventional therapy in advanced 
cancer patients. No benefit on progression-free survival was found, but many 
limitations to trial design were identified including insufficient evidence for efficacy 
of a targeted drug, substantial pre-treatment of patients and incorrect patient-drug 
matches 530. Following up on SHIVA, multiple large, randomized precision medicine 
trials, such as NCI-MATCH 658-663, NCI-MPACT 660,663, ASCO TAPUR 663 and DRUP 664,665, are 
currently ongoing to further elucidate the clinical value of cancer precision medicine. 
Developments and challenges in clinical application of transcriptome assays
One of the first studies reporting on the use of transcriptomics for cancer diagnosis 
was performed by Alizadeh et al. in 2000, applying gene expression measurements for 
subtyping of diffuse large B-cell lymphoma patients 666. From there on, transcriptomics 
technologies have evolved and their (possible) applications have expanded 515. At the 
moment, multiple transcriptomics-based assays have entered the clinic to be applied in 
cancer diagnostics, prognostics or therapeutics, including MammaPrint, Oncotype DX, 
Endopredict and Prosigna 515,571. A comparison of the techniques used in existing assays 
is reported by Sager et al. 515 (Table 1). Being rather equivalent to multiplex quantitative 
RT-PCR combined with sequencing, t/RNA-NGS may combine the advantages of other 
techniques into one and therefore appears to be a more suitable method for clinical 
application. A second promising technique is NanoString’s nCounter, which allows 
quantitative RNA detection with omission of cDNA synthesis and amplification 667,668 
(Table 1).
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Despite technological advancements, clinical applications of transcriptome assays 
remain limited. Transcriptome assays that are commercially available are not 
guaranteed to improve patient outcome, as illustrated by the uncertainty regarding 
health improvements and cost-effectiveness found for MammaPrint and Oncotype DX 
in early-stage breast cancer patients 669,670. Reasons for this uncertainty come from 
lack of evidence due to suboptimal clinical trial design and ignorance of appropriate 
cut-off points or long-term impacts 669,670. Ongoing clinical trials such as RxPONDER and 
TAILORx must provide further evidence for the use of Oncotype DX and Mammaprint 
in guidance of treatment decisions 669,670. These two cases illustrate the difficulty of 
clinical implementation of new (transcriptome) assays, and highlight the importance of 
appropriate clinical trial design with strict molecular patient stratification and sufficient 
existing evidence for coupling transcription profiles to prediction of prognosis and 
therapy.
Table 1. Comparison of RNA detection techniques.
Turn-around time from RNA isolation up to and including data analysis. qRT-PCR, quantitative 
reverse transcriptase PCR. Table is based on Sager et al., 2015 (Expert Rev. Mol. Diagn.).
One decelerating factor for implementation of transcriptome assays is RNA 
vulnerability, especially in areas in the world where resources are limited and biopsy 
material can not directly be processed in the required way. As mentioned, a second 
limiting factor is still the design and execution of clinical trials and the lack of evidence 
for coupling molecular tumour characteristics to prediction of prognosis and targeted 
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therapy. To improve this, increased patient access to clinical trials is needed. Moreover, 
individual patient records should be stored in ‘N=1’ databases, listing all knowledge on 
tumour molecular characteristics, treatment and outcome to provide a larger learning 
source for evidence-based practice 561. 
Clinical assay implementation includes four key elements: regulatory approval, 
commercialization, reimbursement and incorporation in clinical practice guidelines 
571. Regulations, infrastructures and guidelines are not easily adapted and therefore 
implementation of new assays into the clinic requires not only solid evidence of 
efficacy, but also much efforts from amongst others health insurers, pharmaceutical 
companies, clinicians and government agencies. Post-market surveillance should 
support the use of and increase the confidence in clinical biomarker assays.
Concluding remarks
Multiple randomized clinical trials are currently ongoing to improve our insights into 
the potential of cancer precision medicine. Patient stratification seems to be one of the 
most important factors determining the success of targeted therapeutics. Whereas 
cancer treatment is currently often still guided by tumour tissue type or anatomical 
site of origin, therapies are becoming more and more molecularly oriented. This shift in 
paradigm may allow future drug repurposing, as therapeutics approved for one cancer 
type may also be effective in a different cancer type with similar molecular aberrations. 
The high sensitivity, ability to detect cancer-specific splice variants and mutations, 
relatively easy data analysis, and relatively low turn-around times and costs make 
smMIP-based t/RNA-NGS a method with great potential for the detection of diagnostic, 
prognostic and therapeutic biomarkers. As smMIPs are already applied in the clinic for 
DNA analyses, required adaptations in infrastructure are limited. Biomarker detection 
in a clinical setting is usually restricted to a defined subset of genes or transcripts, and 
t/RNA-NGS allows the design of different smMIP panels that are applicable to different 
subsets of patients. 
Computational biology on big datasets will play an essential part in cancer precision 
healthcare development. Machine learning algorithms may eventually be able 
to provide patient diagnosis and prognosis based on gene expression profiles. 
Systems-based approaches may help to better predict patient response to therapy, 
as well as coincidental adverse events. Correct matching of patients to targeted drugs 
has demonstrated potential to improve cancer therapy, thereby improving patient 
prognosis and quality of life and reducing drug-induced toxicity and healthcare costs. 
Achieving this change in cancer therapy will require efforts from many different sides, 
including cancer scientists, clinicians, regulatory authorities, politicians and industry, 
but will hopefully positively impact the lives of many.
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Cancer initiation and progression are complex processes involving aberrations in 
normal (intra)cellular mechanisms, which are described as the hallmarks of cancer. 
Conventional cancer diagnosis, prognosis and therapy are often guided by tissue type 
and anatomical origin. Cancer-specific alterations, however, offer opportunities for 
molecularly oriented diagnosis and prognosis, and precision therapy using targeted 
drugs. Precision healthcare that is currently implemented in clinical oncology is mainly 
focused on genomic aberrations. Some successes, but even more disappointing 
outcomes of precision healthcare have been described in the past years. Reasons 
for failure include suboptimal clinical trial design and companion diagnostics, 
weak molecular aberration-drug matches and development of therapy resistance. 
Whereas genomic aberrations may provide some information on a cancer’s molecular 
biology, gene products are the executors of the information stored in the genome. 
Transcriptomic or proteomic aberrations may therefore provide a more realistic 
view on the pragmatic consequences of these genomic alterations for RNA- and 
protein-mediated activities. As high-throughput proteome analysis still proves to 
be challenging, RNA analysis offers promise for more efficient cancer precision 
diagnostics, prognostics and therapeutics. This thesis describes the use of targeted 
RNA next-generation sequencing (t/RNA-NGS) with single molecule molecular 
inversion probes (smMIPs) for precision oncology on the diagnostic, prognostic and 
therapeutic level. 
Diagnostic and prognostic cancer precision healthcare
Molecular aberrations in cancer may serve as diagnostic or prognostic biomarkers. 
The first requirement of a diagnostic biomarker in oncology is that it can identify 
cancerous tissues, in malignant or even pre-malignant stages. In Chapters 6, 7 and 
8 we demonstrate the diagnostic potential of t/RNA-NGS, as it is able to distinguish 
respectively renal cell carcinoma, lung carcinoma and cervical cancer tissues from 
accompanying healthy tissues. Additionally, in Chapter 5 it is shown that t/RNA-NGS 
allows correct annotation of clinical (histopathological) patient diagnoses in glioma. 
Moreover, pathogenic mutations were successfully identified in this way. One of the 
most important pathogenic mutations in glioblastoma is the isocitrate dehydrogenase 
1 (IDH1) R132H mutation, conferring a favourable prognosis. In Chapter 5 we show 
that t/RNA-NGS expression profiles can be associated with patient survival in glioma, 
offering prognostic value.
Since the best way of cancer therapy is prevention, population-based screening 
programs are aimed at diagnosing cancer in pre-malignant stages. Current cervical 
cancer screening programs use molecular screening for the presence of high-risk human 
papillomavirus (hrHPV) DNA in cervical scrapes. As hrHPV DNA can also be present 
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in non-transformed cervical tissue, many women are overdiagnosed. In Chapter 8, 
we show that t/RNA-NGS offers a possible solution for this problem, as it is able to 
distinguish clinically irrelevant (hrHPV DNA-positive, RNA-negative) hrHPV infections 
from relevant (hrHPV DNA- and RNA-positive) ones. Moreover, t/RNA-NGS provides 
prognostic information by identifying expression of different hrHPV oncogenes, giving 
some information on the stage of a lesion and the chance of regression. Analysis of 
expression of other cancer-related transcripts in different stage lesions may allow 
even further prognostic risk-assessment, to which additional research is warranted.
Therapeutic cancer precision healthcare
Therapeutic cancer precision medicine is aimed at selecting patients who are most 
likely to benefit from a specific treatment, based on predictive biomarkers (companion 
diagnostics). In this thesis, we investigate the value of transcriptome information as 
biomarker for therapy prediction and evaluate t/RNA-NGS as a tool to obtain this 
knowledge. In Chapters 3, 5 and 6 we demonstrate that expression levels as determined 
by t/RNA-NGS correlate well with protein levels for a selected set of genes. 
In Chapters 3, 5, 6, 7, 8 and 9 of this thesis, we apply t/RNA-NGS to profile the 
actionable transcriptome of different types of cancer. Whether molecular targets are 
appropriate for therapy is not only dependent on expression of the transcript itself, 
but also on expression of genes in possible resistance pathways. Both intrinsic and 
acquired resistance through compensatory pathways confer a major complication in 
the use of targeted therapeutics. In Chapter 9 we describe the presence of intrinsic 
radioresistance in a subset of head and neck squamous cell carcinomas (HNSCCs), 
possibly through high expression of ATP citrate lyase (ACLY). Indeed, inhibition of 
ACLY induced radiosensitization in vitro. Additionally, in Chapter 6 we show that MET 
targeting in renal carcinoma cell lines effectively blocks MET activation, but without 
hampering cell proliferation. Dual targeting of MET and other endogenous, highly 
expressed transcripts effectively blocked cell proliferation in vitro. The development of 
acquired resistance through upregulation of compensatory pathways is demonstrated 
in Chapter 2, where therapy-induced kinase expression rescues glioblastomas from 
targeted MET therapy in vivo.
Tumour heterogeneity is an important source for intrinsic therapy resistance. In 
Chapter 4 we apply padlock probe rolling circle amplification to visualize intra-tumoral 
heterogeneity of expression of MET and Epidermal Growth Factor Receptor (EGFR), 
two transcripts that are able to induce resistance by parallel signalling. Due to low 
sensitivity of this assay, evaluation of gene expression profiles from multiple biopsies 
of one tumour would be a more effective way of mapping the level of tumour 
heterogeneity, and this is demonstrated for renal cell carcinoma in Chapter 6. Here, 
we show that expression of targetable genes varies both within and between renal 
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cancers. Inter-patient variability in actionable gene expression is also apparent 
in glioma, lung carcinoma and cervical cancer (Chapters 5, 7 and 8, respectively). 
Together, this illustrates that tumours of similar anatomical origin do not necessarily 
share the same molecular make-up, potentially explaining differences in response to 
therapy.
Concluding remarks & future perspective
This thesis presents evidence that smMIP-based t/RNA-NGS 1) allows identification of 
cancer tissues within a cohort of healthy and cancer tissue biopsies, 2) may be applied 
to measure the expression of cancer-specific diagnostic and prognostic biomarkers, 
3) can be used to identify cancer-specific alterations, that may help in predicting the 
chance of success of targeted therapy protocols in individual patients. 
Resistance to targeted therapy may arise either through outgrowth of intrinsically 
present resistant cells or through acquired molecular adaptations, and may be 
overcome by therapeutic protocols that follow the molecular changes in the tumour. 
For this purpose, it is important that cancers are monitored through molecular profiling. 
Since obtaining tissue biopsies can be difficult, is associated with complications and 
carries the risk of missing important biomarkers due to tumour heterogeneity, liquid 
biopsies offer promise for cancer detection and monitoring. Additional studies to test 
the application of t/RNA-NGS on liquid biopsies are warranted.
Multiple randomized clinical trials are currently ongoing to improve our insights 
into the potential of cancer precision medicine. One of the most important factors 
determining the success of therapeutic precision medicine is appropriate patient 
selection. Molecularly-oriented patient selection also offers the opportunity of drug 
repurposing, where therapeutics approved for one cancer type may effectively be 
used in different cancer types with similar molecular aberrations, or where even 
non-cancer drugs are applied to sensitive cancers. The high sensitivity, ability to 
detect cancer-specific splice variants and mutations, relatively easy data analysis, and 
relatively low turn-around time and costs make smMIP-based t/RNA-NGS a method 
with potential for the detection of diagnostic, prognostic and therapeutic biomarkers 
in tissue or liquid biopsies. 
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Het ontstaan en de progressie van kanker zijn complexe processen, waarbij 
veranderingen in normale (intra)cellulaire mechanismen en signaleringspaden 
een rol spelen. Deze processen zijn samengevat in de zogenaamde kenmerken van 
kanker (‘hallmarks of cancer’). Traditionele methodes voor de diagnose, prognose en 
behandeling van kanker worden vaak geleid door het type weefsel en de plek in het 
lichaam waar de kanker is ontstaan. De kankerspecifieke veranderingen die aanwezig 
zijn in een tumor geven echter de mogelijkheid om op moleculair niveau kanker te 
diagnosticeren, een prognose te stellen en een behandeling voor te schrijven met 
medicijnen gericht op deze specifieke veranderingen, die voor elke tumor verschillen. 
Deze zogenaamde geneeskunde op maat (‘precision healthcare’) wordt in de 
oncologie op dit moment voornamelijk geleid door kankerspecifieke veranderingen 
in het DNA. Hiermee zijn enige successen behaald, maar nog meer teleurstellingen 
van precision healthcare zijn in de afgelopen jaren beschreven. Er zijn verschillende 
redenen voor deze teleurstellingen aangewezen, zoals suboptimale opzet van 
klinische trials, suboptimale markers voor diagnose, prognose of behandeling, 
zwakke combinaties van moleculaire veranderingen met daarop gerichte medicijnen, 
en het ontstaan van therapie resistentie. Hoewel DNA veranderingen een zekere 
mate van informatie kunnen geven over de moleculaire biologie van een kanker, zijn 
het de producten van het DNA die de informatie die in het DNA is opgeslagen tot 
uitvoering brengen. Deze DNA producten zijn onder andere RNA en eiwitten, welke 
een rol spelen in (intra)cellulaire processen. Veranderingen in RNA of eiwitten geven 
daarom wellicht een realistischer beeld van de pragmatische consequenties van DNA 
veranderingen. Omdat het op grote schaal analyseren van eiwitten momenteel nog 
steeds gecompliceerd is, kan RNA analyse een mogelijkheid bieden voor efficiëntere 
diagnose, prognose en behandeling op maat voor individuele kankerpatiënten. In dit 
proefschrift beschrijven we het gebruik van gerichte RNA sequencing (targeted RNA 
next-generation sequencing, t/RNA-NGS) door middel van single molecule molecular 
inversion probes (smMIPs) voor kankergeneeskunde op maat op het niveau van 
diagnostiek, prognose en behandeling.
Kankergeneeskunde op maat: diagnostiek en prognose
Moleculaire veranderingen in kanker kunnen gebruikt worden als marker voor het 
stellen van een diagnose of prognose voor patiënten. De eerste voorwaarde voor 
een diagnostische biomarker in de oncologie is het vermogen om kankerweefsels, 
of weefsels in pre-kanker stadia, te identificeren. In Hoofdstuk 6, 7 en 8 laten we 
zien dat t/RNA-NGS dit vermogen heeft, door aan te tonen dat het respectievelijk 
niercarcinoom, longcarcinoom en baarmoederhalskanker weefsels kan onderscheiden 
van vergelijkbare, gezonde weefsels. In Hoofdstuk 5 laten we bovendien zien dat we 
met t/RNA-NGS in glioom patiënten een diagnose kunnen stellen die overeenkomt 
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met de klinische (histopathologische) diagnose, en dat we pathogene mutaties 
kunnen identificeren. Een van de belangrijkste pathogene mutaties in glioblastoom 
is de isocitraat dehydrogenase 1 (IDH1) R132H mutatie, welke voor patiënten een 
verbeterde prognose biedt ten opzichte van patiënten die deze mutatie niet hebben. In 
dit hoofdstuk presenteren we dat t/RNA-NGS profielen geassocieerd kunnen worden 
met overleving in glioom patiënten, en daarmee prognostische waarde bieden.
Aangezien de beste kankertherapie gevormd wordt door preventie, zijn er 
bevolkingsonderzoek programma’s actief die gericht zijn op het diagnosticeren van 
kanker in pre-maligne stadia. Het huidige baarmoederhalskanker bevolkingsonderzoek 
in Nederland is gebaseerd op moleculaire screening voor de aanwezigheid van DNA 
van hoog risico humaan papillomavirus (hrHPV) in uitstrijkjes van de baarmoederhals. 
Aangezien DNA van hrHPV ook aanwezig kan zijn in gezond baarmoederhalsweefsel, 
bestaat er een aanzienlijke overdiagnose van baarmoederhalskanker. In Hoofdstuk 8 
laten we zien dat t/RNA-NGS een mogelijke oplossing biedt voor dit probleem, door aan 
te tonen dat het klinische niet-relevante, inactieve hrHPV infecties (hrHPV DNA-positief, 
RNA-negatief) kan onderscheiden van relevante, actieve infecties (hrHPV DNA- en 
RNA-positief). Bovendien biedt t/RNA-NGS prognostische informatie doordat het de 
expressie van verschillende hrHPV oncogenen kan identificeren, wat enige informatie 
geeft over het stadium van de laesie en de kans op regressie. Additionele analyse van 
de expressie van andere kanker-gerelateerde genen in laesies van verschillende stadia 
kan wellicht nog uitgebreidere prognostische risicoanalyse mogelijk maken. Om dit 
verder uit te zoeken is nog extra onderzoek nodig.
Kankerbehandeling op maat
Therapie op maat is gericht op het specifiek selecteren van patiënten die de grootste 
kans hebben op een positief effect van een gerichte behandeling, gebaseerd op 
voorspellende biomarkers (‘companion diagnostics’). In dit proefschrift onderzoeken 
we de waarde van RNA als biomarker voor het voorspellen van de werking van 
gerichte therapie in individuele patiënten, en evalueren we t/RNA-NGS als middel 
om deze informatie te verkrijgen. In Hoofdstuk 3, 5 en 6 laten we zien dat expressie 
niveaus van genen, bepaald middels t/RNA-NGS, voor een geselecteerde genenset 
goed overeenkomen met eiwit niveaus.
In Hoofdstuk 3, 5, 6, 7, 8 en 9 van dit proefschrift passen we t/RNA-NGS toe om het RNA 
in kaart te brengen van genen waarvan de producten geschikt zijn voor het toepassen 
van gerichte therapie. Dit doen we voor verschillende soorten kanker. Of genproducten 
geschikt zijn voor therapie is niet alleen afhankelijk van het expressieniveau van 
het gen(product) zelf, maar ook van de mate van expressie van genen in mogelijke 
compensatiepaden. Zowel intrinsieke als verworven therapieresistentie middels 
compensatiepaden in de tumor vormen een grote uitdaging bij de toepassing van 
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gerichte therapie. In Hoofdstuk 9 beschrijven we de aanwezigheid van intrinsieke 
resistentie tegen radiotherapie in een subset van hoofd-halstumoren, mogelijk door 
aanwezigheid van hoge expressie van het gen ATP citraat lyase (ACLY). Op remming 
van ACLY in vitro volgde inderdaad sensitisatie voor radiotherapie. In Hoofdstuk 6 
laten we daarnaast zien dat remming van MET in niercarcinoom cellijnen effectief 
MET activatie blokkeert, maar dat cel proliferatie hierdoor niet verhinderd wordt. 
Het gelijktijdig remmen van MET en andere genproducten met intrinsiek hoge 
RNA expressie niveaus in vitro blokkeerde cel proliferatie wel. De ontwikkeling van 
verworven therapieresistentie tonen we aan in Hoofdstuk 2, waarin we laten zien dat 
therapie-geïnduceerde expressie van mogelijke compensatiepaden glioblastomen 
redt van gerichte MET remming in vivo.
Tumor heterogeniteit is een belangrijke bron van intrinsieke therapieresistentie. 
In Hoofdstuk 4 passen we ‘padlock probe rolling circle’ amplificatie toe om de 
heterogeniteit in expressie van MET en Epidermale Groei Factor Receptor (EGFR) 
binnen een tumor in kaart te brengen. MET en EGFR zijn transcripten die in staat zijn 
onderlinge therapie resistentie te bewerkstelligen. Aangezien deze methode een lage 
sensitiviteit heeft, is het in de klinische praktijk makkelijker om tumor heterogeniteit 
in kaart te brengen middels het analyseren van meerdere biopten van één tumor. Dit 
laten we zien in niercarcinoom in Hoofdstuk 6, waar we beschrijven dat de expressie 
niveaus van te behandelen genproducten zowel binnen een tumor als tussen tumoren 
van eenzelfde origine variëren. Variëteit in expressie van te behandelen genproducten 
is ook aanwezig in gliomen, longcarcinomen en baarmoederhalskanker (respectievelijk 
Hoofdstuk 5, 7 en 8). Tezamen laten deze bevindingen zien dat tumoren van een 
vergelijkbare anatomische origine niet noodzakelijk dezelfde moleculaire markers tot 
expressie brengen, wat mogelijk het verschil in respons op gerichte therapie verklaart. 
Conclusie en toekomstperspectief
In dit proefschrift tonen we aan dat t/RNA-NGS met behulp van smMIPs 1) identificatie 
van kankerweefsels te midden van gezonde weefselbiopten mogelijk maakt, 2) 
toegepast kan worden om de expressie van kankerspecifieke diagnostische en 
prognostische markers te meten, 3) gebruikt kan worden om kankerspecifieke 
veranderingen te identificeren, wat kan helpen in het voorspellen van de effectiviteit 
van gerichte therapieën in individuele patiënten. 
Resistentie tegen gerichte kankertherapie kan zowel ontstaan door uitgroei van 
bestaande resistente tumorcellen, als door vergaarde moleculaire veranderingen 
in tumorcellen die eerder niet resistent waren. Therapie resistentie kan wellicht 
worden tegengaan door het toepassen van therapeutische behandelplannen die de 
veranderingen in de tumor volgen. Om dit mogelijk te maken is het belangrijk dat 
tumoren gemonitord worden om eventuele moleculaire veranderingen te detecteren. 
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Aangezien het nemen van weefselbiopten moeilijk en risicovol kan zijn, en met deze 
methode bovendien belangrijke biomarkers gemist kunnen worden door toedoen van 
tumor heterogeniteit, kunnen biopten uit lichaamsvloeistoffen zoals bloed of urine 
een uitkomst bieden voor kankerdetectie en -monitoring. Aanvullend onderzoek om 
de toepassing van t/RNA-NGS op biopten uit lichaamsvloeistoffen te testen is nodig. 
Meerdere gerandomiseerde klinische trials worden op dit moment uitgevoerd om 
meer te weten te komen over de potentie van gerichte kankertherapie. Een van de 
meest belangrijke factoren die het succes van gerichte therapie bepaalt is selectie 
van de juiste patiënten. Patiëntenselectie gebaseerd op moleculaire markers maakt 
het bovendien mogelijk om medicijnen die voor een bepaald kankertype toegepast 
worden, ook voor te schrijven in patiënten met een ander type kanker, maar met 
dezelfde moleculaire markers. Zelfs medicijnen die momenteel gebruikt worden voor 
de behandeling van andere ziekten dan kanker zouden toegepast kunnen worden op 
tumoren met de juiste moleculaire karakteristieken. De hoge sensitiviteit, mogelijkheid 
om kankerspecifieke genvarianten en -mutaties te detecteren, relatief makkelijke 
data-analyse, en relatief lage omlooptijd en kosten maken t/RNA-NGS door middel van 
smMIPs een methode met potentie voor de detectie van diagnostische, prognostische 
en therapeutische biomarkers in weefselbiopten of lichaamsvloeistoffen. 
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Appendix IV. SmMIP panel composition. All transcripts are grouped by signalling pathway or 
cancer type. RefSeq and Ensembl IDs for each transcript are provided.
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Gene nomenclature of genes included in the smMIP panel is outlined in Appendix IV and 







BNA Bridged nucleic acid
ccRCC Clear cell renal cell carcinoma
CI Confidence interval
CoI Combination index
CIN Cervical intraepithelial neoplasia
CML Chronic myeloid leukaemia
CTC Circulating tumour cell
ctDNA Circulating tumour DNA
DEPC Diethylpyrocarbonate
DMEM Dulbecco’s Modified Eagle’s Medium
DNET Dysembryoplastic neuroepithelial tumour
DRI Dose reduction index
FA Fraction affected
FC Fold change
FCS Fetal calf serum
FDR False discovery rate
FFPE Formalin-fixed paraffin-embedded
FPKM Fragments per kilobase per million




HNSCC Head and neck squamous cell carcinoma
HR Hazard ratio
(hr)HPV (High-risk) human papillomavirus
HUVEC Human umbilical vein endothelial cells
IDH1 Isocitrate dehydrogenase 1





MRI Magnetic resonance imaging
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NGS Next-generation sequencing
NSCLC Non-small cell lung cancer
Oxphos Oxidative phosphorylation
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PPP Pentose phosphate pathway
PTP Protein tyrosine phosphatase
PXA Pleomorphic xanthoastrocyoma
qPCR Quantitative RT-PCR
RCP Rolling circle product
ROI Region of interest
RT Radiotherapy
RTK Receptor tyrosine kinase
SCC Squamous cell carcinoma
SER Sensitiser enhancement ratio
SF Surviving fraction
smMIP Single molecule molecular inversion probe
SNP Single nucleotide polymorphism
SNV Single nucleotide variant
SRB Sulfurhodamine B
TCA Tricarboxylic acid
TCGA The cancer genome atlas
TKI Tyrosine kinase inhibitor
TMZ Temozolomide
TPM Transcripts per million
TPR Translocated promoter region
t/RNA-NGS Targeted RNA next-generation sequencing
UMI Unique molecule identifier
w/RNA-NGS Whole transcriptome RNA next-generation sequencing
WT Wild-type
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 &
VII. Research data management
The research data presented in this thesis was archived according to the FAIR principles 
(Findability, Accessibility, Interoperability and Reuse of research data). Data was 
stored digitally on a local server, supported by the ICT department of the Radboudumc 
and replicated daily to a university server. Experiments were documented in paper 
labjournals and digitally in Labguru.
All experiments involving animals were conducted according to applicable 
international, national and institutional guidelines for the care and use of animals. All 
performed procedures were in accordance with the standards of the animal ethical 
committee of the Radboud University, Nijmegen, The Netherlands and were approved 
by the CCD (Centrale Commissie Dierproeven).
All human studies included in this thesis were conducted in accordance with the 
principles of the Declaration of Helsinki. The medical and ethical review board 
Committee on Research Involving Human Subjects Region Arnhem Nijmegen, 
Nijmegen, The Netherlands has given approval to conduct these studies. 
All data generated or analysed within the scope of this research project are included in 
the chapters of this thesis and in corresponding publications. Additional data files are 
available via the associated corresponding author on reasonable request. 
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Veel mensen hebben, wetenschappelijk of juist door het zorgen voor de nodige 
afleiding en onvermoeibare interesse, bijgedragen aan het uiteindelijke vormen van 
dit proefschrift.
Allereerst het Radboud-front, te beginnen natuurlijk met het promotieteam. Roland, 
bedankt voor je input en nuttige kijk op mijn projecten vanuit een net wat andere hoek 
dan de rest van het team. William, meer onderzoeker dan jij wordt het niet. Altijd vol 
met wilde ideeën, geïnteresseerd in werkelijk elk zijprojectje en een enorm brede bron 
van kennis. Bedankt dat je me 4 jaar geleden de kans hebt geboden om een PhD te 
komen doen in jouw groep. Ik heb enorm veel geleerd. Ondanks dat de weg hier en daar 
wat hobbelig is hoop ik dat de smMIPs een mooie toekomst tegemoet gaan! Wiljan, 
niemand kan een celexperiment zo humaniseren als jij dat kan. Vergelijkingen als twee 
fuserende cellen die gebombardeerd werden tot siamese tweeling is slechts één 
voorbeeld. Ik heb grote bewondering voor jouw enorme kennis en de rust waarmee je 
deze kan overbrengen. Net zo’n pietje precies als ik heb je ook mijn teksten van mooie 
puntjes op de i voorzien, bedankt daarvoor!
Paul, ik heb er letterlijk een strikje omheen gedaan! Bedankt voor de fijne samenwerking 
en voor de nodige ondersteuning (ook als mentor!), soms zonder dat je het zelf 
doorhad. Ik heb veel waardering voor jouw manier van werken. Pieter, hoewel je 
uiteindelijk niet als mijn promotor hier staat heb je toch met name in de eerste 1,5 
jaar regelmatig mijn projecten van nuttige input voorzien. Ook daarna nog heb je me 
regelmatig op het hart gedrukt dat ik het echt moest laten weten als ik nog ergens 
assistentie bij nodig had. Bedankt!
Ons oude kamerclubje bij Pathologie: Sanne, Krissie, René. En Kiek, onze labmam. 
Van brainstormsessies tot pepernoten en paasei festijnen, tot gourmetten bij Kiek 
thuis, kleurige labdrankjes bij de vierdaagsefeesten en vrijdagmiddagborrelen in de 
sql of de stad. Het was altijd een gezellige bende. Bedankt voor alles! Sanne, hoewel 
er altijd een boom tussen ons in stond ben ik blij dat je vandaag naast me wil staan 
zonder boom 😊 (hoewel we met bomen bij Kees van Hondt ook wel veel lol gehad 
hebben). Krissie, jij hebt zo’n beetje mijn hele PhD naast me gezeten en mag hem nu 
als paranimf ook naast me afsluiten. Bedankt voor alle gezelligheid binnen en buiten 
het lab, de brainstorm- en klaaguurtjes, en voor alle steun waar ik nooit aan hoefde te 
twijfelen. Blij dat ik na de verhuizing niet alleen over bleef!
Anneke, als jouw opvolgster mocht ik instappen in een rijdende trein, en dat is denk 
ik de beste start die je kunt hebben. Duaa, smMIPs robotiseren was zonder jou nooit 
gelukt. Tessa, bedankt dat je me alles over smMIPs hebt geleerd! En Karolina, bedankt 
dat ik jou alles over smMIPs mocht leren. We hebben maar korte tijd samengewerkt 
maar het was een genoegen. Jouw enthousiasme en oprechtheid zijn aanstekelijk, en 
Linux leren was een feest 😉.
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Iedereen (analisten, mede-PhD-studenten, onderzoekers, stagiaires etc.) bij Pathologie: 
bedankt voor de eerste 1,5 jaar! Iedereen bij Biochemie en CMBI: bedankt voor de 
tweede helft! Speciale dank voor Carlijn voor het ontwerpen van al onze smMIPs, en 
voor Martijn voor het helpen opzetten van analyse scripts. Theo, bedankt voor je hulp 
met de lay-out van dit boekje en ook dat je deze dag voor me wilt vastleggen!
Jan, het was een plezier om met je samen te werken en het is ontzettend jammer dat 
ik dat alleen mag zeggen over het eerste stukje van mijn PhD traject. Jouw kennis en 
ervaring zijn nog vaak gemist.
Vele studenten hebben met hun stages een bijdrage geleverd aan het onderzoek 
beschreven in dit proefschrift. Arvid, Sandra, Tessa, Carolien, Marise, Anne, Danique, 
Sura, Zosia, Janine, Remco: allemaal bedankt voor jullie werk! Arvid en Anne, bedankt 
ook voor wat ik van jullie mocht leren! 
Krissie, Carlijn, Marika, Thomas, Sanne, Meyke, Péter, John-Melle, Thomas, Jasper, 
Laura en alle andere mensen in de Feest-app. Bedankt voor de altijd gezellige en 
meestal uit de hand lopende borrels, de feestjes, alle hulp en tips waar nodig, en 
gewoon alles wat de afgelopen 4 jaar tot een leuke tijd heeft gemaakt. Dat de sql nog 
gewoon even onze stamkroeg mag blijven en er nog veel feestjes mogen volgen!
Na het Radboud ben ik verder gegaan als studieleider bij Charles River Den Bosch. 
Daarom voor al mijn (inmiddels niet meer nieuwe) collega’s daar: bedankt voor het 
warme welkom en de mogelijkheid om op vrijdag dit boekje af te maken. Zonder dat 
extra dagje in de week was ie nu nog lang niet af geweest. 
En om te voorkomen dat ik iemand vergeet, iedereen die ik nog niet heb genoemd en 
met wie ik heb samengewerkt of die op wat voor manier dan ook aan mijn onderzoek 
of het tot stand komen van dit boekje heeft meegeholpen (onder andere Diede, Bert, 
Willem, Ruud, Leon, Hans, Eva-Leonne, Jan Bussink, Tom Peeters, Annika, Egbert, 
Peter, Gerald, Mark, Femke, Astrid, Tom Würdinger en iedereen van ThromboDX, 
Miguel Angel en de rest van het Barcelona team, en alle nog niet genoemde 
co-auteurs): allemaal bedankt!
Dan het privé-front, al is daar ook wel wat overlap in ontstaan. Onmisbaar voor deze 
periode maar ook voor alles daarbuiten.
BMW vrienden: Tonke, Jolien, Roos, Valerie, Lineke, Evelien, Amy, Sjoerd, Max, Ralph. 
De meesten van jullie zaten en zitten in hetzelfde schuitje en begrijpen als geen ander 
dat dit boekje niet zomaar even uit de lucht is komen vallen. Het Radboud en PhD 
leven waren dan ook veelvoorkomende gespreksonderwerpen. Heel veel succes met 
het afronden van jullie PhDs en ik hoop dat we nog lang BMW vriendjes blijven 😊.
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Anne, ik leerde je pas kennen in het jaar voordat ik aan mijn PhD traject begon en 
ik kan me niet voorstellen hoe het zonder jou geweest was. Bedankt voor alles! De 
koffies, de weekendjes weg, de sportuurtjes, de sportuurtjes die je cancelde zodat we 
konden chillen, het aanhoren van mijn gezeur, het meezeuren etc. Bart, bedankt voor 
alle maaltijden die je voor ons gekookt hebt 😉.
Laura, hoewel je niet meer zo dichtbij woont zien we elkaar toch nog steeds regelmatig. 
Bedankt voor alle diners en squashgevechten tijdens de studie, en voor de leuke tijd in 
Nijmegen maar ook nog steeds daarna! Als ik in de toekomst fysio nodig heb weet ik 
bij wie ik moet zijn.
Lotte, begonnen als huisgenootje maar ik ben blij dat we nog steeds vriendinnen zijn nu 
we niet meer in hetzelfde huis wonen. En nu zelfs niet meer in dezelfde stad, tijd voor 
een bezoek aan Utrecht! Ilja, vriendinnen geworden na de BMW-GNK introductieweek 
en daarna ook nog een paar jaar huisgenootjes geweest. Ik hoop dat we elkaar nog 
lang blijven zien, heel veel succes met de huisartsenopleiding!
Veldhovense vriendjes en vriendinnetjes: Tessa, Veronique, Jitte, Rosanne, Lisette, 
Emmy, Saskia, Marieke, Ruud, William, Jos, Jarno. Bedankt voor alle afleiding en 
momenten van ontspanning, de gezelligheid, leuke tripjes etc. Nijmegen was gelukkig 
nooit te ver weg om deze vriendschappen in stand te houden. 
Ine en Ronnie. Ronnie, jij zei dat je niemand toewenste wat jij moest doorstaan. De 
weg is lang, maar ik hoop daar met dit onderzoek een klein beetje aan te hebben 
bijgedragen. Eeuwig jammer dat het voor jou niet op tijd was.
Pap, mam, Rudy, Maarten, Suus, oma (helaas mogen niet alle opa’s en oma’s dit meer 
meemaken). Het blijft lastig uit te leggen wat ik nou de hele dag deed daar in het 
Radboud (voor wat ik bij Charles River doe geldt volgens mij hetzelfde). Ondanks dat 
deden jullie toch altijd je best te volgen waar ik het over had. En hier is dan eindelijk dat 
‘boekje’ (ja, echt een boekje!). Bedankt voor alles! De rest van de familie: we lopen de 
deuren niet bij elkaar plat maar jullie staan altijd klaar als dat nodig is, en dat is zo fijn 
om te weten. Schoonfamilie: jullie ook bedankt voor het hele warme welkom!
Lieve Thijs, nu je hier vereeuwigd staat zit je aan me vast 😉. Jij was zo slim om er 
begin 2020 nog even een maandje tussenuit te knijpen. Bedankt dat ik toen je huis 
mocht lenen, en bedankt voor alle ‘goed bezig’s. Ik ben blij dat ik jou ontmoet heb en 
heb zin in nog heel veel tijd samen!
En tot slot, voor iedereen voor wie mijn afgelopen 4 jaar nog steeds een mysterie 
waren: er zit een Nederlandse samenvatting in dit boekje!
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